---
document_datetime: 2023-09-21 18:49:09
document_pages: 120
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/perjeta-h-c-002547-ii-0034-epar-assessment-report-variation_en.pdf
document_name: perjeta-h-c-002547-ii-0034-epar-assessment-report-variation_en.pdf
version: success
processing_time: 304.2397082
conversion_datetime: 2025-12-30 12:48:56.388816
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

26 April 2018 EMA/CHMP/366182/2018 Committee for Medicinal Products for Human Use (CHMP)

## CHMP extension of indication variation assessment report

## Perjeta

International non-proprietary name: pertuzumab

Procedure No. EMEA/H/C/002547/II/0034

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                    | 5                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation                                                                                                      | ..................................................................................................5      |
| 1.2. Steps taken for the assessment of the product                                                                          | ........................................................6                                                |
| 2. Scientific discussion................................................................................                    | 6                                                                                                        |
| 2.1. Introduction ........................................................................................................6 |                                                                                                          |
| 2.2. Non-clinical aspects..............................................................................................8    |                                                                                                          |
| 2.2.1. Introduction......................................................................................................8  |                                                                                                          |
| 2.2.2. Ecotoxicity/environmental risk assessment...........................................................8                |                                                                                                          |
| 2.3. Clinical aspects                                                                                                       | ....................................................................................................9    |
| 2.3.1. Introduction......................................................................................................9  |                                                                                                          |
| 2.3.2. Pharmacokinetics                                                                                                     | ..............................................................................................9          |
| 2.3.3. Pharmacodynamics..........................................................................................           | 13                                                                                                       |
| 2.3.4. PK/PD modelling                                                                                                      | ............................................................................................. 13         |
| 2.3.5. Discussion on clinical pharmacology...................................................................               | 20                                                                                                       |
| 2.3.6. Conclusions on clinical pharmacology.................................................................                | 20                                                                                                       |
| 2.4. Clinical efficacy                                                                                                      | .................................................................................................. 20    |
| 2.4.1. Dose response study(ies) .................................................................................           | 20                                                                                                       |
| 2.4.2. Main study                                                                                                           | ..................................................................................................... 21 |
| 2.4.3. Discussion on clinical efficacy............................................................................          | 62                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy                                                                                 | .................................................................... 67                                  |
| 2.5. Clinical safety                                                                                                        | .................................................................................................... 67  |
| 2.5.1. Discussion on clinical safety............................................................................            | 105                                                                                                      |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 107                                                                                                      |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 108  |
| 2.6. Risk management plan                                                                                                   | ..................................................................................... 108                |
| 2.7. Update of the Product information......................................................................                | 113                                                                                                      |
| 2.7.1. User consultation                                                                                                    | .......................................................................................... 113           |
| 3. Benefit-Risk Balance...........................................................................                          | 113                                                                                                      |
| 3.1. Therapeutic Context .........................................................................................          | 113                                                                                                      |
| 3.1.1. Disease or condition                                                                                                 | ...................................................................................... 113               |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 113                                                                                                      |
| 3.1.3. Main clinical studies.......................................................................................         | 114                                                                                                      |
| 3.2. Favourable effects............................................................................................         | 114                                                                                                      |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 114                                                                                                      |
| 3.4. Unfavourable effects.........................................................................................          | 115                                                                                                      |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 115                                                              |
| 3.6. Effects Table....................................................................................................      | 116                                                                                                      |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 117                                                                                                      |
| 3.7.1. Importance of favourable and unfavourable effects............................................                        | 117                                                                                                      |
| 3.7.2. Balance of benefits and risks ..........................................................................             | 118                                                                                                      |
| 3.7.3. Additional considerations on the benefit-risk balance                                                                | ......................................... 118                                                            |
| 3.8. Conclusions.....................................................................................................       | 118                                                                                                      |

<div style=\"page-break-after: always\"></div>

4. Recommendations  ............................................................................... 118

5. EPAR changes ..................................................................................... 120

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

adverse event

AUCss

area under the concentration versus time curve at steady

state

BIG

Breast International Group

bpCR

breast pathologic complete response

BrEAST

Breast European Adjuvant Study Team

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

Cmax,ss

maximum concentration at steady state

Cmin,ss

minimum concentration at steady state

CSR

clinical study report

DFS

disease-free survival

DRFI

distant recurrence-free interval

EBC

early breast cancer

ESMO

European Society for Medical Oncology

EtM

event to monitor

FEC

5-fluorouracil, epirubicin, cyclophosphamide

HER2

human epidermal growth factor receptor 2

HR

hazard ratio

HRQoL

health-related quality of life

IDFS

invasive disease-free survival

IDFS-SPNBC

invasive disease-free survival including second primary

non-breast cancer

IDMC

Independent Data Monitoring Committee

ITT

intent-to-treat

LVEF

left ventricular ejection fraction

LVD

left ventricular systolic dysfunction

MBC

metastatic breast cancer

NYHA

New York Heart Association

OS

overall survival

pCR

pathologic complete response

PCTT

post-chemotherapy targeted therapy

PFS

progression-free survival

PK

pharmacokinetic

PAM

post-approval measure

popPK

population pharmacokinetic

PRO

patient-reported outcome

PT

preferred term

q3w

every 3 weeks

RFI

recurrence-free survival

SAE

serious adverse event

sBLA

supplemental Biologics License Application

SCE

Summary of Clinical Efficacy

SCS

Summary of Clinical Safety

SOC

system organ class

TCH

docetaxel (Taxotere  ), carboplatin and Herceptin

tpCR

total pathologic complete response

TTTC

targeted therapy + taxane chemotherapy

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Roche Registration GmbH submitted to the European Medicines Agency on 23 August 2017 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication for Perjeta in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer. The submission is based on the primary analysis  of  efficacy  and  safety  data  from  the  pivotal  Phase  III  study  BIG-4-11/BO25126/TOC4939g (APHINITY). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

The RMP version 10.2 has also been submitted.

The variation proposed amendments to the SmPC, and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision EMA/973755/2011, CW/1/2011, dated 19/12/2011 on the granting of a class waiver in the treatment of breast carcinoma.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication. Please refer to separate assessment report.

## Scientific advice

Scientific Advice was given from CHMP/SAWP on the study design of the BIG 4-11 / BO25126 / TOC4939g (APHINITY) study, dated 21 October 2010 (EMEA/H/SA/897/3/210/III).

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

Daniela Melchiorri

| Timetable                                                                                                                                              | Actual dates      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Submission date                                                                                                                                        | 23 August 2017    |
| Start of procedure:                                                                                                                                    | 16 September 2017 |
| CHMP Rapporteur Assessment Report                                                                                                                      | 10 November 2017  |
| CHMP Co-Rapporteur Assessment Report                                                                                                                   | 24 November 2017  |
| PRAC Rapporteur Assessment Report                                                                                                                      | 16 November 2017  |
| Updated PRAC Rapporteur Assessment Report                                                                                                              | 24 November 2017  |
| PRAC Outcome                                                                                                                                           | 30 November 2017  |
| CHMP members comments                                                                                                                                  | 4 December 2017   |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                                                                                                   | 8 December 2017   |
| Request for supplementary information (RSI)                                                                                                            | 14 December 2017  |
| CHMP Rapporteur Assessment Report                                                                                                                      | 26 March 2018     |
| PRAC Rapporteur Assessment Report                                                                                                                      | 28 March 2018     |
| PRAC members comments                                                                                                                                  | N/A               |
| Updated PRAC Rapporteur Assessment Report                                                                                                              | N/A               |
| PRAC Outcome                                                                                                                                           | 12 April 2018     |
| CHMP members comments                                                                                                                                  | 16 April 2018     |
| Updated CHMP Rapporteur Assessment Report                                                                                                              | 19 April 2018     |
| Opinion                                                                                                                                                | 26 April 2018     |
| The CHMP adopted a report on the novelty of the indication/significant clinical benefit for Perjeta in comparison with existing therapies (Appendix 1) | 26 April 2018     |

## 2. Scientific discussion

## 2.1. Introduction

Pertuzumab (rhuMab 2C4, Perjeta  )  is  a  recombinant,  humanized immunoglobulin (Ig)G1κ monoclonal antibody, which targets the human epidermal growth factor receptor 2 (HER2, also known as c-erbB-2), a transmembrane glycoprotein with intrinsic tyrosine kinase activity. By binding to the subdomain 2 epitope of the extracellular domain of HER2, it prevents heterodimerization of HER2 with other members of the HER family  (HER1,  HER3 and  HER4), and as a result, ligand-activated downstream signalling is blocked by pertuzumab.  Pertuzumab is also capable of activating antibody-dependent cell-mediated cytotoxicity.

Perjeta was first granted marketing authorization in the United States (US) on 08 June 2012 and in the European  Union  (EU)  on  04  March  2013,  for  use  in  combination  with  trastuzumab  (Herceptin  )  and docetaxel in patients with HER2-positive metastatic breast cancer (MBC). The approval was based on data

<div style=\"page-break-after: always\"></div>

from the pivotal Phase III study, WO20698/TOC4129g (CLEOPATRA), which showed compelling evidence of clinical  benefit  in  patients  with  HER2-positive MBC, with a statistically significant and clinically relevant increase  in  progression-free  survival  (PFS)  and  overall  survival  (OS).  In  addition,  supportive  data  was submitted from more than 15 other clinical studies of Perjeta.

A Type II variation was subsequently submitted in the EU on 15 August 2014 seeking an extension of the indication to include use of Perjeta in the neoadjuvant setting in patients with HER2-positive early breast cancer (EBC), based on the results from two randomized Phase II studies WO20697 (NEOSPHERE) and BO22280  (TRYPHAENA).    Results  of  the  pivotal  NEOSPHERE  study  in  patients  with  HER2-positive inflammatory, locally advanced or EBC showed that the addition of Perjeta to standard neoadjuvant therapy with Herceptin and docetaxel resulted in a significantly higher rate of pathological complete response (pCR) compared to either Perjeta or Herceptin alone in combination with docetaxel, with little additional toxicity (Gianni et al, 2012). TRYPHAENA, designed as a cardiac tolerability study, evaluated Perjeta and Herceptin in combination with clinically established anthracycline- and non-anthracycline-based regimens; pCR was a secondary endpoint. The pCR rates reported in this study compared favorably with published data. The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the use of Perjeta in the neoadjuvant setting and this was followed by an EU Commission Decision on 28 July 2015 for the following indication:

## Use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.

Perjeta  has  been  approved  in  more  than  100 countries  worldwide  for  the  treatment  of  patients  with HER2-positive  MBC,  and  in  more  than  80  countries  for  the  neoadjuvant  treatment  of  patients  with HER2-positive EBC.

The purpose of this Type II variation is to seek approval for the use of Perjeta in the adjuvant treatment of patients with HER2-positive EBC, and to reflect in the PI the results of the study agreed as Annex IID obligation to the approval for the neoadjuvant indication of Perjeta granted on 28 July 2015.

This application is based on the primary analysis of efficacy and safety data from the pivotal (confirmatory) Phase III study, BIG 4-11/BO25126/TOC4939g (hereafter referred to as ″ APHINITY ″ ).  This is a randomized multicenter,  double-blind,  placebo-controlled  study  comparing  Perjeta  plus  Herceptin  plus  standard chemotherapy (Ptz + H + Chemo) versus placebo plus Herceptin plus standard chemotherapy (Pla + H + Chemo) as adjuvant therapy in patients with operable HER2-positive EBC.  The Applicant considers that the efficacy and  safety  data  from  APHINITY  submitted  with  this  Type  II  variation  support  a  positive  benefit-risk assessment in a population with a high unmet medical need.   APHINTY showed that the addition of 1 year (up to 18 cycles) of Perjeta to standard Herceptin and chemotherapy in the adjuvant setting demonstrated a statistically significant and clinically meaningful benefit in invasive disease-free survival (IDFS) in a setting with curative intent.  Based on these results, the Applicant now proposes the following revised wording of the indication.

## Early Breast Cancer

## Perjeta is indicated for use in combination with trastuzumab and chemotherapy in:

- the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence (see section 5.1)

## HER2 Positive Breast Cancer

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths in women worldwide. An estimated 1.7 million new breast cancer cases were diagnosed in 2012 (25% of all cancers in women) and there were 521,900 deaths (Ferlay et al, 2015; DeSantis et al, 2015).

<div style=\"page-break-after: always\"></div>

The HER2 receptor has emerged as an important target for the treatment of breast cancer. HER2 is involved in  regulating  cell  growth,  survival,  and  differentiation  (Sundaresan  et  al,  1999).  Amplification  and/or overexpression of HER2 occurs in around 15% -20% of breast cancers (Wolff et al, 2007; Chia et al, 2008; Ross et al, 2009) and is associated with increased tumor aggressiveness, higher rates of recurrence, and increased mortality (Borg et al, 1990; Ross et al, 1998; Menard et al, 2001; Brown et al, 2008; Curigliano et al, 2009; Ross et al, 2009).

## Current Treatment of HER2-Positive Breast Cancer

Approval of Herceptin for adjuvant use was based on data generated from four large studies, which showed that adjuvant Herceptin reduces the (relative) risk of relapse by about 50% and the risk of death by about 30% in patients with HER2-positive EBC (HERA/BO16348 [Piccart-Gebhart et al, 2005]; NSABP B-31 and NCCTG N9831 [Romond et al, 2005]; BCIRG 006 [Slamon et al, 2009]). Additional studies have been conducted in patients with HER2-positive EBC, in which adjuvant treatment with Herceptin-based therapy was the control arm therapy, notably the BO20906 (BETH) and ALTTO studies (Report No.1056851 [clinical cut-off  date:  30 June  2013];  Piccart-Gebhart  et  al.  2016).  These  studies  showed  similar  high  rates  of disease-free survival (DFS) as seen in the HERA, BCIRG006, NSABP B-31 and NCCTG N9831 studies.

Perjeta also targets HER2 and when combined with Herceptin provides a more complete blockade of the HER2 pathway and greater anti-cancer activity. Perjeta in combination with Herceptin + Chemotherapy has now become the recommended standard of care in MBC and for neoadjuvant use in patients with high risk EBC undergoing neoadjuvant therapy (NCCN Guidelines, Version 1.2017 [Gradishar et al, 2017]; European Society for Medical Oncology [ESMO] guidelines [Senkus et al, 2015]). Apart from Herceptin and Perjeta, trastuzumab emtansine (ado-trastuzumab emtansine, T-DM1; Kadcyla  ) and lapatinib (Tykerb  ; Tyverb  ) are  HER2-targeted  agents  currently  approved  in  many  countries  for  the  treatment  of  patients  with HER2-positive MBC. However, neither is approved for adjuvant use in patients with EBC. In addition, results have been reported from a study with the investigational agent, neratinib (a tyrosine kinase inhibitor), in the extended adjuvant EBC setting after completion of one year of adjuvant Herceptin (ExteNET study; Chan et al, 2016). In this study, extended adjuvant treatment with 12 months of neratinib in patients who had previously received adjuvant Herceptin and chemotherapy, improved the 2-year IDFS rate.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.2. Ecotoxicity/environmental risk assessment

Pertuzumab is a recombinant humanised IgG1 monoclonal antibody. Proteins and peptides are exempted from the need to provide an ERA, because they are unlikely to result in significant risk to the environment. Neither Perjeta as finished product (420 mg concentrate for solution for infusion) including its excipients, poses a significant risk to the environment.

Thus, in accordance with the \"Guideline on the environmental risk assessment of medicinal products for human use\" (EMEA, 2006), the justification presented by the MAH for the not providing an ERA in the context of the current extension of indication, is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

All clinical trials carried out outside the European Union meet the ethical requirements of the EU Clinical Trial Directive [2001/20/EC].

The Application is based on the APHINITY study (pivotal study).

## 2.3.2. Pharmacokinetics

For the present application, the following analyses have been presented:

- PK data from the APHINITY study
- Comparison of PK data from APHINITY with the developed popPK model for pertuzumab
- Comparisons of observed pertuzumab and trastuzumab data from APHINITY with data from previous studies and indications
- A DDI assessment
- Results of an exploratory E-R analysis

## PK data from the APHINITY study

A  total  of  72  patients  consented  to  participate  in  the  global  PK  sub-study,  of  whom  38  patients  were randomized to the Ptz+H+Chemo arm and 34 patients were randomized to Pla+H+Chemo. The blood sample collection time points were Cycle 1 pre- and post-infusion, Cycle 2 pre-infusion, Cycle 10 pre- and post-infusion,  and  Cycle  15  pre-  and  post-infusion.  There  were  36  PK  evaluable  patients  from  the Ptz+H+Chemo arm and 34 PK evaluable patients from the Pla+H+Chemo arm, defined as a patient who had received at least one active pertuzumab and/or trastuzumab treatment and had at least one PK sample collected. Thirty-five patients in the Ptz+H+Chemo arm contributed pertuzumab PK samples to the PopPK analysis. Summary statistics of serum pertuzumab peak and trough concentrations are summarized in the table below:

Table 1 Summery of Pertuzumab Pharmacokinetic Paramerters

<!-- image -->

| Treatment Group         |           | Cycle 1 Cmax (μg/mL)   | Cycle 1 Cmin (μg/mL)   | Cycle 10 Cmin (μg/mL)   | Cycle 10 Cmax (μg/mL)   | Cycle 15 Cmin (μg/mL)   | Cycle 15 Cmax (w/6r)   |
|-------------------------|-----------|------------------------|------------------------|-------------------------|-------------------------|-------------------------|------------------------|
| Pertuzumab+ Trastuzumab | N         | 33                     | 31                     | 31                      | 29                      | 27                      | 24                     |
| Pertuzumab+ Trastuzumab | Mean (SD) | 237(118)               |                        | 68.0 (16.6) 88.1 (34.4) | 222 (92.2)              | 95.5 (51.5)             | 206 (94.9)             |

Cycle 1, 10, and 15 Cm= post-infusion serum concentration; Cycle 1 Cmn=predose serum concentration concentration at Cycle 2:Cycle 10 Cmh=predose serum concentration at Cycle 10: Cycle 15 Cmn=predose serum concentration at Cycle 15.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Following IV administrations of a pertuzumab 840-mg loading dose and subsequent 420-mg maintenance doses,  every  3  weeks,  the  mean  observed  trough  concentrations  increased  over  time  and  the  mean observed peak concentrations remained roughly equivalent over time. In this study, serum pertuzumab exposure reached steady-state by Cycle 10. However, due to the sparse sampling design of the study, the onset  of  steady-state  could  not  be  assessed.  The  PK  data  in  patients  with  HER2-positive  EBC  was comparable to PK data observed in patients with HER2-positive MBC.

Observed pertuzumab peak and trough serum concentrations at Cycles 1, 10, and 15 from APHINITY were compared with observed pertuzumab peak and trough serum concentrations at Cycles 3, 9, and 15 in the previous MBC trial CLEOPATRA, to assess the impact of disease stage on pertuzumab PK.

Table 2 Pertuzumab Serum Cmin and Cmax (in the presence of Trastuzumab and/or Chemotherapy in Patients with EBC and MBC

<!-- image -->

| APHINITY (EBC)   | APHINITY (EBC)   | APHINITY (EBC)                | APHINITY (EBC)   | APHINITY (EBC)                | CLEOPATRA (MBC)   | CLEOPATRA (MBC)   | CLEOPATRA (MBC)               | CLEOPATRA (MBC)   | CLEOPATRA (MBC)                |
|------------------|------------------|-------------------------------|------------------|-------------------------------|-------------------|-------------------|-------------------------------|-------------------|--------------------------------|
| Cycle            | n                | Cmn (ug/mL) AnithmeticMean±SD | n                | Cmx (μg/mL) ArithmeticMean±SD | Cycle             | n                 | Cmn (μg/mL) ArithmeticMean±SD | n                 | Cmax (μg/mL) AnithmeticMean±SD |
| 1                | 30               | 65.9±12.4                     | 30               | 291±99.1                      | 3                 | 18                | 63.4±48.1                     | 18                | 183±33.5                       |
| 10               | 30               | 91.0±30.9                     | 28               | 230±83.4                      | 9                 | 16                | 75.5±22.1                     | 14                | 196±66.3                       |
| 15               | 24               | 98.4±39.6                     | 21               | 233±64.6                      | 15                | 11                | 94.1±30.6                     | 9                 | 221±32.0                       |

Cx = maximum concentration; Cn = minimum concentration; EBC = eary breast cancer; MBC = metastatic breast cancer.

## Pharmacokinetic interaction

Of the 72 patients who participated in the global PK sub-study, 70 patients received at least one dose of trastuzumab (36 in Ptz+H+Chemo arm and 34 in Pla+H+Chemo arm). The blood sample collection time points were Cycle 1 pre- and post-infusion, Cycle 2 pre-infusion, Cycle 10 pre- and post-infusion, and Cycle 15 pre- and post-infusion.

In order to evaluate the impact of pertuzumab on trastuzumab Cmin or Cmax when the two antibodies were administered concurrently in combination with an EBC chemotherapy regimen, the exposures of the two drugs are summarised below:

Table 3 Summery of Serum Cmin and Cmax of Trastuzumab with Pertuzumab or Placebo

| Timepoint             |   n | Piz+H+Chemo Arithmetic Mean (±SD)   |   n | Pla+H+Chemo Arithmetic Mean (±SD)   | Mean Ratio (90% CI)   |
|-----------------------|-----|-------------------------------------|-----|-------------------------------------|-----------------------|
| Cycle 1 Cmax (μg/mL)  |  34 | 179 (±69.1)                         |  33 | 190 (±51.6)                         | 0.873 (0.713-1.07)    |
| Cycle 1 Cmin (μg/mL)  |  31 | 30.8 (±11.3)                        |  31 | 34.1 (±11.4)                        | 0.874 (0.745-1.03)    |
| Cycle 10 Cmax (μg/mL) |  32 | 226 (±87.4)                         |  27 | 225 (±70.7)                         | 0.978 (0.797-1.20)    |
| Cycle 10 Cmin (μg/mL) |  32 | 67.0 (±38.5)                        |  26 | 68.4 (±23.0)                        | 0.878 (0.711-1.09)    |
| Cycle 15 Cmax (μg/mL) |  24 | 195 (±88.6)                         |  21 | 234 (±73.5)                         | 0.765 (0.605-0.968)   |
| Cycle 15 Cmin (μg/mL) |  26 | 75.7 (±44.6)                        |  22 | 71.0 (±30.4)                        | 0.967 (0.737-1.27)    |

Cms = maximum concentration; Cain = minimum concentration ; Pla+H+Chemo = placebo plus Herceptin plus chemotherapy: Piz+H+Chemo = Perjeta plus Herceptin plus chemotherapy.

Ratios of geometric means.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 1 Serum Cmin and Cmax of Trastuzumab with or without Pertuzumab

<!-- image -->

Cma=maximum concentration;Cmn=minimum concentration;Pla+H+Chemo=placebo plus Herceptin plus chemotherapy.Ptz+H+Chemo=Perjeta plus Herceptinpluschemotherapy.

Closed circles=Ptz+H+Chemo,open circles=Pla+H+Chemo;solid green line=arithmeticmean foreach timepoint andtreatmentarm,shadedarea=arithmeticmean±1 SD.

Steady-state concentrations of trastuzumab from patients in the APHINITY study were compared with data from a previous study of adjuvant trastuzumab in patients with EBC. After confirming a lack of PK DDI between pertuzumab and trastuzumab in APHINITY as summarized above, trastuzumab PK data from both arms of the APHINITY study were compared with historical observed PK data from the Study BO16348 (HERA). The HERA study was a pivotal, randomized Phase III study in which patients were treated with 1 year of adjuvant trastuzumab monotherapy or placebo after completion of standard adjuvant chemotherapy (Report  No.  1066908).  Patients  also  received  adjuvant  hormonal  therapy  if  clinically  indicated,  after completion of chemotherapy. The table below shows comparable observed trastuzumab Cmin and Cmax between APHINITY and HERA at similar cycles.

Table 4 Summery of Serum Cmin and Cmax of Trastuzumab (in the Presence of Chemotherapy and Pertuzumab or Placebo) in Two EBS Studies

| APHINITY   | APHINITY                        | APHINITY   | APHINITY                        |    |       |                                  |    |                                 |    |
|------------|---------------------------------|------------|---------------------------------|----|-------|----------------------------------|----|---------------------------------|----|
| Cycle      | Cmin (μg/mL) Arithmetic Mean±SD | n          | Cmax (μg/mL) Arithmetic Mean±SD | n  | Cycle | Cmin (μg/mL) Arithmetic Mlean±SD | n  | Cmax (μg/mL) Arithmetic Mean±SD | n  |
| 10         | 67.7±32.2                       | 58         | 226±79.5                        | 59 | 10    | 66.0±39                          | 3  | 203±7.0                         | 3  |
| 15         | 73.6±38.4                       | 48         | 213±83.3                        | 45 | 12    | 72.3±46                          | 15 | 237±12.0                        | 15 |

Cms = maximum concentration; Cmn= minimum concentration; EBC = early breast cancer.

These findings further support a lack of impact of pertuzumab on trastuzumab PK.

Following IV administrations of a trastuzumab 8 mg/kg loading dose and subsequent 6 mg/kg maintenance doses,  every  3  weeks,  the  mean  observed  trough  concentrations  increased  over  time  and  the  mean observed peak concentrations remained roughly equivalent over time. In this study, serum trastuzumab exposure reached steady-state by Cycle 10. However, due to the sparse sampling design of the study, the onset of steady-state could not be assessed. Trastuzumab PK data was comparable to prior observations in patients with HER2-positive EBC.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Since all patients in the APHINITY study received concurrent pertuzumab and trastuzumab, the potential effect of trastuzumab on the PK of pertuzumab could not be assessed using data from the APHINITY study alone. Instead, it was assessed by comparing the observed pertuzumab concentrations in APHINITY with the popPK model predictions. In contrast to the APHINITY study, the majority of the PK data (&gt;95%) used  to  build  the  popPK  model  came  from  patients  treated  with  pertuzumab  without  concomitant trastuzumab. Additionally, patients in 7 of the 12 studies in the popPK model were treated with pertuzumab as monotherapy (without concomitant chemotherapy or targeted therapies).

Observed pertuzumab data from APHINITY were compared to the observed pertuzumab data from the previous MBC trial CLEOPATRA, table below:

## Table 5 Summery of Serum Cmin and Cmax of Pertuzumab (in the Presence of Trastuzumab +/Chemotherapy) in Patients with EBC and MBC

| APHINITY (EBC)   | APHINITY (EBC)   | APHINITY (EBC)   | APHINITY (EBC)   | CLEOPATRA (MBC)   | CLEOPATRA (MBC)   | CLEOPATRA (MBC)   | CLEOPATRA (MBC)   | CLEOPATRA (MBC)   |    |
|------------------|------------------|------------------|------------------|-------------------|-------------------|-------------------|-------------------|-------------------|----|
| Cycle            | Cmin (μg/mL)     |                  | Cmar (μg/mL)     |                   | Cycle             | Cmin (μg/mL)      | Ⅱ1                | Cmor (μg/mL)      |    |
| 1                | 65.9±12.4        | 08               | 291.2±99.1       | 30                | 3                 | 63.4±48.1         | 18                | 183±33.5          | 18 |
| 10               | 91.0±30.9        | 30               | 229.8±83.4       | 28                | 6                 | 75.5±22.1         | 16                | 196±66.3          | 14 |
| 15               | 98.4±39.6        | 24               | 232.8±64.6       | 21                | 15                | 94.1±30.6         | 11                | 221±32.0          |    |

Serum Cmin and Cmax in APHINITY (Cycles 1, 10, and 15) are comparable to PK data from the CLEOPATRA study (Cycles 3, 9, and 15).

## Paclitaxel and carboplatin

For patients in the anthracycline cohort receiving Ptz+H with paclitaxel, a total of 18 blood samples of 5 mL each were needed for PK evaluation and these were collected over a period of 15 cycles (21 days/cycle). For patients in the non-anthracycline cohort receiving Ptz+H with docetaxel and carboplatin, a total of 20 blood samples of 5 mL each were needed for PK evaluation and these were collected over a period of 15 cycles (21 days/cycle). For paclitaxel, blood samples were collected during Cycle 1 only at pre-infusion, and 3, 5, and 24 hours after the start of infusion. For carboplatin, blood samples were collected during Cycle 1 only at pre-infusion, end-of-infusion, and 1, 2, 4, and 5 hours after the end-of-infusion.

The potential effect of pertuzumab on the PK of paclitaxel and carboplatin was assessed by comparing the arithmetic  means  of  the  carboplatin  or  paclitaxel  plasma  Cmax  and  AUClast  in  Cycle  1  between  the Ptz+H+Chemo and Pla+H+Chemo treatment arms. Paclitaxel and paclitaxel metabolite PK parameters and 90%  CI  of  the  geometric  mean  ratios  in  the  Ptz+H+Chemo  and  Pla+H+Chemo  treatment  arms  are summarized below:

Table 6 Summery of Paclitaxel PK Parameters (in the Presence of Trastuzumab) with or without Pertuzumab

|         | Ptz+H+chemo (±SD)   | Pla+H+chemo (±SD)   | Mean Ratio* (90% CI)   |
|---------|---------------------|---------------------|------------------------|
|         | 23                  | 21                  |                        |
| Cmar    | 665.3 (±494.8)      | 834.6 (±495.5)      | 0.639 (0.387-1.06)     |
| AUClast | 3901.2 (±3073.5)    | 4816.7 (±3859.9)    | 0.731 (0.485-1.1)      |

Arithmetic means. Plasma Cmaz in ng/mL. Plasma AUClast in ng-h/mL. * Ratios of Geometric Means.

<div style=\"page-break-after: always\"></div>

The 90% CI of the mean ratio of PK parameters were wide and most probably affected by the variability in PK parameters and the low statistical power associated with the small sample sizes of the treatment groups. The results suggest that there is no impact of pertuzumab on the PK of paclitaxel, as expected since there is no apparent mechanistic basis for a PK DDI between these agents. The 6-alpha-hydroxy metabolite of paclitaxel was also measured in the global PK substudy and there were detectable levels at 3 and 5 hours post-dose.  The  Cmax  of  the  paclitaxel  metabolite  in  the  Ptz+H+Chemo  and  Pla+H+Chemo  arms  was compared and the mean ratio (90% CI) was 0.882 (0.587-1.33), supporting that in addition to no impact of pertuzumab on the PK of paclitaxel, there is no impact on paclitaxel's 6-alpha-hydroxy metabolite.

Carboplatin  PK  parameters  and  90%  CIs  of  the  geometric  mean  ratios  in  the  Ptz+H+Chemo  and Pla+H+Chemo treatment arms are showed below:

Table 7 Summery of Carboplatin PK Parameters (in the Presence of Trastuzumab) with Pertuzumab or without Pertuzumab (Placebo)

|                 | Ptz+H+Chemo Arithmetic Mean(±SD)   | Pla+H+Chemo Arithmetic Mean (±SD)   | Mean Ratio (90% CI)   |
|-----------------|------------------------------------|-------------------------------------|-----------------------|
| N               | 6                                  | 12                                  |                       |
| Cmax (ng/mL)    | 25100（±3450)                       | 27300(±8880)                        | 0.959 (0.795-1.16)    |
| AUCas (ng*h/mL) | 30000(±18900)                      | 36900 (±20800)                      | 0.833(0.307-2.26)     |

AUCuu = area under the concentration versus time curve over all concentration measurements; Cmu = maximum concentration; PK = pharmacokinetic, Pla+H+Chemo = placebo plus Herceptin plus chemotherapy; Plz+H+Chemo =Perjeta plus Herceptin plus chemotherapy.

Ratios of geometric means.

<!-- image -->

Similar to paclitaxel, the 90% CI of the mean ratio of PK parameters were wide and most probably affected by the variability in PK parameters and the low statistical power associated with the small sample sizes of the treatment groups. The results suggest that there is no impact of pertuzumab on the PK of carboplatin, as expected since there is no apparent mechanistic basis for a PK DDI between these agents.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Perjeta  is  a  recombinant  humanised  monoclonal  antibody  that  specifically  targets  the  extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2), and thereby, blocks ligand-dependent heterodimerisation of HER2 with other HER family members, including EGFR, HER3 and HER4. As a result, Perjeta inhibits ligand-initiated intracellular signalling through two major signal pathways, mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase (PI3K). Inhibition of these signalling pathways can result in cell growth arrest and apoptosis, respectively. In addition, Perjeta mediates antibody-dependent cell-mediated cytotoxicity (ADCC).

## 2.3.4. PK/PD modelling

The Global PK Substudy included 72 patients of whom 38 were in the Ptz+H+chemo treatment arm and 35 contributed pertuzumab concentration data for the PopPK analysis as detailed below:

<div style=\"page-break-after: always\"></div>

Table 8 Summery of Pertuzumab PK Sampling and Patients Included in the Global PK Substudy

|                                                              | Global PK Substudy                                                                  |
|--------------------------------------------------------------|-------------------------------------------------------------------------------------|
| N patients                                                   | 72                                                                                  |
| Patients exposed topertuzumab treatment                      | 38                                                                                  |
| Patients contributing pertuzumab PK samples for the analysis | 35                                                                                  |
| PK Sampling Cycle 1: Cycle 2: Cycle 10: Cycle 15:            | pre-and post-infusion pre-infusion only pre- and post-infusion pre-andpost-infusion |

For more information consult the clinical study protocol.

Pertuzumab data was completely removed for 3 patients: Patient 2093020006 did not have any recorded pertuzumab data (no pertuzumab doses or observations), Patient 2099570001 had non-plausible PK data, and Patient 2469040007 had blank time records for the pertuzumab observations.

A PK model previously developed for pertuzumab based on a large database of patients with solid tumors, including  MBC,  was  subjected  to  external  validation  to  examine  whether  it  is  appropriate  for  patients included in the APHINITY study.

The previously developed PopPK model was built on data from 5 Phase I/Ib studies, 6 Phase II studies, and 1 pivotal Phase III study. In contrast to the current study, the majority of the data (&gt;95%) used to build the PopPK model was based on pertuzumab without concomitant trastuzumab treatment. Additionally, 7 of the 12  studies  in  the  PopPK  model  investigated  pertuzumab  as  monotherapy  (without  concomitant chemotherapy or targeted therapies).

Pertuzumab PK was described by a two-compartment linear model with a clearance (CL), central volume of distribution (Vc), and terminal elimination half life (t1/2) of 0.235 L/ day, 3.11 L, and 18 days, respectively. LBW and baseline serum albumin (ALBU) were identified as statistically significant covariates inuencing pertuzumab PK.

The PopPK analysis was carried out using NONMEM (Version 7.3, ICON Development Solutions, Elicott City, MD,  USA).  The  NONMEM  installation  was  validated  according  to  qPharmetra  information  system  and information technology (ISIT) Policies. Post-processing of NONMEM analysis results was carried out in R version 3.2.2. Estimation of individual PK parameters was carried out using first order conditional estimation with Interaction (FOCE-I).

Pertuzumab PK results from patients in APHINITY were compared with those predicted from the pertuzumab popPK  model  that  was  developed  using  data  from  481  patients  in  12  clinical  studies.  The  observed pertuzumab peak and trough serum concentrations (black circles) from the APHINITY patients and the covariate-adjusted, model-predicted median serum concentrations for the population (green line) and the 5th through 95th percentiles (green shaded area; 95% prediction interval) are showed in the figure below:

<div style=\"page-break-after: always\"></div>

Figure 2 Observed versus Model-Simulated Pertuzumab Peak and Trough Concentrations in APHINITY

<!-- image -->

Overall, the popPK model predicted the observed serum concentrations of pertuzumab reasonably well across cycles after correcting for baseline differences in weight and albumin concentrations. A slight increase in observed pertuzumab concentrations (minimum concentration [Cmin]) was seen in later cycles although the majority of the observed pertuzumab concentrations were within the 95% prediction interval.

According to the MAH, the ability of the popPK model to predict the pertuzumab serum concentrations in the APHINITY study suggests that trastuzumab does not affect pertuzumab PK. These results are consistent with previous results from the CLEOPATRA and NEOSPHERE studies, which showed no impact of trastuzumab on pertuzumab PK.

Graphical assessment of the match between observed and model predicted pertuzumab concentrations, as well as conditional weighted residuals, suggested an adequate fit of the model to the data, although trends can be seen for low pertuzumab population predictions. Diagnostic plots of observed data vs. population prediction (PRED) and individual prediction (IPRED) were examined for adequate fit. Plots of conditional weighted residual (CWRES) versus PRED and versus time (time after last dose as well as time after first dose) are reported below:

<div style=\"page-break-after: always\"></div>

Figure 3 Observed Versus Model-Simulated Pertuzumab Serum Concentrations

<!-- image -->

Solid Black Line:Line of identity.Solid Green Line and Shaded Green Area: Gaussian Loess smooth with 95% Cl.Left Panel:Circles:Individual observations /Population predictions,Right Panel:Circles:Individual observations /Individual predictions.

Figure 4 Conditional Weighted Residuals - by Time Point

<!-- image -->

Circles: Individual CWRES, Solid Green Line: Mean CWRES for each timepoint Shaded Area: The shaded areas indicate the 95% CI for the mcan CWRES.

<div style=\"page-break-after: always\"></div>

Figure 5 Conditional Weighted Residuals Versus Population Predictions

<!-- image -->

Circles:Individual CWRES Solid Green Line and Shaded Green Area:Gaussian Loesssmoothwith95%Cl.

## Exposure-response Analysis

To generate individual pertuzumab exposure for patients in the Ptz+H+chemo treatment arm of the Global PK Substudy, a simulation dataset was constructed based on estimated individual parameters for the PopPK model.  For  all  patients  with  at  least  one  available  valid  concentration  measurement  of  pertuzumab, predictions of Cmax;ss, Cmin;ss and AUCss were derived. The simulation dataset consisted of a loading dose and 3 maintenance doses. The loading dose, including infusion duration, was taken from the NONMEM dataset for each patient in the Ptz+H+chemo treatment arm in the Global PK Substudy, thereafter, 3 doses of  420  mg  pertuzumab  were  administered  using  a  30  minute  infusion  with  3  weeks  dosing  interval. Individual predictions of concentration at the end of infusion (Cmax;ss) and before next dose (Cmin;ss) were generated following the third maintenance dose for all patients.

The efficacy endpoint in the exposure-efficacy analysis was the primary study endpoint, IDFS, defined as the time from randomization until the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or death attributable to any cause. Patients who had not had an event at the time of data analysis were censored at the date they were last known to be event free. The primary exposure metrics used in the exposure-efficacy analysis were individual predicted Cmin;ss and AUCss.

A total of 35 patients in the Ptz+H+chemo arm with predicted AUCss and Cmin;ss were included in the exposure-efficacy analysis.

<div style=\"page-break-after: always\"></div>

Figure 6 Pertuzumab AUCss and Cmin, ss for Patients with or without an IDFS event (Ptz+H+chemo Treated Patients

<!-- image -->

Solid GreenLine:Arithmeticmean for eachgroup Shaded Area:Arithmeticmean ±lSD

<!-- image -->

Selection of adverse events (AEs) to be included in the safety-exposure analysis was based on the APHINITY data (overall safety population). AEs were considered if there was a difference of ≥5% in the incidence of Grade ≥ 3 AEs between the Ptz+H+chemo and Pla+H+chemo arms. Furthermore, to be considered for the analysis, pertuzumab PK data was required for 5-10 patients experiencing the AE, and 'Any Grade ≥ 3 AE\" (incidence 64.25% in the Ptz+H+chemo arm and 57.3% in the Pla+H+chemo arm) and Grade ≥ 3 diarrhea (incidence 9.9% in th Ptz+H+chemo arm and 3.7% in the Pla+H+chemo arm) met these criteria.

Table 9 Number of Patients (%) with Grade &gt; 3 AE in the Global PK Substudy by Treatment Arm

| Treatment   |   Number of subjects | Any AE     | Diarrhea   |
|-------------|----------------------|------------|------------|
| Pla+H+chemo |                   34 | 25 (73.5%) | 2 (5.9%)   |
| Ptz+H+chemo |                   35 | 27 (77.1%) | 7 (20.0%)  |

The occurrence of Grade ≥3 AEs for the Pla+H+chemo treated patients and for the Ptz+H+chemo treated patients with pertuzumab exposure (AUCss or Cmax;ss) below or above median are summarized below:

Table 10 Number of Patients (%) with Grade &gt; 3 AE in the Global PK Substudy by AUCss Group

| AUCgroup                    |   Number of subjects | Any AE     | Diarrhea   |
|-----------------------------|----------------------|------------|------------|
| placebo                     |                   34 | 25 (73.5%) | 2 (5.9%)   |
| Pertuzumabbelowmedian AUC   |                   18 | 13(72.2%)  | 4 (22.2%)  |
| Pertuzumab above median AUC |                   17 | 14 (82.4%) | 3 (17.6%)  |

<div style=\"page-break-after: always\"></div>

Table 11 Number of Patients (%) with Grade &gt; 3 AE in the Global PK Substudy by C max,ss Group

| Cmaz group                  |   N total | Any AE     | Diarrhea   |
|-----------------------------|-----------|------------|------------|
| placebo                     |        34 | 25 (73.5%) | 2 (5.9%)   |
| Pertuzumabbelowmedian Cmar  |        18 | 13 (72.2%) | (22.2%)    |
| Pertuzumababove median Cmat |        17 | 14 (82.4%) | 3 (17.6%)  |

The figure below presents the possible relationships between AUCss or Cmax;ss and occurrence of any Grade  ≥3 AE:

Figure 7 Pertuzumab AUC ss and C max,ss for Ptz+H+chemo-treated Patients with or without any Grade &gt; 3 AE

<!-- image -->

Solid Green Line:Arithmetic mean foreach group Shaded Area:Arithmetic mean ±lSD

The figure below presents the possible relationships between AUCss or Cmax;ss and occurrence of Grade  ≥3 diarrhea:

Figure 8 Pertuzumab AUC ss and C max,ss for Ptz+H+chemo-treated Patients with or without Grade &gt; 3 Diarrhea

<!-- image -->

Solid Green Line:Arithmetic mean foreach group Shaded Area:Arithmetic mean ±lSD

<div style=\"page-break-after: always\"></div>

According to the MAH, the incidence of Grade ≥ 3 AEs (any AE) was similar in the Pla+H+chemo and Ptz+H+chemo-treated patients in the Global PK Substudy and the incidence of Grade ≥ 3 AEs was similar in high and low pertuzumab exposure groups (10% difference but a difference of only 1 patient in two groups). The  incidence  of  Grade  ≥  3  diarrhea  was  more  frequent  in  Ptz+H+chemo-treated  patients  than  in Pla+H+chemo-treated patients but the occurrence of Grade ≥3 diarrhea does not increase with increasing pertuzumab  exposure.  It  should  be  noted  that  grouping  of  patients  based  on  AUCss  or  Cmax;ss  was identical, i.e. all patients with AUCss above the median also had a Cmax;ss above the median. Hence, results are identical for Cmax;ss and AUCss.

## 2.3.5. Discussion on clinical pharmacology

New PK data and analyses from Study BO25126 (APHINITY/BIG 4-11/TOC 4939G) have been submitted to support  extension  of  the  Perjeta  indication  to  include  its  use  in  combination  with  Herceptin  and chemotherapy for the adjuvant treatment of patients with HER2-positive EBC.

Comparing pertuzumab peak and trough serum concentrations at Cycles 1, 10, and 15 between EBC patients (APHINITY study) and MBC patients (CLEOPATRA study), it has been observed that, after the first cycles, pertuzumab mean Cmax value was slightly higher in EBC patients. This is not considerate clinically relevant, therefore, tumour burden not seems to affect the PK profile.

Results  from  the  pertuzumab  popPK  model  suggest  that  trastuzumab  does  not  affect  pertuzumab  PK. Diagnostic plots of observed data vs. population prediction (PRED) and individual prediction (IPRED) as well as plots of conditional weighted residual (CWRES) versus PRED and versus time show some uncertainties in the model performance. Observed data vs. individual prediction plot results in the best fit and the VPC show a  good  fit  of  the  data.  A  systematic  lack  of  fit  can  be  excluded,  even  if  information  derived  from  the developed pop PK can be considered only supportive.

Findings and analyses presented support a lack of DDI between pertuzumab and trastuzumab. No dosage adjustment is needed also for paclitaxel and carboplatin.

The exposure-efficacy analysis showed that higher exposure to pertuzumab, namely higher mean AUCss and Cmin values, were not associated with low number of IDFS events. MAH's conclusion on exposure-safety relationship are supported: no relationship is suggested from available data.

## 2.3.6. Conclusions on clinical pharmacology

Based on PK data from the Global PK Substudy (APHINITY study), no dose adjustment is needed either for pertuzumab, paclitaxel or carboplatin when administered in combination with trastuzumab. Overall, the clinical pharmacology data support the proposed variation application.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

An  exposure-response  analysis  was  performed  based  on  a  PopPK  model.  The  efficacy  endpoint  in  the exposure-efficacy analysis was the primary study endpoint, IDFS, defined as the time from randomization until the date of first occurrence of one of the following events: ipsilateral invasive breast tumor recurrence, ipsilateral local-regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or death attributable to any cause. Patients who had not had an event at the time of data analysis were censored at the date they were last known to be event free. The primary exposure metrics used in the

<div style=\"page-break-after: always\"></div>

exposure-efficacy  analysis  were  individual  predicted  Cmin;ss  and  AUCss.  Results  showed  that  higher exposure to pertuzumab was not associated with low number of IDFS events

The  safety-exposure  analysis  was  based  on  the  APHINITY  data  (overall  safety  population).  AEs  were considered if there was a difference of ≥5% in the incidence of Grade ≥ 3 AEs between the Ptz+H+chemo and Pla+H+chemo arms. No relationship is suggested from available data.

For further details, see Section 2.3.

## 2.4.2. Main study

## The APHINITY study

The APHINITY study: Phase III, prospective, two-arm randomized, multicenter, multinational, double-blinded, placebo-controlled study in patients with HER2-positive primary breast cancer who have had their primary tumor excised.

## Methods

## Study design

The APHINITY study  is  an  ongoing,  Phase  III,  prospective,  two-arm  randomized,  multicenter, multinational,  double-blinded,  placebo-controlled  study  in  patients  with  HER2-positive  primary  breast cancer who have had their primary tumor excised.

The primary objective of the study is to compare invasive disease-free survival (IDFS) in patients with HER2-positive early breast cancer (EBC) randomized to adjuvant treatment with Perjeta plus Herceptin and chemotherapy (Ptz + H + Chemo) or placebo plus Herceptin and chemotherapy (Pla + H + Chemo).

The  primary  tumour  had  to  be  confirmed  as  HER2-positive  by  a  central  pathology  laboratory  prior  to enrollment. For each individual patient, the Investigator in consultation with the patient selected one of the standard anthracycline-based or non-anthracycline-based regimen  defined in the protocol before randomization.

A total of 4805 patients were randomized in a 1:1 ratio to one of the two treatment arms. One patient was excluded from all analyses due to unreliable data, resulting in a total of 4804 patients being included in efficacy analyses and the following treatment allocations:

## Perjeta plus Herceptin and chemotherapy (Ptz + H + Chemo) (2400 randomized patients):

- -Herceptin: loading dose of intravenous (IV) 8 mg/kg, followed by 6 mg/kg IV every three weeks (q3w)
- -Perjeta: loading dose of 840 mg/kg IV, followed by 420 mg/kg IV q3w

## Placebo plus Herceptin and chemotherapy (Pla + H + Chemo) (2404 randomized patients):

- -Herceptin: loading dose of 8 mg/kg IV, followed by 6 mg/kg IV q3w
- -Placebo: IV infusion q3w

Patients  were  stratified  according  to  nodal  status,  type  of  standard  adjuvant  chemotherapy  regimen (anthracycline-based versus non-anthracycline-based), hormone receptor status, geographical region and protocol version (Protocol A versus Protocol Version B). Protocol version (A versus B) was introduced as a stratification factor at the time of the first protocol amendment (Version B, dated 20 November 2012).

Randomized HER2-targeted treatment (Herceptin plus Perjeta OR Herceptin plus placebo) had to start concurrently with the taxane component of chemotherapy. All patients were required to have a screening

<div style=\"page-break-after: always\"></div>

left ventricular ejection fraction (LVEF) ≥ 55% prior to randomization. Patients receiving anthracyclines were required  to  have  an  LVEF  of ≥ 50% after  completion  of  anthracyclines  and  prior  to  commencing HER2-targeted treatment. HER2-targeted treatment was administered for a total of up to 52 weeks (i.e., 18 cycles within 1 year).

## Figure 9 Study Design

## ANTHRACYCLINEBASED CHEMOTHERAPY

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Study participants

Main inclusion and exclusion criteria

## Inclusion Criteria

- Non-metastatic, histologically confirmed primary invasive breast carcinoma that had been adequately excised
- Node-positive disease (any tumor size except T0) or node-negative disease (only under Protocol Version A) were allowed to enroll. For patients with node-negative disease, one of the following conditions had to be met:
- o Tumor size &gt; 1cm
- o Tumor size &gt; 0.5 cm and ≤ 1cm and at least one of the following three features:
- -Histologic/nuclear Grade 3, OR
- -Negative for ER and PgR, OR
- -Age &lt; 35 years.

Enrollment of patients with node-negative tumors ≤ 1.0 cm was limited to &lt; 10% of the total number of randomized patients.

- The hormone receptor status of the tumor (ER and PgR) had to be known.
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1
- HER2-positivity of the breast cancer had to be confirmed by a central laboratory.
- Baseline left ventricular ejection fraction (LVEF) ≥ 55%

•

## Exclusion Criteria

- History of any prior invasive breast carcinoma or a history of non-breast malignancies within 5 years prior to study entry (although certain exceptions were permitted to the prior malignancies clause)
- Any clinical T4 tumor (including inflammatory breast cancer)
- Any node-negative tumor
- Any previous systemic chemotherapy for cancer or radiotherapy for cancer
- Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for cancer
- Serious cardiac or cardiovascular disease or condition
- Other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions/illness
- Abnormal laboratory tests immediately prior to randomization
- Pregnant or lactating women

<div style=\"page-break-after: always\"></div>

## Treatments

The Perjeta dosing regimen used in APHINITY (i.e., 840 mg intravenous (IV) loading dose, followed by a maintenance dose of 420 mg IV every 3 weeks [q3w]) is the approved Perjeta dosing regimen for patients with HER2-positive MBC and for the neoadjuvant treatment of patients with locally advanced, inflammatory and EBC. Perjeta/placebo was administered for a total of 52 weeks plus a window of 3 days (i.e., maximum of 18 cycles within 1 year).

Herceptin was administered IV as an 8 mg/kg loading dose followed by 6 mg/kg q3w. This regimen is licensed in many countries for Herceptin in the adjuvant breast cancer setting. Herceptin was administered for a total of 52 weeks, plus a window of 3 days (i.e., maximum of 18 cycles within 1 year).

The anthracycline-based and non-anthracycline-based chemotherapy regimens were based on published data, clinical guidelines, and routine clinical practice, see table 12.

## Table 12 Protocol Approved Chemotherapy Regimens (Investigators' Choice)

| All study treatments were given intravenously. For all regimens, the maximum allowed cumulative dose of doxorubicin was 360 mg/m 2 and of epirubicin was 720 mg/m 2 .   | All study treatments were given intravenously. For all regimens, the maximum allowed cumulative dose of doxorubicin was 360 mg/m 2 and of epirubicin was 720 mg/m 2 .   | All study treatments were given intravenously. For all regimens, the maximum allowed cumulative dose of doxorubicin was 360 mg/m 2 and of epirubicin was 720 mg/m 2 .   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| REGIMEN                                                                                                                                                                 | DOSE                                                                                                                                                                    | FREQUENCY                                                                                                                                                               |
| Anthracycline therapy: FEC (or FAC) → T                                                                                                                                 | Anthracycline therapy: FEC (or FAC) → T                                                                                                                                 | Anthracycline therapy: FEC (or FAC) → T                                                                                                                                 |
| 3 or 4 cycles x FEC (or FAC) → 3 or 4 cycles x docetaxel                                                                                                                | F: 500 to 600mg/m 2 E: 90 to 120mg/m 2 or A: 50mg/m 2 C: 500 to 600mg/m 2                                                                                               | q3w                                                                                                                                                                     |
| 3 or 4 cycles x FEC (or FAC) → 3 or 4 cycles x docetaxel                                                                                                                | Followed by: Docetaxel: 100mg/m 2 OR Docetaxel: 75mg/m 2 for 4 cycles a OR Docetaxel: 75mg/m 2 in the first cycle, escalating to 100mg/m 2 in subsequent cycles         | q3w q3w q3w                                                                                                                                                             |
| 3 or 4 cycles x FEC (or FAC) → 12 weekly cycles of paclitaxel                                                                                                           | F: 500 to 600mg/m 2 E: 90 to 120mg/m 2 or A: 50mg/m 2 C: 500 to 600mg/m 2                                                                                               | q3w                                                                                                                                                                     |
| 3 or 4 cycles x FEC (or FAC) → 12 weekly cycles of paclitaxel                                                                                                           | Followed by: Paclitaxel: 80mg/m 2                                                                                                                                       | q1w                                                                                                                                                                     |
| Anthracycline therapy: AC (or EC)  T                                                                                                                                   | Anthracycline therapy: AC (or EC)  T                                                                                                                                   | Anthracycline therapy: AC (or EC)  T                                                                                                                                   |
| 4 cycles x AC b (or EC) → 3 or 4 cycles x docetaxel                                                                                                                     | A: 60mg/m 2 or E: 90 to 120mg/m 2 C: 500 to 600mg/m 2                                                                                                                   | q3w                                                                                                                                                                     |
| 4 cycles x AC b (or EC) → 3 or 4 cycles x docetaxel                                                                                                                     | Followed by: Docetaxel: 100mg/m 2 OR Docetaxel: 75mg/m 2 for 4 cycles a OR Docetaxel: 75mg/m 2 in the first cycles, escalating to 100mg/m 2 in subsequent cycles        | q3w                                                                                                                                                                     |
| 4 cycles x AC b (or EC) → 12 weekly cycles of paclitaxel                                                                                                                | A: 60mg/m 2 or E: 90 to 120mg/m 2 C: 500 to 600mg/m 2                                                                                                                   | q3w                                                                                                                                                                     |
| 4 cycles x AC b (or EC) → 12 weekly cycles of paclitaxel                                                                                                                | Followed by: Paclitaxel: 80mg/m 2                                                                                                                                       | q1w                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Non-Anthracycline therapy: Docetaxel and Carboplatin as in BCIRG006   | Non-Anthracycline therapy: Docetaxel and Carboplatin as in BCIRG006   | Non-Anthracycline therapy: Docetaxel and Carboplatin as in BCIRG006   |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
| 6 x docetaxel + carboplatin                                           | Docetaxel: 75mg/m 2 Carboplatin AUC 6 (max 900 mg)                    | q3w                                                                   |

A = doxorubicin; AUC = area under the curve; C = cyclophosphamide, E = epirubicin, F = 5-fluorouracil; T = taxane; q1w = every week; q3w = every 3 weeks.

a If docetaxel 75 mg/m 2 was used and not escalated to 100mg/m 2

, then 4 cycles had to be given. b EC or AC could be given at the same dose (A: 60mg/m 2 or E: 90 to 120mg/m 2 ) every 2 weeks (dose dense) with G-CSF support, for a total of 4 cycles.

All patients entering the study were to receive radiotherapy and/or adjuvant hormone therapy, if indicated, according  to  standard  practice.  Before  actively  enrolling  patients,  each  center  had  to  define  their radiotherapy and hormone therapy policies for APHINITY trial patients at their site.

In the responses to the LOQ, radiotherapy use was analyzed according to surgery type (mastectomy or breast  conserving  surgery  [BCS])  and  according  to  nodal  status,  as  these  are  two  key  factors  which determine  the  need  for  adjuvant  radiotherapy.  Finally,  radiotherapy  use  has  also  been  compared  by geographic region.

Table 13 Randomization Stratification Factors by Treatment Regimen Adjuvant Radiotherapy (ITT Population)

Randomization Stratification Factors by Treatment Regimen, Adjuvant Radiotherapy, ITT Population Prot00ol: BIG 4-11/B025126/T0C4939G

|                                                          | Pertuzumab + Chemotherapy (N=1746)   | Placebo + Chemotherapy (N=1735)   |
|----------------------------------------------------------|--------------------------------------|-----------------------------------|
| Nodal status                                             |                                      |                                   |
| I                                                        | 1746                                 | 1735                              |
| 0 positive nodes and tumor <= lcm*                       | 60(3.4)                              | 58 ( 3.34)                        |
| 0 positive nodes and tumor > 1om*                        | 517 (29.6%)                          | 506 (29.2%)                       |
| 1-3 positive nodes                                       | 634(36.36)                           | 638(36.8)                         |
| = 4 positive nodes                                       | 535 (30.6)                           | 533 (30.7%)                       |
| Adjuvant chemotherapy regimen (xandomized)               |                                      |                                   |
|                                                          | 1746                                 | 1735                              |
| Anthracycline containing regimen                         | 1403(80.49)                          | 1401 (80.7)                       |
| Non-anthracycline containing regimen                     | 343(19.6%)                           | 334(19.3)                         |
| Hormone receptor status (central)                        |                                      |                                   |
|                                                          | 1746                                 | 1735                              |
| Negative (ER and PgR negative)                           | 607 (34.89)                          | 587(33.8%)                        |
|                                                          | 1139 (65.2%)                         | 1148 (66.2)                       |
| Goographical Region                                      |                                      |                                   |
| n                                                        | 1746                                 | 1735                              |
| USA                                                      | 192 (11.0%)                          | 188 (10.8)                        |
| Canada/Western Europe/Australia-New Zealand/South Africa | 1050(60.1)                           | 1060 (61.1*)                      |
| Eastern Europe                                           | 124( 7.19)                           | 136 ( 7.8)                        |
| Rsia Pacific                                             | 346 (19.8)                           | 316 (18.24)                       |
| Latin America                                            | 34(1.9)                              | 35 ( 2.0)                         |
| Protocol Version                                         |                                      |                                   |
| n                                                        | 1746                                 | 1735                              |
| Protocol A                                               | 1299(74.4)                           | 1282 (73.9)                       |
| Protocol Amendment B                                     | 447(25.6%)                           | 453 (26.1)                        |

Program: /opt/B10sTAT/prod/odp11450/r25126a/ah\\_9a973.9as

11JAN2018 15:21

Page l of 1

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 14 Sites of Radiotherapy in Patients who underwent Breast Conserving Surgery by Geographic Region

|                             | GeographicReglon         | GeographicReglon         | GeographicReglon         | GeographicReglon           | GeographicReglon         | GeographicReglon           |
|-----------------------------|--------------------------|--------------------------|--------------------------|----------------------------|--------------------------|----------------------------|
|                             | WesternEurope            | US                       | EasternEurope            | Asia-Pacific               | Latin America            | Totalacrossall Regions     |
| SiteofRadiotherapy          | Ptz(n=778)vs. Pla(n=750) | Ptz(n=100)vs. Pla(n=116) | Ptz(n=62) vs. Pla (n=72) | Ptz(n=165) vs. Pla (n=121) | Ptz(n=13)vs. Pla (n =17) | Ptz(n=1118)vs.Pla (n=1076） |
| Breast                      | 92.7%VS.93.3%            | 91.0% VS.86.2%           | 90.3%VS.90.3%            | 98.2%VS.96.7%              | 92.3% VS.94.1%           | 93.2%6VS.92.8%             |
| Axilla/LNs                  | 30.6% V5. 25.3%          | 22.0% v5. 26.7%          | 41.9% V5.33.3%           | 29.1% V5. 24.0%            | 7.7% VS.35.3%            | 30.0% V5.26.0%             |
| Breastand axilla/LNs        | 30.1% VS. 24.9%          | 22.0% Vs. 25.9%          | 41.9%6VS.33.3%           | 29.1% vs. 23.1%            | 7.7%VS.35.3%             | 29.6%6 VS. 25.6%           |
| Chest wall                  | 1.3%V5.1.1%              | 0 v5.0.9%                | 3.2% v5.1.4%             | 0 v5. 0                    | 0 v5. 0                  | 1.1% V5.9.3%               |
| Chest&axilla/LNs            | 0.8%6 VS. 0.4%           | 0 vs.0.9%                | 1.6% VS.0                | 0 vs. 0                    | 0 vs. 0                  | 0.6%6 Vs. 0.4%             |
| Breast,chest and axilla/LNs | 0.5%vs.0.3%              | 0vs.0.9%                 | 1.6% vS.0                | 0 vs.0                     | 0 vs. 0                  | 0.4%6vS.0.3%               |

Note: patients may be counted in more than one category. For example, a patient counted in the 'Breast &amp; axilla/LNs' category is also counted in both the individualBreast' and Axilla/LNs'categories

WestemEurope alsoincludesCanada,SouthAfrica,AustraliaandNewZealand

Source:ah\\_sa993\\_EUR\\_SB\\_IT;ah\\_sa993\\_USA\\_SB\\_IT;ah\\_sa993\\_EEUR\\_SB\\_IT;ah\\_sa993\\_APA\\_SB\\_IT;ah\\_sa993\\_LAM\\_SB\\_IT.

Table 15 Sites of Radiotherapy in Patients who underwent Mastectomy by Geographic Region

|                             | GeographicRegion                       | GeographicRegion             | GeographicRegion                       | GeographicRegion                      | GeographicRegion                       | GeographicRegion                                   |
|-----------------------------|----------------------------------------|------------------------------|----------------------------------------|---------------------------------------|----------------------------------------|----------------------------------------------------|
| SlteofRadlotherapy          | WesternEurope Ptz（n=514）vs. Pla(n=538) | US Ptz(n=196)vs. Pla(n=1786) | EasternEurope Ptz（n=138）vs. Pla(n=128） | Asia-Pacific Ptz（n=385）vs. Pla(n=436） | LatinAmerica Ptz (n=47) vs. Pla (n=47) | Totalacross all Regions Ptz（n=1280)vs.Pla (n=1327) |
| Breast                      | 4.1% vs.7.4%                           | 13.8%6VS.19.7%               | 9.4% VS. 6.3%                          | 2.6% Vs. 2.5%                         | 2.1% VS. 0                             | 5.6% VS. 7.1%                                      |
| Axilla/LNs                  | 46.1%6 VS.47.6%                        | 35.7%VS.33.7%                | 42.8%6 VS.46.9%                        | 43.1% vS. 40.1%                       | 21.3% vS. 17.0%                        | 42.3% VS.42.1%                                     |
| Breastandaxilla/LNs         | 3.1% vs.5.9%                           | 10.7%6 V5.15.7%              | 8.0% vs.5.5%                           | 2.3% v5. 1.8%                         | 2.1% v5. 0                             | 4.5% v5. 5.7%                                      |
| Chest wall                  | 61.7% VS. 63.8%                        | 50.0% VS. 47.2%              | 34.8% VS.43.0%                         | 47.3% Vs. 44.5%                       | 44.7% VS. 38.3%                        | 52.0% VS. 52.3%                                    |
| Chest&axilla/LNs            | 45.1%VS.45.4%                          | 34.7%6VS.32.6%               | 31.2%VS.34.4%                          | 42.6%6 VS. 39.4%                      | 19.1%VS.14.9%                          | 40.396VS.39.6%                                     |
| Breast,chest and axilla/LNs | 2.7% V5.4.8%                           | 10.7%v5.15.7%                | 2.9%v5.2.3%                            | 2.3%v5.1.8%                           | 0 v5. 0                                | 3.896 V5.4.9%                                      |

Note:patientsmay be countedin more than one category.Forexample,apatient counted in the'Breast&amp;axilla/LNs'category isalso counted inboththe individualBreast'and Axilla/LNs'categonies

Westem Europe alsoincludes CanadaSouthAfrica,Australia andNewZealand.

Source:ah\\_sa993\\_EUR\\_SM\\_IT;ah\\_sa993\\_USA\\_SM\\_IT;ah\\_sa993\\_EEUR\\_SM\\_IT;ah\\_sa993\\_APA\\_SM\\_IT;ah\\_sa993\\_LAM\\_SM\\_IT.

Table 16 Sites of Radiotherapy in Patients with Node-Positive Disease by Geographic Region

|                            | GeographicRegion            | GeographicRegion          | GeographicRegion            | GeographicRegion         | GeographicRegion          | GeographicRegion           |
|----------------------------|-----------------------------|---------------------------|-----------------------------|--------------------------|---------------------------|----------------------------|
| SiteofRadiotherapy         | WesternEurope Ptz(n=778)vs. | US                        | EasternEurope Ptz(n=142)vs. | Asia-Pacific             | LatinAmerica Ptz(n=36)vs. | Totalacrossall Regions     |
|                            | Pla (n=773)                 | Ptz（n=182)vs. Pla (n=182) | Pla (n=142)                 | Ptz（n=365)vs. Pla(n=366) | Pla (n=39)                | Ptz(n=1503)vs.Pla (n=1502) |
| Breast                     | 49.9%6 VS.49.4%             | 36.8%VS.44.0%             | 31.7%VS.31.0%               | 23.3%6VS.16.7%           | 8.3%6VS.20.5%             | 39.1%VS.38.3%              |
| Axilla/LNs                 | 58.4% V5.56.1%              | 50.5%6 V5.47.8%           | 57.7% V5.56.3%              | 57.0% VS. 55.2%          | 30.6%6VS.30.8%6           | 56.4% V5. 54.3%            |
| Breastandaxilla/LNs        | 30.7% VS.27.2%              | 23.6% VS.29.7%            | 24.6%VS.19.0%               | 14.5%VS.9.8%             | 5.6%6VS.12.8%             | 24.896VS.22.1%             |
| Chest wall                 | 36.0%V5.39.5%               | 51.6% V5. 44.0%           | 33.1% V5.38.7%              | 48.8%6 V5. 51.4%         | 58.3%6V5.38.5%            | 41.3% v5.42.8%             |
| Chest&axilla/LNs           | 29.2%6VS.31.2%              | 37.4%VS.31.3%             | 31.0% VS. 31.0%             | 44.1% VS. 46.4%          | 25.0% Vs. 15.4%           | 33.9%6VS.34.5%             |
| Breast,chestand axilla/LNs | 2.2%v5.3.2%                 | 11.5%6v5.14.8%            | 3.5%V5.2.1%                 | 2.2%V5.2.2%              | 0 v5.0                    | 3.4% v5. 4.2%              |

Source:ah\\_sa975\\_NPOS\\_EUR\\_IT:ah\\_sa975\\_NPOS\\_USA\\_IT:ah\\_sa975\\_NPOS\\_EEUR\\_IT:ah\\_sa975\\_NPOS\\_APA\\_IT:ah\\_sa975\\_NPOS\\_LAM\\_IT:ah\\_sa975\\_NPOS\\_IT

Note:patients may be counted in more than one category.Forexample,apatient counted in theBreast&amp;axilla/LNs'category is also counted inboth the individualBreastand Axilla/LNs'categories.

Table 17 Sites of Radiotherapy in Patients with Node-Positive Disease by Geographic Region

|                            | GeographicRegion         | GeographicRegion           | GeographicRegion       | GeographicRegion          | GeographicRegion          | GeographicRegion         |
|----------------------------|--------------------------|----------------------------|------------------------|---------------------------|---------------------------|--------------------------|
|                            | WesternEurope            | US                         | Eastern Europe         | Asia-Pacific              | LatinAmerica Ptz(n=24)vs. | Totalacrossall Regions   |
| SiteofRadiotherapy         | Ptz(n=516)vs. Pla(n=516) | Ptz(n=114) vs. Pla (n=112) | Ptz(n=58)vs. Pla(n=58） | Ptz(n=185)vs. Pla (n=191) | Pla(n=25)                 | Ptz(n=897)vs.Pla (n=902） |
| Breast                     | 68.8%6 V5. 69.6%         | 44.7% v5. 49.1%            | 41.4% vs.50.0%         | 47.0% V5. 35.1%           | 41.7% v5. 32.0%           | 58.8%6 v5.57.4%          |
| Axilla/LNs                 | 4.1% VS. 2.5%            | 0 vs. 3.6%                 | 5.2% Vs. 6.9%          | 3.2% VS.1.0%              | 0vs.8.0%                  | 3.3% Vs.2.8%             |
| Breaslandaxilla/LNs        | 2.1% vS.1.9%             | 0vs.3.6%                   | 3.4%6 VS.6.9%          | 2.2% Vs.0                 | 0vS.4.0%                  | 1.9%Vs.2.1%              |
| Chest wall                 | 9.5% vs. 8.9%            | 3.5% V5. 4.5%              | 5.2% V5.1.7%           | 2.2%6 V5.3.1%             | 0 v5. 12.0%               | 6.7% v5. 6.8%            |
| Chest&axilla/LNs           | 2.1% vs 1.2%             | 0 vs.1.8%                  | 0 vs. 0                | 1.6% Vs. 1.0%             | 0 vs. 4.0%                | 1.6% Vs. 1.2%            |
| Breast,chestand axilla/LNs | 0.2% VS. 0.6%            | 0 vs. 1.8%                 | 0 vs. 0                | 0.5% Vs. 0                | 0 vs. 0                   | 0.2% vs. 0.6%            |

Note:patients maybe countedinmore than 1category.Forexample,apatient countedin theBreast&amp;axilla/LNs'category is alsocountedinboth the individualBreastandAxila/LNs categories.

Westem Europe also includes Canada, South Africa, Australia and New Zealand

Source:ah\\_sa975\\_NNEG\\_EUR\\_IT:ah\\_sa975\\_NNEG\\_USA\\_IT:ah\\_sa975\\_NNEG\\_EEUR\\_IT:ah\\_sa975\\_NNEG\\_APA\\_IT;ah\\_sa975\\_NNEG\\_LAM\\_IT;ah\\_sa975\\_NNEG\\_IT

<div style=\"page-break-after: always\"></div>

Table 18 Randomization Stratification Factors by Treatment Regimen, Adjuvant Hormone Therapy and Central Hormone Receptor Positive Cohort (ITT Population)

Contral Hemene Rooeptor Poaitive Cohort, Itr Pepulatien Prot00ol: B1G 4-11/3025126/10049396

<!-- image -->

|                                                          | Fextuzumab Trastuzumsb Chemotherapy (N=1311)   | Placebo + Trastuzumab + Chemotherapy (N=1337)   |
|----------------------------------------------------------|------------------------------------------------|-------------------------------------------------|
| Nodal status                                             |                                                |                                                 |
|                                                          | 1311                                           | 1337                                            |
| 0 positive nodes and tumor c= lem*                       | 34 (2.61)                                      | 35 (2.6)                                        |
| 0 positive nedes and tumor > lem*                        | 472 ( 36.04)                                   | 483 ( 36.1%)                                    |
| 1-3 positive nodes                                       | 507( 38.74)                                    | 523 ( 39.1)                                     |
| 2 4 positive nodes                                       | 299 ( 22.74)                                   | 296 ( 22.14)                                    |
| Adjuvant chemotherapy regimen (randomized)               |                                                |                                                 |
| n                                                        | 1311                                           | 1337                                            |
| Anthracyeline containing regimen                         | 1013 ( 77.34)                                  | 1056 ( 79.06)                                   |
| Non-hnthrhcyeline conthining reginon                     | 298 ( 22.74)                                   | 281( 21.04)                                     |
| Hermone reooptor status (eentral)                        |                                                |                                                 |
|                                                          | 1311                                           | 1337                                            |
| Positive (ER and/or FgR positive)                        | 1311 (100.04)                                  | 1337 (100.04)                                   |
| Geographical Region                                      |                                                |                                                 |
| n                                                        | 1311                                           | 1337                                            |
| UBA.                                                     | 169 ( 12.91)                                   | 159 ( 11.96)                                    |
| Canada/Hestern Europe/kustralia-Nen Zesland/South Africa | 765( 56.41)                                    | 781( 58.49)                                     |
| Easterm Europe                                           | 106(0.14)                                      | 112 (9.4)                                       |
| Asia Paeifie                                             | 249 ( 19.04)                                   | 262 ( 19.64)                                    |
| Latin kmerica                                            | 22 1.74)                                       | 23 (1.75)                                       |
| Protocol Version                                         |                                                |                                                 |
| n                                                        | 1311                                           | 1337                                            |
| Protoeol A                                               | 998 ( 76.1%)                                   | 1021 ( 76.4)                                    |
| Protocol Amoncmont B                                     | 313 ( 23.94)                                   | 316 ( 23.64)                                    |

Progr6m: /ept/B1091Ar/prod/etp11450/r25126a/ah\\_sa973.sas

Output: /opt/B1o9TAr/prod/edl1450g/j25126a/reports/sh\\_s4970\\_TRr1P\\_CHRP\\_AD0HY\\_IT.out

11JAN2018 15:21

Page l of 1

## Objectives

## Outcomes/endpoints

## Primary objective/endpoint

The  primary  efficacy  endpoint  was  IDFS  (Invasive  Disease-Free  Survival),  defined  as  the  time  from randomization to the first occurrence of one of the following events:

- -Ipsilateral invasive breast tumor recurrence (i.e., an invasive breast cancer involving the same breast parenchyma as the original primary lesion)
- -Ipsilateral local-regional invasive breast cancer recurrence (i.e., an invasive breast cancer in the axilla, regional lymph nodes, chest wall, and/or skin of the ipsilateral breast)
- -Distant recurrence (i.e., evidence of breast cancer in any anatomic site - other than the two above mentioned  sites-that  was  either  histologically  confirmed  or  clinically  diagnosed  as  recurrent invasive breast cancer)
- -Death attributable to any cause including breast cancer, non-breast cancer, or unknown cause (but cause of death was specified if at all possible)

<div style=\"page-break-after: always\"></div>

- -Contralateral invasive breast cancer

All second primary non-breast cancers and in situ carcinomas (including DCIS and LCIS) and non-melanoma skin cancer were excluded as an event in this endpoint. If a patient experienced an event on the same day as randomization their time from randomization to event was set as 1 day. Patients who did not have an event at the time of data analysis were censored at the date they were last known to be alive and event-free.

Note: this definition of IDFS (which excludes second primary non-breast cancers as events) is not the same as IDFS defined by Hudis et al. (2007) (which includes second primary non-breast cancers as events).

## Secondary objectives/endpoints

The secondary efficacy endpoints included IDFS-including second primary non-breast cancer (IDFS-SPNBC), disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), and distant recurrence-free interval (DRFI).

- -IDFS-SPNBC,  was  defined  in  the  same  way  as  IDFS  but  including  second  primary  non-breast invasive cancer as an event (with the exception of non-melanoma skin cancers and in situ carcinoma of any site). This definition of IDFS is often the primary endpoint for breast cancer adjuvant therapy trials since i) it can be difficult to distinguish second primaries from breast cancer metastasis and ii) second cancers may be treatment related.
- -DFS was defined as the time between randomization and the date of the first occurrence of an invasive  disease-free  survival  event  including  second  primary  non-breast  cancer  events  or contralateral or ipsilateral DCIS. Patients who did not have an event at the time of data analysis were censored at the date last known to be alive and event free.
- -OS was defined as the time from randomization to death attributable to any cause.  Patients who were alive (including lost to follow-up) at the time of the analysis were censored at the last known alive date.
- -RFI was defined as the time between randomization and the date of local, regional or distant breast cancer recurrence. Patients who did not have a recurrence event at the time of data analysis were censored at the date last known to be alive or at date of death.
- -DRFI  was  defined  as  the  time  between  randomization  and  the  date  of  distant  breast  cancer recurrence. Patients who did not have a distant recurrence event at the time of data analysis were censored at the date last known to be alive or at date of death. DRFI was included since distant recurrence was anticipated to account for the majority of first disease recurrence events based on previous published trials.

## Exploratory efficacy endpoints

An assessment of breast cancer-free interval (BCFI) was also performed. BCFI was defined as the time between  randomization  and  the  date  of  local,  regional  or  distant  breast  cancer  recurrence,  invasive contralateral breast cancer or DCIS (contralateral or ipsilateral). Patients who did not have a recurrence event at the time of data analysis were censored at the date when they were last known to be alive or at their date of death.

HRQoL was defined as symptoms of therapy, patient functioning, and global health status and assessed by the EORTC QLQ-C30, QLQ-BR23, and EQ-5D questionnaires. Patients were to complete patient-reported outcome (PRO) measures until recurrence or until 36 months after randomization, regardless of whether the patient completed study treatment or not. The timing of the chemotherapy PRO assessment was tailored to the patient's treatment regimen to ensure that PROs were assessed at key time points, namely the end of anthracycline treatment (only in patients receiving an anthracycline-based regimen), the end of taxane therapy (all patients), and the end of HER2-targeted treatment (all patients).

<div style=\"page-break-after: always\"></div>

## Assessment of disease

Physical examinations were performed at screening, during the HER2-targeted treatment period (every 3 months at a minimum) and at the end of treatment safety follow-up visit. Thereafter, physical examinations were performed at least every 3 months in Year 2 after the start of treatment, every 6 months during Year 3-5, and annually during Year 6-10.

A  mammogram  or  breast  magnetic  resonance  image  (MRI)  and  chest  X-ray/computed  tomography (CT)/MRI/positron emission tomography (PET) had to be completed within 6 months prior to randomization. Bone scan and liver imaging was performed at screening if clinically indicated to exclude metastatic disease.

Mammograms  or  breast  MRIs  were  repeated  at  yearly  intervals,  as  per  routine  clinical  practice.  All mammograms/breast MRIs were bilateral, unless the patient had had a mastectomy. After the screening period, chest X-rays/CT/MRI/PET, bone scan, and liver imaging were only performed if clinically indicated. Additional  assessments  could  be  performed  at  any  time,  if  clinically  indicated  (for  suspected  disease recurrence).

Patients who had disease recurrence at any time were followed for survival and new relapse events, annually (starting 1 year after the first relapse) until Year 10 after randomization of the last patient. Post-recurrence anticancer-related therapies were also collected.

## Confirmation of Disease Recurrence

The diagnosis of a first breast cancer recurrence or second primary cancer was made only when clinical, radiological and laboratory findings met specific 'acceptable' criteria as defined in the protocol. In cases of diagnostic  doubt  (e.g.,  ill-defined,  palpable  mass  in  an  irradiated  breast),  histological  or  cytological confirmation  of  recurrence  was  to  be  obtained  whenever  possible.  If  a  patient  developed  a  suspected recurrence that led to death before relapse was confirmed, efforts were made to obtain an autopsy report.

The earliest date of diagnosis of recurrent disease was recorded, based on clinical, radiological, histological or cytological evidence. The date of recurrence of disease was the date of the first diagnosis of a lesion (i.e., an objective finding), not the date of occurrence of the first symptom. Recurrent disease included local, regional, distant recurrence and contralateral breast cancer (see Table below). The following events were not considered recurrent disease as per protocol: ipsilateral and contralateral lobular carcinoma in situ (LCIS); ipsilateral and contralateral ductal carcinoma in situ (DCIS); carcinoma in situ of the cervix; and basal or squamous cell carcinoma of the skin.

Second primary non-breast malignancies had to be confirmed histologically and were reportable as SAEs throughout the study. Myelodysplastic syndrome was not considered a progression event but had to be reported as an SAE.

<div style=\"page-break-after: always\"></div>

| Types of recurrent disease a                                                                 | Acceptable methods of confirmation of recurrence                                                                                                                                                                                                             |
|----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Local invasive recurrence                                                                    |                                                                                                                                                                                                                                                              |
| In the ipsilateral breast after previous lumpectomy                                          | Positive histology or cytology                                                                                                                                                                                                                               |
| Ipsilateral after previous mastectomy                                                        | Positive histology or cytology                                                                                                                                                                                                                               |
| Regional recurrence                                                                          | Positive histology or cytology, or Chest X-ray, CT-scan or MRI (especially in case of internal mammary lymph nodes if no biopsy was performed)                                                                                                               |
| Distant recurrence Skin, subcutaneous tissue, and lymph nodes (other than local or regional) | Positive cytology, aspirate or biopsy, OR radiological (by CT scan or MRI or ultrasound) evidence of metastatic disease                                                                                                                                      |
| Bone                                                                                         | X-ray, CT scan, or MRI evidence of lytic or blastic lesions consistent with bone metastasis, OR bone scan (required additional radiological investigation, alone not acceptable in case of diagnostic doubt), OR biopsy proof of bone metastases or cytology |
| Bone marrow                                                                                  | Positive cytology or histology or MRI scan                                                                                                                                                                                                                   |
| Lung                                                                                         | Radiologic evidence of multiple pulmonary nodules consistent with pulmonary metastases; OR positive cytology or histology (practically rarely performed with the exception of solitary nodules)                                                              |
| Liver                                                                                        | Abdominal CT scan, liver scan, ultrasound, or MRI consistent with liver metastases, OR liver biopsy or fine needle aspiration.                                                                                                                               |
| Central Nervous System                                                                       | Positive MRI or CT scan, usually in a patient with neurologic symptoms, OR biopsy or cytology                                                                                                                                                                |
| Contralateral invasive breast cancer                                                         | Positive cytology or histology                                                                                                                                                                                                                               |
| Second primary malignancy (breast or other cancer)                                           | Histology                                                                                                                                                                                                                                                    |

## Sample size

It is assumed that the true HR is 0.75. In order to have 80% power to identify a statistically significant difference on a 2-sided 5% significance level, approximately 379 IDFS events are required.

A total of 3806 patients was initially planned assuming a 10% drop-out rate.

During the enrollment phase, it was observed that the monthly recruitment rate was more than 50% higher than expected an, the proportion of patients with node-negative disease was nearly twice that expected based on the BCIRG 006 study, resulting in a population inconsistent with the protocol assumptions upon which the protocol design was based. Hence, the protocol was amended to cap recruitment of patients with node-negative  disease,  the  total  planned  sample  size  was  increased  to  4800  patients,  and  statistical

<div style=\"page-break-after: always\"></div>

assumptions were adjusted accordingly. The decision to amend the protocol and changes to the sample size were  made  on  the  basis  of  overall  recruitment  rates  into  the  study,  without  unblinding  of  any  study personnel.

Original protocol (Version A dated 28 June 2011) recruitment rate and event rate assumptions were as follows:

- It was foreseen when the protocol was designed that the study would enroll a similar population to the adjuvant Herceptin trial BCIRG 006 (Slamon et al, 2006; Slamon et al, 2009). Therefore, based on the data from that trial, the Kaplan-Meier estimate of IDFS at 3 years for the Herceptin control group for this study was estimated to be 88%, regardless of the chemotherapy regimen (with annual decreases in Kaplan-Meier estimates of 2% during the first year after randomization, 5% during Years 2 and 3, and 2% during Year 4 and beyond).  Based on this and a projected monthly accrual rate of 0.29 patients at 700 sites, it was estimated that with 3806 patients, enrolled in approximately 27 months, 379 IDFS events would occur at around 55 months.

The  following  revised  sample  size  assumptions  became  applicable  with  Protocol  Version  B  (dated  20 November 2012):

-  The  annual  decrease  in  Kaplan-Meier  estimates of  the  IDFS  function  in  the  Herceptin  control  group (regardless  of  the  chemotherapy  regimen)  was  anticipated  to  be  1.9%  during  the  first  year  after randomization, 4.5% during Year 2, 4.4% during Year 3, and 1.8% during Year 4 and beyond. Therefore, the Kaplan-Meier estimate of IDFS at 3 years for the Herceptin control group was 89.2%. These assumptions were based on 5-year follow up data from BCIRG 006. Under the alternative hypothesis and with the assumption that IDFS for both groups was exponentially distributed, the magnitude of treatment effect in terms of increase in IDFS at 3 years was 2.6%, meaning a Kaplan-Meier estimate of IDFS at 3 years for the Perjeta group of 91.8%. The smallest estimated difference detectable at a 5%, 2 sided significance level was HR= 0.818, under which the magnitude of treatment effect would be 1.9%. Under these assumptions, it was planned that 4800 patients would be enrolled over an estimated 25 months, and assuming a 10% drop-out rate, the 379 IDFS events required for the primary analysis would occur at 46 months.

## Randomisation

A total of 4805 patients were randomized in a 1:1 ratio to one of the two treatment arms using a web-based randomization system. Patients were stratified according to nodal status (0 positive nodes and tumour ≤ 1cm, 0 positive nodes and tumour &gt; 1 cm, 1-3 positive nodes, ≥ 4  positive  nodes),  type  of  standard adjuvant chemotherapy regimen (anthracycline-based versus non-anthracycline-based), hormone receptor status  (ER  and  PgR  negative,  ER  and/or  PgR  positive),  geographical  region  (USA,  Canada/Western Europe/Australia-New-Zealand/South Africa) and protocol version (Protocol A versus Protocol Version B). Protocol version (A versus B) was introduced as a stratification factor at the time of the first protocol amendment (Version B, dated 20 November 2012).

## Blinding (masking)

The trial was a double-blind placebo-controlled trial. Pertuzumab and placebo were both given as IV. The formulation of the placebo pertuzumab was equivalent to pertuzumab but without the active agent.

Unblinding  should  only  be  considered  if  deemed  essential.  For  instance,  the  sponsor  will  not  routinely unblind the investigator in case of for SAEs. Unblinding for ongoing safety monitoring is performed through an independent data-coordinating centre. All entities directly involved in the study will remain blinded until the final analysis of the primary efficacy endpoint.

<div style=\"page-break-after: always\"></div>

## Statistical methods

## Analysis strategy:

The primary analysis takes place after 379 IDFS events have occurred. If the result of the analysis is statistically significant, then  secondary  endpoints  are  tested  in  the following hierarchical order: IDFS-SPNBC, DFS, and OS. The secondary endpoints RFI and DRFI will be tested but not included in the multiplicity adjustment.

The primary analysis after 379 IDFS events is the first interim analysis for OS. In addition, two interim analyses will be performed approximately 4-5 years, and 7-8 years, after last patient was randomized. The final  OS  analysis  will  be  performed  when  640 OS events have occurred. Thus, there are in total 4 OS analyses. The overall alpha-level for these analyses will be controlled at 0.05 according to O'Brien-Fleming Lan-DeMets.

Table 19 Planned OS Analysis Timings

| Analysis   | Timing of Analysis                                       | Percent   | Adjusted thwo- Information sided alphalevel   |   Cumulabive Power |
|------------|----------------------------------------------------------|-----------|-----------------------------------------------|--------------------|
| 1-atIDFSfi | 379 IDFSevents (-2-3 yearsafer Lastpatient randomized)   | 26%       | 10000'OD                                      |             96     |
| 2d         | 45years afterLastpatient randomized                      | 4996      | 0.0027                                        |             17.496 |
| 3d         | 7S years after Last patient randomized                   | 7096      | 0.0139                                        |             47.996 |
|            | 640 OS events (~9-10 years after Last patient randomized | 10096     | 0.0453                                        |           9608     |

If the OS analyses are stopped early for efficacy, safety follow-up will still continue until approximately 10 years after randomization of the last patient.

At the time of each of the 2 nd , 3 rd , and 4 th OS analysis, exploratory analyses of IDFS for the ITT population and in key demographic subgroups will also be performed.

## Endpoints:

The primary endpoint as well as all secondary and exploratory endpoints are time-to-event endpoints, which are defined as the time from randomization to first occurrence of the relevant event.

## Analysis populations:

ITT : All  randomized  subjects.  Analysed  as  randomized.  All  efficacy  analyses  will  be  based  on  the  ITT population.

Safety Population: All randomized subjects who have received any amount of study drug. Analysed as treated.  All safety analyses will be based on the Safety Population.

## Missing data handling:

For the time-to-event analyses, patients not experiencing an event will be censored at the date when they were last known to be alive and event-free. Randomized patients with no post-baseline data will be censored at the day of randomization plus 1 day. Other ways of censoring will be explored in the sensitivity analyses for the primary endpoint.

## Primary endpoint:

## Statistical analysis of primary endpoint:

The primary endpoint, IDFS, defined as time from randomization to first occurrence of either ipsilateral invasive  breast  tumor  recurrence,  ipsilateral  local-regional  invasive  breast  cancer  recurrence,  distant

<div style=\"page-break-after: always\"></div>

recurrence, death, or contralateral invasive breast cancer, will be compared between the two treatment groups using the stratified log-rank test. The stratification factors are the same as the ones used in the randomization, apart from geographical region, which is not included. The Kaplan-Meier plot of the IDFS rates will be presented, and so will the hazard ratios estimated from the stratified Cox proportional hazards model with the corresponding 95% confidence intervals.

## Sensitivity analyses:

Two  types  of  sensitivity  analyses  are  planned.  First  descriptive  analyses  to  assess  whether  there  are imbalances in number of assessments or in follow-up time between the two treatment arms. Then analyses to assess the robustness of the primary endpoint with respect to the impact of imbalances. The specific descriptive analyses are:

1. Kaplan-Meier plot of time to censoring
2. Number of assessments per treatment group
3. Reason for withdrawal
4. Time between event and previous assessment

The analysis to assess robustness, all using the ITT population and the same analysis method as the primary analysis, unless otherwise stated, are:

1. Censoring patients when they begin a new anti-cancer therapy
2. Considered start of new anti-cancer therapy as event
3. Censoring patients who withdraw from the protocol-specified assessments
4. Considering events to have occurred at the planned assessment date for patients who have missed this date but relapsed or died later
5. Considering patients who withdraw due to toxicity as having an event one day after they were last known to be event free
6. Considering patients with incomplete follow-up according to the protocol-defined schedule as having an event one day after the tie they were event free
7. The primary analysis but without stratification
8. Including actual chemotherapy regimen as stratification factor instead of planned chemotherapy regimen
9. Including stratification factors reported in the IxRS system instead of the ones reported in the eCRF

Statistical  analysis  of  secondary  endpoints:  analysed  in  analogy  with  the  primary  endpoint.  Similar sensitivity analyses are also planned.

Statistical analysis of exploratory endpoints: analysed in analogy with the primary endpoint.

## Results

## Participant flow

A total of 6263 patients were screened for the study. Patient enrollment took place over a period of 22 months, from 08 November 2011 (first patient in) to 31 August 2013 (last patient in), in 548 centers from 42 countries. Of the patients screened, 4805 patients were randomized in a 1:1 ratio to one of the two treatment arms (2400 patients to the Ptz+H+Chemo arm and 2405 patients to the Pla+H+Chemo arm); see

<div style=\"page-break-after: always\"></div>

Figure 10. The most common cause of screen failure was lack of confirmation of HER2-positivity by the central laboratory, which accounted for approximately half of the screen failures.

Figure 10 Disposition of Patients

<!-- image -->

H=Herceptin;FUP=followup:Pla=placebo;Plz=Perjeta

Patlent No. 250848-2508480020 in the Pla+H+Chemo am was randomized but not included in the ITT population (due to provislon of some false personal information by the patlent) Source: t\\_ds\\_pp\\_RA:I\\_ds\\_xrs; t\\_ds\\_pstat\\_IT: t\\_ef\\_fut\\_IT and Iist of screen fallures

Of the randomized patients, 22 in the Ptz + H + Chemo arm and 13 in the Pla + H + Chemo did not receive any study treatment. In the majority of cases, in both treatment arms, the reason for not receiving any study treatment was the patient's decision to withdraw from the study. Of the 4805 patients randomized, 14 patients in the Ptz + H + Chemo arm and 24 patients in the Pla + H + Chemo arm received at least one dose of non-randomized treatment in error. The 14 patients in the Ptz + H + Chemo arm received only 1 cycle of placebo in error and, therefore, remain in the pertuzumab arm for safety analyses. However, the 24 patients in the Pla + H + Chemo arm who received at least 1 dose of pertuzumab are included in the Ptz + H + Chemo arm for safety analyses.

<div style=\"page-break-after: always\"></div>

Table 20 Patient Disposition during Treatment Period by Treatment Regimen (Randomized Patients)

<!-- image -->

Output:/opt/BI08TAT/prod/cdli450g/j25126a/reports/t\\_ds\\_Pp\\_RA.out

25FEB2017 11:54

At the time of clinical cut-off, 2368 patients (98.7%) in the Ptz+H+Chemo arm had entered the follow-up period, and 370 (15.4% of randomized patients) had subsequently discontinued from follow-up. Similarly, in the Pla+H+Chemo treatment arm 2381 patients (99.0%) had entered the follow-up period and 399 (16.6%) had subsequently discontinued. The main reasons for discontinuing during the follow-up period were withdrawal by patient (6.8% of patients in the Ptz+H+Chemo arm vs. 6.2% in the Pla+H+Chemo arm) and recurrence of disease (5.5% of patients in the Ptz+H+Chemo arm vs. 7.1% in the Pla+H+Chemo arm).

| Status                                        | Bertusumsb+ Trastusumsb Chemotherapy (N=2400)   | Bertusumsb+ Trastusumsb Chemotherapy (N=2400)   | Placebo+ Trastusimsb Chemotherapy (N=2404)   | Placebo+ Trastusimsb Chemotherapy (N=2404)   |
|-----------------------------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------|----------------------------------------------|
| Number entering follow-up period 2368 (98.7t) |                                                 |                                                 |                                              | 2381(99.0)                                   |
| Conpleted Follow-up                           | D                                               |                                                 | D                                            |                                              |
| Digcontinued from Follow-up                   | 370                                             | (15.43)                                         | 668                                          | (16.6)                                       |
| Pdverse event                                 | 10                                              | 0.4)                                            | 16                                           | 0.7#1                                        |
| Death                                         | 17                                              | (0.7)                                           | 17                                           | 0.74)                                        |
| Lost to follow-up                             | 19                                              | 0.84)                                           | 20                                           | 0.8)                                         |
| Fhysician decision                            | 10                                              | 0.44)                                           | 8                                            | 0.34)                                        |
|                                               | 132                                             | 5.5)                                            | 171                                          | 7.131                                        |
| Recurrence of disease                         |                                                 |                                                 | 1                                            | 0.54)                                        |
| Contralateral breastcancer                    | 5                                               | 0.2)                                            | 148                                          | 6.2#)                                        |
| Withdrawal by subject                         | 163                                             | 6.8)                                            |                                              |                                              |
| Other                                         | 14                                              | 0.6)                                            | 自                                            | 0.31                                         |

<!-- image -->

## Recruitment

Patient enrollment took place over a period of 22 months, from 08 November 2011 (first patient in) to 31 August 2013 (last patient in), in 548 centers from 42 countries. The top recruiting countries were the United States (US), France and Germany, each recruiting more than 450 patients. Only three countries (Argentina, El Salvador, and Slovenia) recruited less than 10 patients. Individual centers recruited between 1 and 94 patients. The top recruiting individual centers were in China (94 patients), South Korea (59 patients) and Poland (51 patients).

<div style=\"page-break-after: always\"></div>

## Conduct of the study

There were three amendments to the study protocol. A summary of the protocol amendments, including the rationale and key changes, is provided in Table 22. Version A dated 28 June 2011 was the original protocol.

Table 22 Summary of Protocol Amendments

<!-- image -->

| Protocol Amendment (Date)          | Rationale and Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Version B (dated 20 November 2012) | of recruitment of node-negative patients. Statistical assumptions in the negative/node-positive patients and recruitment rates seen in prior Herceptin adjuvant studies (particularly BCIRG-006). However, the patient population enrolled in APHINITY in September 2012 was not consistent with these assumplions. Therelore, the trial sample size was increased from N = 3806 to N = 4800 and node-negative patients were no longer permitted to enroll. The recruitment period was adjusted (from 27 to 25 months) and a clause was included to ensure that the primary analysis did not take place until at least 30 months after the last patient enrolled. for Version B and include the following. The time from randomization to first treatment was increased from 7 weeks to 8weeks to allowpatientsmore time to enter the study. The number of cenlers was reduced from 700 to 600. The number of cycles of FEC/FAC was made more flexible (3 or 4) to more closely reflect local practice. line with protocol-specified endpoints. The minimum observation period after administration of Perjela was adjusted to align with the current Perjeta label. The order of administration of TCH was updated in line with current practice, in addition to clarifying the dose and time period of administration. Criteria for highly effective contraception were adjusted to include surgical sterilization and to allow patients with a previously implanted progesterone-coated intra-uterine device to continue to use this for therapy was added. Arange of clarifications were added including to the eligibility criteria (examples of concurrent serious diseases added), the requirements for patients undergoing sentinel lymph node biopsies, the reporting of concomitant medications and prior treatments for breast cancer, the information to be collected at the time of partial withdrawal from the study.and to the timing of assessments and sample collection |

FAC = Slandard therapy for breast cancer consisting of 5-fluorouracil, doxorubicin and cyclophosphamide FEC = Standard therapy for breast cancer consisting of 5 fluorouracil, epirubicin and cyclophosphamide; TCH= docetaxel (Taxotere°), carboplatin and Herceptin

<div style=\"page-break-after: always\"></div>

## Summary of Protocol Amendments (Cont.)

AE=adverse event; IMP=Investlgatlonal medlcinal product

<!-- image -->

| Protocol Amendment (Date)         | Rational and Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Version C (dated 3 December 2013) | This amendment consisted mainly of clarifications, corrections of minor inconsistencies and minor adjustments, as follows: A 3-day window for the last dose of targeted therapy was added at the end of 52 weeks. The IIMP terminology was clarified to refer specifically to Perjeta ('targeted treatment' referred to Perjeta + Herceptin; 'study drugs' referred to Perjeta + Herceptin + chemotherapy). Due to multiple queries from sites, the language associated with the Investigators' choice of adjuvant chemotherapy was revised, and information on excluded anli-cancer agents was added. Follow-up of AEs was clarified (until resolution or end of study); also the assessment schedules for patients according to treatments received. Footnotes to the schedule of assessment tables were also added or revised, for example relating to the requirements for yearly mammograms Mentions of optional cores from the original tumor block for non- heritable factors were removed Additional protocol revisions are detailed in the protocol amendment history for Version C. |
| Version D (2 February 2015)       | This amendment was made primarily to include details of enhanced measures for reporting of pregnancies that occur during study treatment or within 6 months after completion of Perjeta treatment. In addition, the following changes were made: The washout period for Herceptin was increased to 7 months based on updated half-life data for trastuzumab Related wamings (pregnancy exclusion and cardiac toxicity risk) were revised based on the updated Herceptin washout period Endocrine therapy recommendations were revised (to allow endocrine therapy administration as per local practice) An additional plasma sample at disease recurrence was added Various clarifications were made (to sample collection, definitions and reporting requirements). Additional protocol updates are detailed in the protocol amendment history for Version D                                                                                                                                                                                                                                 |

## Protocol deviations

Major protocol deviations were reported in relation to inclusion/exclusion criteria, and on study procedures and assessments. Approximately 28% of patients in each treatment arm had at least one major protocol deviation reported, with a similar incidence observed in the two treatment arms, regardless of the protocol deviation category (Table 23). The most common deviations were: time interval between definitive surgery for breast cancer and randomization outside protocol-specified criteria; inability to start treatment within 1 week  of  randomization  (an  inclusion  criterion);  completion  of  all  necessary  baseline  laboratory  and radiographic investigations prior to randomization (an inclusion criterion); and abnormal laboratory results immediately prior to randomization (an exclusion criterion).

Of note, one major protocol deviation led to a patient being excluded from both the efficacy and safety analysis  populations.  This  patient  (Patient  2508480020)  was  excluded  after  she  had  completed  study treatment because she was found to have used some false personal information when consenting to the

<div style=\"page-break-after: always\"></div>

study. The patient did this in an attempt to use her sister's medical insurance (as she did not have medical insurance herself). This patient does not appear in Table 23 and no safety or efficacy data from this patient are included in this report, as they are considered unreliable.

Two patients were randomized despite the presence of metastatic disease at baseline. Patient 2324810007 did not start study treatment and Patient 2470700009 completed study treatment. For both patients, a decision was made not to consider them as having an IDFS event in the primary analysis. For all other efficacy endpoints, except for overall survival, the patient was censored at the date of randomization. A listing of patients with protocol deviations was also provided, but is not shown here.

Table 23 Major Protocol Deviations by Treatment Regimen, Randomized Patients

Prot0co1: BIG 4-11/B025126/10C4939G

|                                                                                                                                                                                                     | Pertuzumab + Trastuzumab + Chemotherapy (N=2400)   | Placebo + Trastuzumab + Chemotherapy (N=2404)   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|-------------------------------------------------|
| No. of Patients with at least one Major Protocol Deviation                                                                                                                                          | 674 (28.1)                                         | 688 (28.61)                                     |
| Protocol Deviations Number of Major Inclusion Criteria Deviations                                                                                                                                   | 310                                                | 308                                             |
| Number of Major Exclusion Criteria Deviations                                                                                                                                                       | 192                                                | 211                                             |
| Number of Major On-study Doviations                                                                                                                                                                 | 402                                                | 432                                             |
| No. Violating at least one Inclusion Criterion Deviation                                                                                                                                            | 285 (11.94)                                        | 280 (11.64)                                     |
| Baseline LVeF >=55t measured by echocardiography (preferred) or MuGA scan                                                                                                                           | 3 ( 0.14)                                          | 9 (0.40)                                        |
| Conpletion of all ncccssary baseline laboratory and radiologic investigations prior to randomization.                                                                                               | 101 (4.24)                                         | 109 ( 4.54)                                     |
| HER2-positive breast cancer confirmed by a central laboratory.                                                                                                                                      | 0                                                  | 1 (<0.14)                                       |
| candomisation at lcast3 wceks but no more than 7 wcoks and patient is willing and able to start treatment within                                                                                    | 123 ( 5.16)                                        | 114 (4.74)                                      |
| 1 week of randomization Non-metastatic operable primary invasive carcinoma of the breast that is Adequately excised                                                                                 | 0                                                  | 2 (≤0.14)                                       |
| Non-metastatic operable primary invasive carcinoma of the breast that is Histologically confimed                                                                                                    | 1 (<0.16)                                          | 0                                               |
| node ncqative (pNo)andeither tumor size <o lom or for 0.5cm must be histologic/nuclear grade 3 or negative ER                                                                                       | 12 ( 0.5)                                          | 8( 0.34)                                        |
| and PgD or age <35 years Signed informed consent.                                                                                                                                                   | 30( 1.34)                                          | 24 ( 1.04)                                      |
| Women of childbearing potential (or male partners) agrce to use highly-effective, non-hormonal fom of contraception during study treatment and for at least 6 months after the last study treatment | 40( 1.76)                                          | 41 ( 1.7%)                                      |
| No.Violating at least one Major Exclusion Criterion Total Mumber of Patients with at least one Major Exclusion Deviation                                                                            | 189 ( 7.90)                                        | 200 (8.34)                                      |
| Any clinical T4 tumor as defined by TNM, including inflammatory breast cancer.                                                                                                                      | 1 (<0.10)                                          | 0                                               |
| prior_to randomization:_Total bilirubin: ALAT and/or AsAT; ALP; Serum creatinine; WBC; ANC; Platelets.                                                                                              | 107 (4.54)                                         | 113 (4.74)                                      |
| Any,previous systemic chemotherapy (eg, neo-adjuvant or adjuvant) for cancer OR radiation therapy for cancer                                                                                        | 1 (<0.10)                                          | 1 (<0.11)                                       |
| History of any prior (ipsi- and/or contralateral) invasive breast carcinoma.                                                                                                                        | 0                                                  | 2(<0.1)                                         |
| History of non-breast malignancies within the 5 years prior to study entry (with exceptions)                                                                                                        | 1 (<0.10)                                          | 0                                               |
| Pregnant, lactating or women of childbearing potential without a negative prcgnancy test (serun), within 7 days prior to randomization, irrespective of the method of contraception used            | 80(3.34)                                           | 90( 3.74)                                       |
| Serious cardiac iilness or medical conditions.                                                                                                                                                      | 2 (<0.14)                                          | 5 ( 0.24)                                       |

Table continues

<div style=\"page-break-after: always\"></div>

## Major Protocol Deviations by Treatment Regimen, Randomized Patients (cont.)

Major Protocol Deviations by Treatment Regimen,Randomized Patients Protoco1: BIG 4-11/B025126/T0C4939G

|                                                                                                                  | Pertuzumab + Trastuzumab Chemotherapy (N=2400)   | Placebo + Trastuzumab + Chemotherapy (N=2404)   |
|------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|-------------------------------------------------|
| No.Violating at least one On-study Criterion Total Number of Patients with at least one Major On-study Deviation | 332 (13.86)                                      | 340(14.1)                                       |
| 2 or more consecutive LVeF assessments missed                                                                    | 18 0.8%)                                         | 19 0.89)                                        |
| 2 or more consecutive visits missed                                                                              | 7 0.36)                                          | 9 0.4)                                          |
| Biomarker sample not taken prior to first dose                                                                   | 40 (1.7%)                                        | 24 1.0号)                                        |
| Chemotherapy given despite ANc <10oo (paclitaxel)                                                                | 1 (<0.1)                                         | 0                                               |
| Chemotherapy given despite ANC <1500 (docetaxel)                                                                 | 9 0.48)                                          | 16 0.76)                                        |
| Chemotherapy given if ANC or platelets not known                                                                 | 26 1.1)                                          | 20 (0.8)                                        |
| Completion of baseline assessments (other)                                                                       | 0                                                | 1 (<0.1号)                                       |
| Did not receive chemotherapy                                                                                     | 3 (0.1)                                          | 1 (<0.1)                                        |
| Dosage: Not modified according to LVEF algorithm                                                                 | 2 (<0.16)                                        | 5 (0.2)                                         |
| Dosage: Overdosage - pertuzumab                                                                                  | 0                                                | 1 (<0.1$)                                       |
| Dosage: Overdosage - trastuzumab                                                                                 | 8 0.30)                                          | 3 (0.1号)                                        |
| Dosage: Treatment beyond 1 year                                                                                  | 50 2.1)                                          | 47 (2.0)                                        |
| End of anthracycline LVEF not done                                                                               | 2 (<0.18)                                        | 1 (<0.16)                                       |
| Inadequate endof anthracycline LWEF or not done                                                                  | 33 [1.4)                                         | 32 (1.3)                                        |
| Missed pregnancy (if inadequate contraception)                                                                   | 10 0.48)                                         | 11 0.56)                                        |
| No HER2 targeted treatment administered                                                                          | 10 0.46)                                         | 9 0.4)                                          |
| Not following the cardiac algorithm                                                                              | 11 0.58)                                         | 15 0.68)                                        |
| Not repeating LVEF as per cardiac algorithm                                                                      | 5 0.2)                                           | 11 0.5)                                         |
| OS1 No HER2 targeted treatment administered                                                                      | 2 (<0.16)                                        | 3 0.1)                                          |
| 0Sl Received incorrectly assigned ptz/pla                                                                        | 0                                                | 1 (<0.1)                                        |
| 0S10 Missed pregnancy (if inadeguate contraception                                                               | 3 (0.16)                                         | 4 (0.26)                                        |
| OS5 Inadequate end of anthracycline LVEF or not do                                                               | 1 (<0.1号)                                        | 4 (0.2)                                         |
| Pregnancy - no baseline test Pregnancy within 7 months of treatment                                              | 0 1 (<0.1号)                                      | 2 (<0.16) 4 0.2)                                |
| Prohibited concomitant medication (anti-cancer)                                                                  | 13 0.5)                                          | 12 0.58)                                        |
| QoL not performedprior to first dose                                                                             | 29 1.26)                                         | 36                                              |
| Prohibited concomitant medication (other)                                                                        | 65 2.7%)                                         | 93 3.9%)                                        |
|                                                                                                                  |                                                  | 1.5)                                            |
| Receivedincorrectly assignedptz/pla                                                                              | 52 (2.2)                                         | 47 2.0号)                                        |
| Two or more consecutive LvEF assessments missed Two or more consecutive visits missed                            | 1 0                                              | 0                                               |
|                                                                                                                  | (<0.16)                                          | (<0.1%)                                         |

counted in different categories.

Program:/opt/BI0sTAT/prod/cdpl1450/r25126a/t\\_dv.sas Output:\\_/opt/BI0sTAT/prod/cdl1450g/j25126a/reports/t\\_dv\\_RA.out 30MAY201712:05

## Baseline data

An overview of  the  key  demographic  data,  baseline  disease  characteristics  and  stratification  factors  is provided in Table 24.

<div style=\"page-break-after: always\"></div>

Table 24 Key Demographic Data, Baseline Disease Characteristics and Stratification Factors, ITT Population

|                        |                                                | Ptz + H + Chemo N = 2400                | Pla + H + Chemo N = 2404                |
|------------------------|------------------------------------------------|-----------------------------------------|-----------------------------------------|
| Demo-graph ics         | Age, median, range (yrs) < 65 years ≥ 65 years | 51.0 (22 - 86) 2085 (86.9%) 315 (13.1%) | 51.0 (18 - 85) 2111 (87.8%) 293 (12.2%) |
| Demo-graph ics         | Weight, median, range (kg)                     | 65 (37 - 154)                           | 65 (37 - 162)                           |
| Demo-graph ics         | Sex, female/male                               | 99.9/ 0.1%                              | 99.7/ 0.3%                              |
| Demo-graph ics         | Race, White/ Asian/ Other                      | 71.2/ 24.7/ 4.1%                        | 70.5/ 24.9/ 4.6%                        |
| Cancer                 | Histologic grade of Primary tumor a            |                                         |                                         |
| Demo-graph ics         | Grade 1                                        | 53 (2.2%)                               | 42 (1.7%)                               |
|                        | Grade 2                                        | 770 (32.0%)                             | 764 (31.7%)                             |
|                        | Grade 3                                        | 1493 (62.1%)                            | 1506 (62.5%)                            |
|                        | Unevaluable                                    | 87 (3.6%)                               | 94 (3.9%)                               |
|                        | Unknown                                        | 0                                       | 2 (<0.1%)                               |
| Breast Characteristics |                                                |                                         |                                         |
|                        | HER2 status by Central lab (IHC Result) a,b    |                                         |                                         |
|                        | 0                                              | 6 (0.3%)                                | 2 (<0.1%)                               |
| Baseline               | 1+                                             | 16 (0.7%)                               | 9 (0.4%)                                |
| Baseline               | 2+                                             | 193 (8.0%)                              | 200 (8.3%)                              |
| Baseline               | 3+                                             | 2184 (91.0%)                            | 2190 (91.2%)                            |
| Baseline               | Type of Primary Surgery c                      |                                         |                                         |
| Baseline               | Mastectomy                                     | 1280 (53.3%)                            | 1327 (55.2%)                            |
| Baseline               | Breast Conserving Surgery                      | 1118 (46.7%)                            | 1076 (44.8%)                            |
|                        | Nodal status                                   |                                         |                                         |
|                        | 0 positive nodes and tumor ≤ 1 cm d            | 90 (3.8%)                               | 84 (3.5%)                               |
|                        | 0 positive nodes and tumor > 1 cm d            | 807 (33.6%)                             | 818 (34.0%)                             |
|                        | 1-3 positive nodes                             | 907 (37.8%)                             | 900 (37.4%)                             |
|                        | ≥ 4 positive nodes                             | 596 (24.8%)                             | 602 (25.0%)                             |
| Factors                | Adjuvant Chemotherapy Regimen (randomized)     |                                         |                                         |
|                        | Anthracycline containing regimen               | 1865 (77.7%)                            | 1877 (78.1%)                            |
|                        | Non-anthracycline containing regimen           | 535 (22.3%)                             | 527 (21.9%)                             |
| Stratification         | Hormone receptor status (central)              |                                         |                                         |
|                        | Negative (ER and PgR negative)                 | 864 (36.0%)                             | 858 (35.7%)                             |
|                        | Positive (ER and/or PgR positive)              | 1536 (64.0%)                            | 1546 (64.3%)                            |
| Randomization          | Geographic Region                              |                                         |                                         |
|                        | USA                                            | 296 (12.3%)                             | 294 (12.2%)                             |
|                        | Canada/Western Europe/Australia-               | 1294 (53.9%)                            | 1289 (53.6%)                            |
|                        | New Zealand/South Africa                       |                                         |                                         |
|                        | Eastern Europe                                 | 200 (8.3%)                              | 200 (8.3%)                              |
|                        | Asia-Pacific                                   | 550 (22.9%)                             | 557 (23.2%)                             |
|                        | Latin America                                  | 60 (2.5%)                               | 64 (2.7%)                               |
|                        | Protocol Version                               |                                         |                                         |
|                        | Protocol A                                     | 1828 (76.2%)                            | 1827 (76.0%)                            |
|                        | Protocol Amendment B                           | 572 (23.8%)                             | 577 (24.0%)                             |

a  For patients with bilateral tumors, the grade and HER2 status for each tumor was counted separately.

b Tumors that were anything other than IHC3+, had to be HER2-positive according to FISH.

c  Mastectomy included radical mastectomy, modified radical mastectomy and simple mastectomy. Breast conserving surgery included partial mastectomy and breast lumpectomy and others that did not meet the criteria for mastectomy. Information on type of surgery was not available for 3 patients (2 in Ptz + H + Chemo arm and 1 in Pla + H + Chemo arm).

d  Randomized under Protocol Version A only.

Source: Primary CSR.in module 5.3.5.1

<div style=\"page-break-after: always\"></div>

## Table 25 Randomization Stratification Factors by Treatment Regimen, ITT population Protocol: BIG 4-11/BO25126/TOC4939G

Randomization Stratification Factors by Treatment Regimen,ITT Population Prot0co1:BIG 4-11/B025126/T0C4939G

|                                                         | Pertuzumab+ Trastuzumab + Chemotherapy (N=2400)   | Placebo+ Trastuzumab + Chemotherapy (N=2404)   |
|---------------------------------------------------------|---------------------------------------------------|------------------------------------------------|
| Nodal status                                            |                                                   |                                                |
| n                                                       | 2400                                              | 2404                                           |
| 0positivenodesand tumor<=1cm*                           | 90（3.8%)                                          | 84(3.5%)                                       |
| 0positive nodes and tumor>1cm*                          | 807 (33.68)                                       | 818 (34.08)                                    |
| 1-3positive nodes                                       | 907 (37.8%)                                       | 900(37.4%)                                     |
| >=4positive nodes                                       | 596 (24.88)                                       | 602 (25.0%)                                    |
| Adjuvant chemotherapy regimen (randomized)              |                                                   |                                                |
| n                                                       | 2400                                              | 2404                                           |
| Anthracycline containing regimen                        | 1865 (77.78)                                      | 1877(78.18)                                    |
| Non-anthracycline containing regimen                    | 535（ (22.3%)                                      | 527 (21.9%)                                    |
| Hormone receptor status (central)                       |                                                   |                                                |
| n                                                       | 2400                                              | 2404                                           |
| Negative (ER and PgR negative)                          | 864(36.0%)                                        | 858(35.7%)                                     |
| Positive (ER and/or PgR positive)                       | 1536 (64.08)                                      | 1546 (64.38)                                   |
| Geographical Region                                     |                                                   |                                                |
| n                                                       | 2400                                              | 2404                                           |
| USA                                                     | 296 (12.38)                                       | 294 (12.28)                                    |
| Canada/Western Europe/Australia-New Zealand/SouthAfrica | 1294 (53.9%)                                      | 1289 (53.6%)                                   |
| Eastern Europe                                          | 200 (8.38)                                        | 200(8.38)                                      |
| Asia Pacific                                            | 550 (22.9%)                                       | 557(23.2%)                                     |
| Latin America                                           | 60(2.58)                                          | 64(2.78)                                       |
| Protocol Version                                        |                                                   |                                                |
| n                                                       | 2400                                              | 2404                                           |
| Protocol A                                              | 1828 (76.28)                                      | 1827 (76.08)                                   |
| Protocol Amendment B                                    | 572 (23.8%)                                       | 577 (24.0%)                                    |

## Pathological characteristics of primary tumour

The treatment arms were well balanced with respect to patients' breast cancer history. The majority of patients had primary tumours that were at least 2 cm in diameter. Most patients (91% of patients in either treatment  arm)  had  tumours  that  were  HER2  3+  based  on  immunohistochemistry  and  Grade  2  or  3, histologically.

## Breast Cancer Surgery

The majority of patients underwent mastectomy (53.3% vs. 55.2%). The majority of patients underwent sentinel lymph node biopsy (SLNB), with a median of 2 sentinel lymph nodes examined. The majority of patients underwent axillary dissection with a median of 15 lymph nodes examined. There were no apparent imbalances in lymph node surgery between treatment arms.

## Previous and Concurrent Diseases Other than Primary Breast Cancer

The  treatment  arms  were  comparable  with  respect  to  the  proportion  of  patients  with  previous disorders/conditions other than breast cancer (26.8% vs. 27.9%). Infections and Infestations (6.3% vs. 7.0%)  and  Gastrointestinal  Disorders  (3.6%  vs  3.6%)  were  the  most  common  classes  of  previous disorders/conditions, and the incidence was similar in the two treatment arms.

Twenty-eight patients (1.2%) vs 24 patients (1.0%) reported previous Cardiac Disorders, most commonly, palpitations (8 patients [0.3%] vs. 2 [&lt;0.1%]), supraventricular tachycardia (2 patients [&lt;0.1%] vs. 4 [0.2%]) and myocardial infarction (2 patients [&lt;0.1%] vs. 3 [0.1%]). All other cardiac disorders (preferred term) occurred in 2 or less patients.

<div style=\"page-break-after: always\"></div>

Around 67% of patients in each treatment arm reported concurrent disorders/conditions other than breast cancer at baseline and there were no notable differences between the treatment arms. The most frequently reported class of concurrent disorders/conditions was vascular disorders (594 patients [24.8%] vs. 605 [25.2%]), in particular, hypertension (523 patients [21.8%] vs. 513 [21.3%]).

The frequency of diabetes, hypertension, coronary artery disease and/or hyperlipidemia (that are commonly accepted risk factors for cardiovascular disease,) was similar in the two treatment arms.

Table 26

|                                 | Pertuzumab + Trastuzumab+ Chemotherapy (N=2400)   | Placebo + Trastuzumab + Chemotherapy (N=2404)   |
|---------------------------------|---------------------------------------------------|-------------------------------------------------|
| Diabetes n1 Yes No              | 2400 138 (5.8%) 2262 (94.3$)                      | 2404 137(5.7%) 2267 (94.3$)                     |
| Hypertension n Yes NO           | 2400 544(22.7%) 1856 (77.3$)                      | 2404 539 （22.4%) 1865 (77.6%)                   |
| Coronaryartery disease n Yes NO | 2400 21(0.9%) 2379 (99.1$)                        | 2404 21(0.9%) 2383 (99.1$)                      |
| Hyperlipidaemia n Yes No        | 2400 247 (10.3%) 2153 (89.7%)                     | 2404 255 (10.6) 2149(89.4%)                     |

Diabetes identified using HLGT Glucose metabolism disorders (incl diabetes mellitus)

## Concurrent treatments

## Adjuvant Radiotherapy

The majority of patients in both treatment arms (72.8% vs. 72.2%) received adjuvant radiotherapy. Of these patients, around half received radiation to the right side and the other half to the left side (as would be expected). About 20% of patients received radiotherapy to the left chest wall (Table 27).

Table 27 Summary of Adjuvant Radiotherapy for Primary Breast Cancer by Treatment Regimen Protocol: BIG 4-11/BO25126/TOC4939G

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Adjuvant radiotherapy

Side

Left chest wall

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

|                 | Pertuzumab + Trastuzumab + Chemotherapy (N=2400)   | Pertuzumab + Trastuzumab + Chemotherapy (N=2400)   | Placebo + Trastuzumab + Chemotherapy (N=2404)   | Placebo + Trastuzumab + Chemotherapy (N=2404)   |
|-----------------|----------------------------------------------------|----------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Adjuvant        | radiotherapy                                       |                                                    |                                                 |                                                 |
| No              | 654                                                | (27.3%)                                            | 669                                             | (27.8%)                                         |
| Yes             | 1746                                               | (72.8%)                                            | 1735                                            | (72.2%)                                         |
| Side            |                                                    |                                                    |                                                 |                                                 |
| n               | 1746                                               | 1746                                               | 1735                                            | 1735                                            |
| Left only       | 897                                                | (51.4%)                                            | 877                                             | (50.5%)                                         |
| Right only      | 846                                                | (48.5%)                                            | 857                                             | (49.4%)                                         |
| Bilateral       | 3                                                  | ( 0.2%)                                            | 1                                               | (<0.1%)                                         |
| Left chest wall |                                                    |                                                    |                                                 |                                                 |
| n               | 357                                                | (20.4%)                                            | 370                                             | (21.3%)                                         |

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_dm\\_adj.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_dm\\_adj\\_IT.out 21MAR2017 19:56                                                                   Page 1 of 1

## Adjuvant Hormone Therapy

The great majority of patients with central hormone receptor-positive disease received adjuvant hormone therapy (1317/1508 [87.3%] vs. 1330/1551 [85.8%]; Table 28).

<div style=\"page-break-after: always\"></div>

## Table 28 Summary of Adjuvant Hormone Therapy by Treatment Regimen

Summary of Hormone Therapy: Central Hormone Receptor Positive Cohort, Safety Evaluated Population

Protocol: BIG 4-11/BO25126/TOC4939G

| _________________________________________________________________________   |   Pertuzumab + Trastuzumab + Chemotherapy (N=1508) | Pertuzumab + Trastuzumab + Chemotherapy (N=1508)   |   Placebo + Trastuzumab + Chemotherapy (N=1551) | Placebo + Trastuzumab + Chemotherapy (N=1551)   |
|-----------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Patients with no Adjuvant Hormone Therapy                                   |                                                191 | (12.7%)                                            |                                             221 | (14.2%)                                         |
| Patients with Adjuvant Hormone Therapy                                      |                                               1317 | (87.3%)                                            |                                            1330 | (85.8%)                                         |
| SERM alone                                                                  |                                                663 | (44.0%)                                            |                                             681 | (43.9%)                                         |
| AI alone                                                                    |                                                440 | (29.2%)                                            |                                             412 | (26.6%)                                         |
| Ovarian Suppression alone                                                   |                                                  5 | ( 0.3%)                                            |                                               4 | ( 0.3%)                                         |
| SERM -> AI or AI -> SERM                                                    |                                                 63 | ( 4.2%)                                            |                                              71 | ( 4.6%)                                         |
| Ovarian Suppression + SERM                                                  |                                                 92 | 6.1%)                                              |                                              96 | 6.2%)                                           |
| Ovarian Suppression + AI                                                    |                                                 21 | ( ( 1.4%)                                          |                                              17 | ( ( 1.1%)                                       |
| Other                                                                       |                                                 33 | ( 2.2%)                                            |                                              49 | ( 3.2%)                                         |

AI: Aromatase Inhibitor; LHRH: Luteinizing hormone releasing hormone;

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

SERM: Selective estrogen receptor modulator; -&gt;: followed by; +: concurrent

Total line may exceed sum of individual lines because sex hormones are not included in any subclass of hormone therapies.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_cm\\_ht.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_cm\\_ht\\_CHRP\\_SE.out 21MAR2017 20:39                                                                   Page 1 of 1

## Numbers analysed

## Randomized Population -Intent-to-Treat (ITT)

The  primary  analysis  population  for  all  efficacy  endpoints  was  the  intent-to-treat  (ITT)  population.  All randomized patients were included in the ITT population. Patients were grouped according to the treatment assigned at randomization. Patients who received any amount of study medication (chemotherapy, Perjeta/ placebo, or Herceptin) were included in the safety population. Patients were analysed as treated: patients who received at least one full or partial dose of Perjeta were included in the Perjeta arm; all other treated patients were included in the control arm.

## Outcomes and estimation

Primary endpoint

<div style=\"page-break-after: always\"></div>

## Table 29 Summary of Time to First IDFS Event, Stratified Analysis (ITT Population)

Summary of Time to First IDFS Event by Treatment Regimen, Stratified Analysis, ITT Population Protocol: BIG 4-11/BO25126/TOC4939G

```
Invasive Disease Free Survival Pertuzumab +                   Placebo + Trastuzumab +                 Trastuzumab + Chemotherapy                  Chemotherapy (N=2400)                      (N=2404) ____________________________________________________________________________ Patients with event (%)           171 ( 7.1%)                   210 ( 8.7%) Patients without event (%)       2229 (92.9%)                  2194 (91.3%) Stratified Analysis p-value (log-rank)                               0.0446 Hazard Ratio                                      0.81 95% CI                                      (0.66, 1.00) 3 year duration Patients remaining at risk       2101                          2108 Event Free Rate (%)                94.06                         93.24 95% CI                      (93.09, 95.03)                (92.21, 94.26) ____________________________________________________________________________ Time to IDFS Event (months) - Censoring: IDFS (1=censored, 0=event). Strata are: nodal status, protocol version, central hormone receptor status, and adjuvant chemotherapy regimen. Hazard ratios were estimated by Cox regression. Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t_ef_tte.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t_ef_tte_STR1_IDFS_IT.out 25FEB2017 11:57                                                                   Page 1 of 1
```

## Figure 11 Kaplan-Meier Plot of IDFS (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table 30 Summary of First Occurrence of an IDFS Event Applying Hierarchy and Time Window

Summary of First Occurrence of an IDFS Event Applying Hierarchy and Time Window by Treatment Regimen, ITT Population

|                                   | Pertuzumab + Trastuzumab + Chemotherapy (N=2400)   | Pertuzumab + Trastuzumab + Chemotherapy (N=2400)   | Placebo + Trastuzumab + Chemotherapy (N=2404) ___________________________________________________________________   | Placebo + Trastuzumab + Chemotherapy (N=2404) ___________________________________________________________________   |
|-----------------------------------|----------------------------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Total Patients with IDFS Event: n | 171                                                | (7.1%)                                             | 210                                                                                                                 | (8.7%)                                                                                                              |
| Category of IDFS Event: n (%)     |                                                    |                                                    |                                                                                                                     |                                                                                                                     |
| Distant recurrence                | 112                                                | (4.7%)                                             | 139                                                                                                                 | (5.8%)                                                                                                              |
| CNS metastases                    | 45                                                 | (1.9%)                                             | 44                                                                                                                  | (1.8%)                                                                                                              |
| Locoregional recurrence           | 26                                                 | (1.1%)                                             | 34                                                                                                                  | (1.4%)                                                                                                              |
| Contralateral breast cancer       | 5                                                  | (0.2%)                                             | 11                                                                                                                  | (0.5%)                                                                                                              |
| Death without prior event         | 28                                                 | (1.2%)                                             | 26                                                                                                                  | (1.1%)                                                                                                              |

Protocol: BIG 4-11/BO25126/TOC4939G

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Patients who experience additional IDFS event(s) within 61 days of their 1st IDFS event are reported in the category according to the following hierarchy: [1] Distant recurrence; [2] Locoregional recurrence; [3] Contralateral breast cancer; [4] Death without prior event. CNS metastases is a subset of Distant recurrence.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ef\\_fo.sas

25FEB2017 11:59                                                                   Page 1 of 1

Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ef\\_fo\\_FTIDFS\\_IT.out

## Secondary endpoints

As required by the SAP, since the result for the primary endpoint, IDFS, showed statistical significance, key secondary endpoints were tested sequentially at an overall two-sided significance level of 5% by use of a hierarchical testing procedure in the following order:

1. IDFS including second primary non-breast cancer (IDFS-SPNBC)
2. DFS
3. OS.

RFI and DRFI were tested but not included in the multiplicity adjustment.

## IDFS including second primary non-breast cancer (IDFS-SPNBC)

## Table 31 Summary of Time to First IDFS Including Second Primary Non-breast Cancer Event, Stratified Analysis (ITT Population)

Summary of Time to First IDFS Including Second primary non-breast Cancer Event by Treatment Regimen, Stratified Analysis, ITT Population Protocol: BIG 4-11/BO25126/TOC4939G

IDFS including second primary non-breast cancer

|                                                                       | Pertuzumab + Trastuzumab + Chemotherapy (N=2400)   | Pertuzumab + Trastuzumab + Chemotherapy (N=2400)   | Placebo + Trastuzumab + Chemotherapy (N=2404)   |
|-----------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-------------------------------------------------|
| Patients with event (%) Patients without event (%)                    | 189 2211                                           | ( 7.9%) (92.1%)                                    | 230 ( 9.6%) 2174 (90.4%)                        |
| Stratified Analysis p-value (log-rank) Hazard Ratio 95% CI            |                                                    |                                                    | 0.0430 0.82 0.99)                               |
| 3 year duration Patients remaining at risk Event Free Rate (%) 95% CI | 2093 93.50 (92.49,                                 | 94.51)                                             | 2095 92.51 (91.43, 93.58)                       |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Time to IDFS including second primary non-breast cancer (IDFS-SPNBC) event (months) Censoring: IDFS-SPNBC (1=censored, 0=event). Strata are: nodal status, protocol version, central hormone receptor status, and adjuvant chemotherapy regimen. Hazard ratios were estimated by Cox regression.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ef\\_tte.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ef\\_tte\\_STR1\\_IDFSS\\_IT.out 25FEB2017 12:13                                                                   Page 1 of 1

<div style=\"page-break-after: always\"></div>

## Figure 12 Kaplan-Meier Plot of IDFS-SPNBC (ITT Population)

Kaplan-Meier Plot of Time to First IDFS Including Second primary non-breast Cancer Event (Months) by Treatment Regimen,ITT Population Protocol:BIG 4-11/B025126/TOC4939G

<!-- image -->

Time (months)

Pregram: /epu/BI0 STAT/proc/cdp11450e25126a/g\\_ef\\_km.sas Output fopt/BI0STAT/pred/c d11450gr|25126a/reperts/g\\_ef\\_km\\_IDFSS\\_T.pef 21MAR2017 18:27

## Disease-Free Survival (DFS)

## Table 32 Summary of Time to First DFS Event, Stratified Analysis (ITT Population)

Summary of Time to First DFS Event by Treatment Regimen, Stratified Analysis, ITT Population Protocol: BIG 4-11/BO25126/TOC4939G

| Disease Free Survival                                                 | Pertuzumab + Trastuzumab + Chemotherapy (N=2400)   | Pertuzumab + Trastuzumab + Chemotherapy (N=2400)   | Placebo + Trastuzumab + Chemotherapy (N=2404) ____________________________________________________________________________   | Placebo + Trastuzumab + Chemotherapy (N=2404) ____________________________________________________________________________   |
|-----------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Patients with event (%) Patients without event (%)                    | 192 2208                                           | ( 8.0%) (92.0%)                                    |                                                                                                                              | 236 ( 9.8%) 2168 (90.2%)                                                                                                     |
| Stratified Analysis p-value (log-rank) Hazard Ratio 95% CI            |                                                    |                                                    | 0.0327 0.81 (0.67, 0.98)                                                                                                     |                                                                                                                              |
| 3 year duration Patients remaining at risk Event Free Rate (%) 95% CI | 2091 93.42 (92.40,                                 | 94.43)                                             |                                                                                                                              | 2090 92.29 (91.21, 93.38)                                                                                                    |

```
Disease Free Survival Pertuzumab +                   Placebo + Trastuzumab +                 Trastuzumab + Chemotherapy                  Chemotherapy (N=2400)                      (N=2404) ____________________________________________________________________________ Patients with event (%)           192 ( 8.0%)                   236 ( 9.8%) Patients without event (%)       2208 (92.0%)                  2168 (90.2%) Stratified Analysis p-value (log-rank)                               0.0327 Hazard Ratio                                      0.81 95% CI                                      (0.67, 0.98) 3 year duration Patients remaining at risk       2091                          2090 Event Free Rate (%)                93.42                         92.29 95% CI                      (92.40, 94.43)                (91.21, 93.38) ____________________________________________________________________________ Time to DFS Event (months) - Censoring: DFS (1=censored, 0=event). Strata are: nodal status, protocol version, central hormone receptor status, and adjuvant chemotherapy regimen. Hazard ratios were estimated by Cox regression. Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t_ef_tte.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t_ef_tte_STR1_DFS_IT.out 23MAR2017 17:11                                                                   Page 1 of 1
```

<div style=\"page-break-after: always\"></div>

Figure 13 Kaplan-Meier Plot of Time to First DFS Event (Months) by Treatment Regimen: ITT Population

Kaplan-Meier Plot of Time to First DFS Event (Months) by Treatment Regimen, ITT Population Protocol:BIG4-11/BO25126/TOC4939G

<!-- image -->

Time (months)

Frogram: /optrBIO/STAT/peod/cdp11450A25126a/g\\_ef\\_km.sas Oulput: fopt/BIO:STATIprod/cd11450g/2512Gafreports/g\\_ef\\_km\\_DFS\\_IT.pdf 23MAR2017 16:59

## Overall Survival (OS)

## Table 33 Summary of Overall Survival, Stratified Analysis (ITT Population)

Protocol: BIG 4-11/BO25126/TOC4939G

| Overall Survival                                                      | Pertuzumab + Trastuzumab + Chemotherapy (N=2400) ____________________________________________________________________________   | Pertuzumab + Trastuzumab + Chemotherapy (N=2400) ____________________________________________________________________________   | Placebo + Trastuzumab + Chemotherapy (N=2404)   |
|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| Patients with event (%) Patients without event (%)                    | 80 2320                                                                                                                         | ( 3.3%) (96.7%)                                                                                                                 | 89 ( 3.7%) 2315 (96.3%)                         |
| Stratified Analysis p-value (log-rank) Hazard Ratio 95% CI            |                                                                                                                                 | 0.4673 0.89 (0.66, 1.21)                                                                                                        |                                                 |
| 3 year duration Patients remaining at risk Event Free Rate (%) 95% CI | 2186 97.65 (97.03, 98.27)                                                                                                       |                                                                                                                                 | 2209 97.67 (97.06, 98.29)                       |

25FEB2017 12:15                                                                   Page 1 of 1

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 14 Kaplan-Meier Plot of Overall Survival (ITT Population)

Kaplan-Meier Plot of Overall Survival (Months) by Treatment Regimen, ITT Population Protocol:BIG4-11/B025126/TOC4939G

<!-- image -->

Time (months)

Pragram: /opp/BIO5TATprod/ccp11-50/r25125arg\\_ef\\_krr.sas Output: /ep/BIO5TAT/prod/ed1 1450g J25126a/reperis/g\\_ef\\_km\\_O5\\_IT.pel/ 25FEB2017 12:16

## Results of sensitivity analyses

## Primary endpoint:

For the patients who were censored (7.1% in Ptz+H+Chemo versus 8.7% in Pla+H+Chemo), the median time  to  censoring  was  45.4  months/45.5  months  for  patients  treated  with  Ptz+H+Chemo  respectively Pla+H+Chemo, i.e. there was no indication of a difference in follow-up time, which is also seen in the Kaplan-Meier time of time to censoring. The hazard ratio for time to censoring was 1.02 (0.96; 1.08). Moreover, the number of assessments appeared to be balanced between the two groups, as was the mean and median time from the previous assessment to the IDFS event.

The analysis of time to censoring showed very similar median times to censoring in the two treatment arms.

<div style=\"page-break-after: always\"></div>

## Table 34 Time to Censoring for IDFS Events, ITT Population

Summary of Time to Censoring for IDFs Event by Treatment Regimen, ITT Population Prot0col: BIG 4-11/B025126/T0C4939G

|                                                           | Pertuzumab + Trastuzumab  Chemotherapy (N-2400)   | Placebo + Trastuzumab Chemotherapy (N-2404)   |
|-----------------------------------------------------------|---------------------------------------------------|-----------------------------------------------|
| Patients with event (&) Patients without event (&)        | 2229(92.9%) 171 (7.1$)                            | 2194 (91.34) 210 (8.7%)                       |
| Time to event (months) Median 10$56 25% and 75$-ile Range | 45.4 (45.2,45.6) 42.1,50.2 0 to 59                | 45.5 (45.2,45.7) 42.1,50.2 0 to 59            |
| Hazard Ratio 95+ CI                                       |                                                   | 1.02 (0.96,1.08)                              |

<!-- image -->

## Figure 15

Kaplan-MeierPlotof Time to Censoring of IDFSEvent(Months)byTreatment Regimen,ITT Population

Protocol:BIG4-11/B025126/T0C4939G

<!-- image -->

Also, the number of assessments that could detect recurrence was balanced between the two arms (mean [SD]: 14.75 [4.04] vs. 14.79 [3.71]).

<div style=\"page-break-after: always\"></div>

## Table 35

Bumnry of Nunber of Aggeasmenta thnt could dateet Racirrence by Tmntment Regimen,ItT Population P20t0001:B1G4-11/8025126/1004939G

<!-- image -->

|                                             | Pertueumab + Tmatusumnb+ Chemotheropy (00P2-N)   | Pertueumab + Tmatusumnb+ Chemotheropy (00P2-N)   | Placebo + Chemotherapy (F012-N)   |
|---------------------------------------------|--------------------------------------------------|--------------------------------------------------|-----------------------------------|
| Hhnbar of naseaamenta for recurrenca: n (u) |                                                  |                                                  |                                   |
|                                             | 0                                                |                                                  | 0                                 |
| 1                                           | 23                                               | (1.01)                                           | 16 0.701                          |
| 2-7                                         | DET                                              | 15.46]                                           | 1.05 [4.40)                       |
| 8-14                                        |                                                  | 727(30.34)                                       | 804(33.44)                        |
| 214                                         |                                                  | 1520(63.31)                                      | 1479 (61.54)                      |
| n                                           |                                                  |                                                  | POPZ                              |
| Henn (80)                                   |                                                  | 14.75(4.04)                                      | 14.79(3.71)                       |
| Median                                      |                                                  | 15.00                                            | 15.00                             |
| Range                                       |                                                  | 1.0 - 36.0                                       | 1.0 - 36.0                        |

## Table 36 Overview of Sensitivity Analysis Results for IDFS (ITT Population)

| Sensi- tivity Analysis   | HR [95% CI]       | p-value   | P(z+H+Chemo   | P(z+H+Chemo   | Pla+H+Chemo   | Pla+H+Chemo   | Analysis Description                                                                                                                          |
|--------------------------|-------------------|-----------|---------------|---------------|---------------|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Sensi- tivity Analysis   | HR [95% CI]       | p-value   | Events        | 3-year IDFS   | Events        | 3-year IDFS   | Analysis Description                                                                                                                          |
| ITT                      | 0.81 [0.68. 1.00] | 0.0446    | 171           | 94.06%        | 210           | 93.24%        | Strala: nodal status, prolocol version, central HR status. adjuvant chemotherapy regimen (eCRF)                                               |
|                          | 0.81 [0.65, 0.99] | 0.0434    | 157           | 94.32%        | 198           | 93.46%        | Censor at NACT if start date priorto first IDFS event                                                                                         |
|                          | 0.24 [0.79, 1.11] | 0.4511    | 253           | 90.38%        | 273           | 90.30%        | Count patients 3s having an event at date of NACT if date prior to firstIDFS event                                                            |
|                          | 0.77 [0.62. 0.98] | 0.0183    | 143           | 94.82%        | 184           | 93.80%        | Censor patients who discontnued study follow-up at last deaths as events)                                                                     |
|                          | 0.93 [0.80, 1.07] | 02837     | 371           | 87.48%        | 308           | 87.55%        | Patients who discontinued study follow-up without a recurrence plannedassessment,had theycontinued inthestudy                                 |
|                          | 0.05 [0.82, 1.11] | 0.5418    | 325           | 92.799%       | 344           | 92.35%        | Count patients who withdrew from targeted treatment due to toxicity 3s having an IDFS event 1 day after d3te lsst known to be recurrence-free |
|                          | 0.89 [0.78, 1.02] | 0.1020    | 410           | 91.31%        | 457           | 90.44%        | Count patients who discontinued study follow-up 3s having an IDFS event 1 day after the last assessment known to be recurrence-free           |
|                          | 0.82 [0.67, 1.00] | 0.0549    | 171           | 94.06%,       | 210           | 93.24%        | Unstrstified analysis                                                                                                                         |

| Sensi- tivity   | HR [95% CI]       | p-value   | Plz+H+Chemo   | Plz+H+Chemo   | Pla+H+Chemo   | Pla+H+Chemo   | Analysis Description                                            |
|-----------------|-------------------|-----------|---------------|---------------|---------------|---------------|-----------------------------------------------------------------|
| Analysis        | HR [95% CI]       |           | Events        | 3-year IDFS   | Events        | 3-year IDFS   | Analysis Description                                            |
| 0               | [0.66,0.98] 0.80  | 0.0345    | 171           | 94.06%        | 210           | 93.24%%       | Adjuvant chemotherapy strata based on regimen actually received |
| C               | 0.81 [0.67, 1.00] | 0.0467    | 171           | 94.08%        | 210           | 93.249        | Protocol version excluded fromstrala                            |
| 10              | 0.82 [0.67, 1.00] | 0.0471    | 171           | 04.089%       | 210           | 03.24%        | Strata defined according to IxRS                                |

Chemo-chemotherapy: Cl-confidence interval; H-trastuzumab: HR-hazard ratio: IDFS-invasive disease-free survival; ITT-Intention-to-Treat; NACT - new anti- cancer therapy: Pla-placebo: Piz-pertuzumab.

Note: The methooological details of the individual sensitivity analyses are described in Secton 3.8.3.4.

Sens#9: Sens#10.

## Secondary endpoints:

<div style=\"page-break-after: always\"></div>

Sensitivity analyses were planned but not performed, since the results of the sensitivity analyses of the primary endpoint showed no inconsistencies with the result of the primary analysis.

## Exploratory endpoints

Recurrence-Free Interval (RFI)

## Table 37 Summary of RFI, Stratified Analysis (ITT Population)

```
Population Protoco1: B1G 4-11/B025126/T0C4939G Recurrence Free Interval + qewmznaxaa Placebo + Trastuzumab + Trastuzumab + Chemotherapy Chemotherapy (N=2400) (N=2404) Patients with event (b) 138 (5.84) 173 ( 7.24) Fatients without event (b) 2262 (94.35) 2231 (92.84) Stratified Analysis p-value_(log-rank) 0.0430 Hazard Ratio 0.79 956 C1 (0.63,0.99) 3 year duration Patients temaining at risk 2116 2129 Event Free Rate (t) 95.18 94.27 95+ C1 (94.30,96.06) (93.32,95.21) RFI (months) =Censoring:RFI (l=censored,O=event) Strata are: nodal status, protocol version, central hormone receptor status, and adjuvant chemotherapy regimen. Hazard ratios Were estimated by Cox regression. Program:/opt/B10sTAT/prod/cdp11450/r25126a/t_ef_tte.sas Outputi_/opt/Bi0sTAT/prod/cdli450g/j25126a/reports/t_ef_tte_SIRl_RFI_IT.out 21MAR2017 18:42 Page 1 of 1
```

## Distant Recurrence-Free Interval (DRFI)

Table 38 Summary of DRFI, Stratified Analysis (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 39 Breast Cancer-Free Interval (BCFI)

<!-- image -->

## Patient-reported outcomes

Timing of the chemotherapy PRO assessment was tailored to the patient's treatment regimen, namely the end of anthracycline treatment (only in patients receiving an anthracycline-based regimen), the end of taxane therapy (all patients), and the end of HER2-targeted treatment (all patients). Note that in the PRO outputs, while the time point denoted as 'Week 13' corresponds to the end of taxane treatment in all patients, the actual time of this assessment depends on the type of chemotherapy. For patients receiving anthracycline-based  chemotherapy,  the  actual  time  point  was  Week  10  or  Week  13  of  HER2-targeted treatment (depending on the chemotherapy regimen given). For patients receiving non-anthracycline-based chemotherapy (i.e., the Ptz + TCH regimen), this was Week 19 of HER2-targeted treatment.

For the analyses of function, treatment-related symptoms, and global health status/HRQoL, as assessed by the scales of the EORTC QLQ-C30 and the QLQ-BR23 questionnaires, a difference of ≥ 10 points from the baseline score within a treatment arm is considered a clinically meaningful change.

Key results from PRO analyses are provided below.

- Completion rates for all questionnaires were consistently high throughout the study ( &gt; 85.0%).
- Patients experienced a clinically considerable decline in physical function (Figure 16) and global health  status  (Figure  17)  during  chemotherapy  (Week  13)  similarly  in  both  treatment  arms; thereafter,  scores  improved  and  returned  to  baseline  levels  during  HER2-targeted  treatment. Patients' ability to conduct daily activities, as assessed by role function (Figure 18), was maintained in both arms over the course of study treatment.
- Diarrhea symptoms scores as measured by EORTC QLQ-C30 were highest (i.e., worst) at the end of taxane treatment (Week 13) in both arms (Figure 19). The scores in both arms remained elevated during  the  HER2-targeted  treatment  period,  but  the  difference  from  baseline  was  clinically considerable  ( ≥ 10  points)  only  in  the  pertuzumab  arm  at  the  end  of  taxane  and  during  the HER2-targeted  treatment  period.  Symptoms  of  fatigue,  dyspnea,  body  image,  and  systemic chemotherapy side effects clinically significantly deteriorated at the end of taxane treatment (Week

<div style=\"page-break-after: always\"></div>

- 13) in both arms. Appetite loss showed a clinically considerable deterioration at the end of taxane treatment in the pertuzumab arm only. Of the patients reporting hair loss (only ~300 in each arm), a clinically considerable deterioration was observed in patients' upset by hair loss at the end of taxane treatment and during HER2-targeted treatment in both arms. Around 300 patients in each arm recorded sexual activity. Amongst these patients, the decline in sexual enjoyment scores was clinically considerable for both arms at the end of taxane treatment, but only in the pertuzumab arm during  HER2-targeted  treatment  (after  cessation  of  chemotherapy).  Differences  in  all  other symptom scores were not clinically considerable.
- No clinically considerable differences in patient-reported treatment-related symptoms, all function scales,  or  global  health  status  were  observed  in  either  arm  after  cessation  of  HER2-targeted treatment. All returned to or remained at baseline levels during the follow-up period (Months 18, 24, and 36).
- There were no major differences ( ≥ 5 percentage points) between treatment arms in the five EQ-5D domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression).

Figure 16 Mean Scores of EORTC QLQ-C30 Physical Functioning (ITT Population)

PlotofMeanEORTCQLQ-C30physicalfunctioningbyTreatmentRegimen,ITTPopulation

<!-- image -->

Note: The programmed outputs shift the two curves for greater visual clarity. The time points are the same in both treatment arms. The time point 'Week 13' in this table and the associated programmed outputs corresponds to the end of taxane treatment; the actual time depends on the type of chemotherapy received.

<div style=\"page-break-after: always\"></div>

Figure 17 Mean Scores of EORTC QLQ-C30 Global Health Status (ITT Population)

PlotofMeanEORTCQLQ-C30global healthstatusbyTreatmentRegimen,ITTPopulation Protocol:BIG4-11/BO25126/T0C4939G

<!-- image -->

Note: The programmed outputs shift the two curves for greater visual clarity. The time points are the same in both treatment arms. The time point 'Week 13' in this table and the associated programmed outputs corresponds to the end of taxane treatment; the actual time depends on the type of chemotherapy received.

Figure 18 Mean Scores of EORTC QLQ-C30 Role Functioning (ITT Population)

PlotofMeanEORTCQLQ-C30rolefunctioningbyTreatmentRegimen,ITTPopulation Protocol:BIG4-11/B025126/TOC4939G

<!-- image -->

Note: The programmed outputs shift the two curves for greater visual clarity. The time points are the same in both treatment arms. The time point 'Week 13' in this table and the associated programmed outputs corresponds to the end of taxane treatment; the actual time depends on the type of chemotherapy received.

<div style=\"page-break-after: always\"></div>

Figure 19 Mean Scores of EORTC QLQ-C30 Diarrhea (ITT Population)

PlotofMeanEORTCQLQ-C30diarrhoeabyTreatmentRegimen,ITTPopulation Protocol:BIG4-11/BO25126/TOC4939G

<!-- image -->

Note: The programmed outputs shift the two curves for greater visual clarity. The time points are the same in both treatment arms. The time point 'Week 13' in this table and the associated programmed outputs corresponds to the end of taxane treatment; the actual time depends on the type of chemotherapy received.

## Ancillary analyses

## Subgroup analyses

## Nodal status

Patients with node-positive disease (a pre-defined subgroup) showed statistically significant benefit with Ptz + H + Chemo treatment with IDFS event-free rates of 91.99% vs. 90.15% at 3 years (HR 0.77, 95%CI 0.62, 0.96) (KM curve below). These results indicate a 23% reduction in risk of recurrence or death in patients randomized to Ptz + H + Chemo; the event-free rates at  were 89.88% vs. 86.68%, respectively.

In comparison, the estimated HR for IDFS for the node-negative subgroup (HR 1.13, 95%CI 0.68, 1.86) did not show evidence of treatment benefit at this time; nor did the subgroup of patients with node-negative disease and a tumour &gt; 1cm in diameter (i.e., a subset of the node-negative subgroup; HR 1.23, 95%CI 0.72, 2.10).

Kaplan-Meier curve for Event-free rates for IDFS over Time by Treatment Regimen, Node Positive Cohort, ITT Population:

<div style=\"page-break-after: always\"></div>

## Figure 20

Kaplan-Meier Plot of Time to First IDFS Event (Months)by Treatment Regimen,Node Positive Cohort,ITTPopulation

Protocol:BIG4-11/B025126/T0C4939G

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 21. Forest Plot of Hazard Ratios and 95% Confidence Intervals for IDFS by Subgroup Forest Plot of Time to First IDFS Event (Months) by Subgroup, ITT Population Protocol:BIG4-11/B025126/T0C4939G

<!-- image -->

|                                                                                                                 |                       | Placebo + Trastuzumab+ Chemotherapy (N=2404)   | Placebo + Trastuzumab+ Chemotherapy (N=2404)   | Pertuzumab+ Trastuzumab+ Chemotherapy (N=2400)   | Pertuzumab+ Trastuzumab+ Chemotherapy (N=2400)   |                                                                                 | Trastuzumab+ Pertuzumab +   | Placebo + Trastuzumab + Chemotherapy better   |
|-----------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------------|------------------------------------------------|--------------------------------------------------|--------------------------------------------------|---------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------|
| Baseline Risk Factors                                                                                           | Total n               | Patients perGroup                              | NEvents                                        | Patients perGroup                                | NEvents                                          | Hazard Ratio 95% C1                                                             | Chemotherapy better         |                                               |
| All Patients                                                                                                    | 4804                  | 2404                                           | 210                                            | 2400                                             | 171                                              | 0.82 (0.67, 1.00)                                                               |                             |                                               |
| Nodal status                                                                                                    |                       |                                                |                                                |                                                  |                                                  |                                                                                 |                             |                                               |
| positive nodes,tumor<=1cm 0positive nodes,tumor >1cm 1-3 positive nodes >=4positive nodes                       | 174 1625 1807 1198    | 84 818                                         |                                                | 396                                              | 23 35                                            | 0.48 (0.09,2.60) 1.23 (0.72,2.10) 0.73 (0.52,1.04) 0.79 (0.59,1.05)             |                             |                                               |
| 0positive nodes >=1 positive nodes                                                                              | 1799 3005             | 902 1502                                       | 29 181                                         | 897 1503                                         | 粥                                                | 1.13 (0.68,1.86) 0.77 (0.62,0.96)                                               |                             |                                               |
| Adjuvantchemotherapy regimen Anthracycline Non-anthracycline                                                    | 3742 1062             | 1877 527                                       | 171 39                                         | 1865 535                                         | 139 32                                           | 0.82 (0.66,1.03) 0.82 (0.51, 1.31)                                              |                             |                                               |
| Centralhormonereceptorstatus Positive (ER andlorPgR positive) Negative (ER and PgR negative)                    | 392                   | 5号                                             | 19                                             |                                                  |                                                  | 8.96  (0.66,1.13) (0.56,1.04)                                                   |                             |                                               |
| Protocol version ProtocolA Protocol Amendment B                                                                 | 365                   |                                                | 昂                                              | 182                                              | 6%.                                              | 0.84 (0.66,1.08) 0.77 (0.53, 1.11)                                              |                             |                                               |
| Region                                                                                                          |                       |                                                |                                                |                                                  |                                                  | 0.66                                                                            |                             |                                               |
| USA Canada/W Europe/Aus-NZ/SA Eastern Europe Asia-pacific Latin America                                         | 590 2583 400 1107 124 | 12                                             | 20 3501                                        | 12  60                                           | 33.726                                           | (0.33.1.32) 60 (0.70, 1.23) 0.61 (0.33,1.11) 0.85 (0.56,1.28) 0.59 (0.22, 1.61) |                             |                                               |
| CentralER/PgRstatus ERPositive,PgR Positive ERPositive,PgRNegative ERNegaive,PgRPosiive ERNegative,PgR Negative | 2282 779 24 1719      | 1127                                           | 8.329                                          | 1155 373 9 863                                   | 80                                               | 0.98 (0.72,1.33) 0.62 (0.36,1.08) 10:0> (0.00,NE) 0.76 (0.56,1.04)              |                             |                                               |
| Menopausal status at screening Pre-menopausal Post-menopausal                                                   | 222                   | 1223                                           |                                                | 1242                                             | %                                                | 888 (0.75.1.32) (0.51, 0.91)                                                    |                             |                                               |
| Age group (years)                                                                                               |                       |                                                |                                                |                                                  |                                                  |                                                                                 |                             |                                               |
| 40-49 <40 50-64                                                                                                 | 1410 653 2133         | 327                                            | 2.39                                           | 708 326 1051                                     | 30                                               | 0.96 0.89 (0.59, 1.59) (0.60,1.32) 0.78 (0.57,1.07)                             |                             |                                               |
| <65 >=65                                                                                                        | 4196 608              | 2111 293                                       | 1746                                           | 2095                                             |                                                  | 8:95  (0.68,1.05) (0.41, 1.17)                                                  |                             |                                               |
| Histological grade Grade 1 Grade 2 Grade3                                                                       | 95 1529 2997          | 42 761 1505                                    | 3 18                                           | 53 768 1492                                      | 2 43 118                                         | 0.50 (0.08,3.03) 0.67 (0.45.0.99) 0.88 (0.69,1.13)                              |                             |                                               |
| Surgery typeforprimary tumor Breast-conserving Mastectomy                                                       | 2607                  | 1939                                           | 146                                            | 1118 1280                                        |                                                  | 0.75 (0.52,1.08) 0.88 (0.69, 1.12)                                              |                             |                                               |
| Tumor size (cm) 2.5 2 >=5                                                                                       | 126  321              | 128  174                                       | 31                                             | 1273 977 147                                     | 10 22                                            | 0.62 960 (0.42,0.92) (0.74, 1.24) 0.85 (0.49, 1.47)                             |                             |                                               |
| Loco-regional radiotherapy Yes No                                                                               | 3481 1323             | 1735 669                                       | 150 60                                         | 1746 654                                         |                                                  | 0.79 (0.62,1.01) 0.90 (0.62, 1.31)                                              |                             |                                               |
| Race                                                                                                            | 3399                  | 1694                                           | 141                                            |                                                  |                                                  | 0.84 (0.66, 1.07) 0.77                                                          |                             |                                               |
| White Black                                                                                                     | 73                    | 41                                             | 2                                              | 1705 32                                          | 118 1                                            | (0.07,8.49)                                                                     |                             |                                               |
| Asian Other                                                                                                     | 1188 135              | 598 69                                         |                                                | 590 66                                           | 45                                               | 0.85 (0.57.1.26) 0.52 (0.19,1.38)                                               |                             |                                               |
| Sex                                                                                                             | 4793                  | 2396                                           | 209                                            | 2397 23                                          | 171                                              | 0.82 (0.67, 1.01)                                                               |                             |                                               |
| Female                                                                                                          |                       |                                                |                                                |                                                  | 85                                               |                                                                                 |                             |                                               |
| Protocolversionnodepositive Protocol A,node positive Protocol amendment B, node positive                        | 1858 1147             | 号引                                             | 乱                                              |                                                  |                                                  | 0.77 (0.58,1.01) 0.77 (0.54, 1.11)                                              |                             |                                               |

All Patients refers to the unstratified analysis for the ITT population Program:/opt/BIOSTAT/prod/cdp11450/r25126a/g\\_ef\\_tte\\_sub.sasOutput:/opt/BIOSTAT/prod/cd11450g/j25126a/reports/g\\_ef\\_te\\_sub\\_IDFS\\_IT.pdf25FEB201712:07

## Hormone receptor status

Central hormone receptor status is another pre-specified factor of particular interest. Improved IDFS was observed in patients irrespective of hormone receptor status (see Forest plot). The benefit of adding Perjeta to trastuzumab and chemotherapy was not significantly dependent on hormone receptor status, i.e. for patients with hormone receptor-negative disease the results were HR 0.76 (95%CI 0.56, 1.04) (KM curve below), and for patients with hormone receptor-positive disease the results showed HR 0.86 (95%CI 0.66, 1.13).

<div style=\"page-break-after: always\"></div>

The  3-year  IDFS  event-free  rates  for  the  hormone  receptor-negative  subgroup  were  92.77%  in  the Ptz + H + Chemo arm vs. 91.17% in the Pla + H + Chemo arm. At 4 years, the IDFS event-free rates for this subgroup  were  90.96%  vs.  88.67%,  respectively.  For  the  hormone  receptor-positive  subgroup,  IDFS event-free rates were 94.79% vs. 94.37% at 3 years and 93.03% vs. 91.63% at 4 years.

Kaplan-Meier curve for Event-free rates for  IDFS  over  Time  by  Treatment  Regimen,  hormone receptor-negative patients, ITT Population:

Figure 22 Kaplan-MeierPlotofTime toFirstIDFSEvent(Months)byTreatmentRegimen,Central Hormone ReceptorNegative Patients,ITT Population Protocol:BIG4-11/B025126/T0C4939G

<!-- image -->

## HER2 subgroups

Exploratory  analyses  were  carried  out  to  assess  potential  relationships  between  different  levels  of HER2-overexpression and improvements in IDFS with the addition of Perjeta to H+Chemo in the adjuvant setting. These subgroups were not specified in the SAP, but were documented in a separate, more detailed data analysis plan, finalized prior to database lock.

Time (months)

<div style=\"page-break-after: always\"></div>

Table 40

Summary of Time to First IDES Event Protoco1:BIG 4-11/B025126/T0C4939G

|                                |                                    | Pertusumab+Trastusumab+ Chemotherapy (N=2400)   | Pertusumab+Trastusumab+ Chemotherapy (N=2400)   | Pertusumab+Trastusumab+ Chemotherapy (N=2400)   | Placebo+ Trastusumab Chemotherapy (N=2404)   | Placebo+ Trastusumab Chemotherapy (N=2404)   | Placebo+ Trastusumab Chemotherapy (N=2404)   |              |                           |
|--------------------------------|------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|--------------|---------------------------|
|                                |                                    | Patients per Group                              | N Events                                        | 3 Year KM                                       | Patients per Group                           | N Events                                     | 3 Year KM                                    | Hasard Ratio | 95e CI                    |
| A11                            |                                    | 2400                                            | 171                                             | 94.1                                            | 2404                                         | 210                                          | 93.2                                         | 0.82         | (0.67, 1.00)              |
| HER2 IHC Status                | IHC2+                              | 193                                             | 18                                              | 93.1                                            | 200                                          | 15                                           | 93.7                                         | 1.25         | (0.63， 2.49)              |
|                                | IHC 3+                             | 2181                                            | 148                                             | 94.3                                            | 2186                                         | 194                                          | 93.2                                         | 0.77         | (0.62) 0.95)              |
| FISH Status                    | FISH Positive                      | 2393                                            | 171                                             | 94.0                                            | 2389                                         | 209                                          | 93.2                                         | 0.82         | (0.67, 1.01)              |
| IHC Statusand of cells stained | IHC3+， >=80                        | 953                                             | 65                                              | 94.3                                            | 888                                          | 73                                           | 93.5                                         | 0.85         | (0.61, 1.18)              |
| IHC Statusand of cells stained | IHC 3+, >=30 <80                   | 580                                             | 42                                              | 94.0                                            | 620                                          | 62                                           | 92.6                                         | 0.71         | (0.48, 1.06)              |
| IHC Statusand of cells stained | IHC 3+, >=10# -<30                 | 56                                              | 3                                               | 96.2                                            | 57                                           | 10                                           | 87.6                                         | 0.27         | (0.07, 1.00)              |
| IHC Statusand of cells stained | IHC2+, >=80                        | 23                                              |                                                 | 95.7                                            | 21                                           | 0                                            | 100.0                                        | 66*666<      | (0.00,NE)                 |
| IHC Statusand of cells stained | IHC 2+, >=30 <80 IHC 2+, >=10 -<30 | 36 3                                            | 26 1                                            | 85.8 100.0                                      | 29 6                                         | 1 0                                          | 96.4 100.0                                   | 4.91 66*666< | (0.59,40.79) (0.00,NE)    |
|                                | IHC2+/3+ combined, >=80            | 976                                             | 67                                              | 94.3                                            | 909                                          | 73                                           | 93.7                                         | 0.87         | (0.63, 1.21)              |
|                                | >=30 <808                          | 616                                             | 48                                              | 93.5                                            | 649                                          | 63                                           | 92.8                                         | 0.80         | (0.55, 1.16)              |
|                                | IHC2+/3+combined, >=10 <30         | 59                                              |                                                 | 96.4                                            | 63                                           | 10                                           | 88.6                                         | 0.37         | (0.11, 1.21)              |
| HER2 FISH Ratio                | <4 >=4                             | 608 1792                                        | 57 114                                          | 92.0 94.8                                       | 620 1784                                     | 54 156                                       | 94.0 93.0                                    | 1.10 0.73    | (0.76, 1.60) (0.57, 0.93) |
|                                | 1st quartile                       | 606                                             | 57                                              | 91.9                                            | 619                                          | 54                                           | 94.0                                         | 1.10         | (0.76， 1.60)              |
|                                | 2nd quartile                       | 604                                             | 34                                              | 95.1                                            | 619                                          | 63                                           | 91.5                                         | 0.56         | (0.37, 0.85)              |
|                                | 3rd quartile                       | 609                                             | 44                                              | 94.7                                            | 579                                          | 46                                           | 93.3                                         | 0.89         | (0.59) 1.35)              |
|                                | 4th quartile                       | 581                                             | 36                                              | 94.5                                            | 587                                          | 47                                           | 94.2                                         | 0.79         | (0.51, 1.22)              |

3year KM represents the Kaplan-Meier estimate for IDeS at 3 years. Hasard ratio represents the hasard for patients taking pertusumab + trastusumab + chemotherapy versus patients on placebo + trastusumsb + chemotherapy. HER2 data based on central readings.

In order to explore the potential relationship between HER2-related tumor heterogeneity and the IDFS hazard ratio, subgroups were defined by levels of HER2 protein overexpression, using the two main IHC categories (IHC2+ and IHC3+) and the percentage of cells staining positive for HER2 (using pragmatic cut offs of 80%, 30%, and 10%). It is important to note that the great majority of patients had IHC3+ disease; only 8.2% of patients in the study had IHC2+ disease, and there were only 33 IDFS events in this subgroup.

<div style=\"page-break-after: always\"></div>

## ForestPlotof Time toFirstIDFS Event(Months)by HER2IHCand FISHSubgroups,ITT

Table 41 Population Protocol:BIG4-11/B025126/TOC4939G

<!-- image -->

|                                 |           | Placebo + Trasticumab+   | Placebo + Trasticumab+   | Pertuzumab+ Trastuzumab+   | Pertuzumab+ Trastuzumab+   |             |                      | Penucumab+                    |                             |
|---------------------------------|-----------|--------------------------|--------------------------|----------------------------|----------------------------|-------------|----------------------|-------------------------------|-----------------------------|
|                                 |           | Chemotherapy (N=2404)    | Chemotherapy (N=2404)    | Chemotheapy (N=2400)       | Chemotheapy (N=2400)       |             |                      |                               | Placebo+                    |
| Baseline Fisk Factors           | Total     | Pabens per Group         | NEvents                  | Pabens per Group           | NEvents                    | Hazare Rabo | 1D56                 | Testcumeb+ Chemotrerapy beder | Tasteumab+ Chemoheaoy beter |
| AlPatents                       | 4804      |                          | 210                      | 2400                       | 171                        | 0.82        | (0.67.1.00)          |                               |                             |
| HER2 IHC Status                 |           |                          |                          |                            |                            |             |                      |                               |                             |
| HC2+ HC.3+                      | 398 4367  | 200 2186                 | 15 194                   | 193 2181                   | 18                         | 125 0.77    | 0.63.249)            |                               |                             |
| FISHStas                        |           |                          |                          |                            |                            |             | (0.62,0.55)          |                               |                             |
| FISH Poelilive                  | 4782      | 2389                     |                          |                            |                            |             | 00.67.1.0)           |                               |                             |
| IHC Status and %ofcells stained |           |                          |                          |                            |                            |             |                      |                               |                             |
| HC3+,2=80%                      | 1841      |                          | 209                      | 2393                       | 171                        | 0.82        |                      |                               |                             |
|                                 |           | 888                      | 73                       | 953                        | 5                          | 0185        | 0.61.1.18)           |                               |                             |
| HC 3+,p=30%<809                 | 1200      | 620                      |                          | 580                        |                            | 071         | 00.48,1.06)          |                               |                             |
| HC3+x=10-30%                    | 113       | 57                       | 10                       | 56                         | 3                          | 0.27        | 00.07.1.00)          |                               |                             |
| IHC 2+,-60k                     | 4         | 21                       |                          | 23                         | 2                          | >499.99     | (0.00,NE)            |                               |                             |
| IHC 2+p=30980%                  | 65        | 29                       | 1                        | 36                         | 6                          | 4.91        | (0.59, 40.79)        |                               |                             |
| IHC2+,2=10%-≤30%                | 9         | 6                        |                          | C                          | 1                          | 999.99      | (0.00_NE)            |                               |                             |
| HC2+3+combinec-Bo%              |           |                          |                          |                            |                            |             |                      |                               |                             |
| HC2+3+combined=30%-80%          | 1885 1265 | 909                      | 73                       | 575 416                    |                            | 0.80        | 0120                 |                               |                             |
| HC2+3+combined=10%-c30%         | 122       | 649 63                   | 69 10                    | 59                         | 8 4                        | LED         | 0.55.1.16 (0.11,121) |                               |                             |
| HER2FI5HRato                    |           |                          |                          |                            |                            |             |                      |                               |                             |
| 4                               | 1228      | 620                      | 54                       | 608                        | 57                         | 1.10        | (0.76, 1.60)         |                               |                             |
| 2=4                             | 3576      |                          | 156                      | 1792                       | 114                        | 0.73        | (0.57,0.90)          |                               |                             |
| lstqate                         | 1225      | 619                      | 54                       | 606                        | 57                         | 1.10        | (0.76, 1.60)         |                               |                             |
| 2dqe                            | 1223      | 619                      |                          | 604                        | E                          | 0.56        | (0.37, 0.85)         |                               |                             |
| 3rdquartle                      | 1168      | 579                      | 46                       | 609                        | 44                         | 0.89        | 00.59.1.35)          |                               |                             |
| 4hquare                         |           |                          |                          |                            |                            |             |                      |                               |                             |
|                                 | 1168      | 587                      | 47                       | 581                        | 36                         | 0.79        | (0.51, 1.22)         |                               |                             |

Similar analyses were performed based on HER2 gene amplification. Subgroups were defined using the HER2 FISH ratio (i.e., the number of HER2 gene copies relative to the number of signals for CEP17) with subgroups based on a pragmatic cutoff of 4.0 ( &lt; 4.0 or ≥ 4.0) and by quartiles of the HER2 FISH ratio. Again, the majority of patients had a HER2 FISH ratio ≥ 4.0 with only 25.6% of patients in the subgroup with a HER2 FISH ratio &lt; 4.0 (and 111 events in that subgroup).

Considering HER2 protein levels, a lower HR (suggesting greater benefit) was observed for patients with IHC3+ disease (HR 0.77, 95%CI 0.62, 0.95) than for patients with IHC2+ disease (HR 1.25, 95%CI 0.63, 2.49). Similarly, a lower HR (suggesting greater benefit) was observed for patients with greater HER2 gene amplification in their tumor indicated by a FISH ratio ≥ 4 (HR 0.73, 95%CI 0.57, 0.93) compared with a FISH ratio &lt; 4.0 (HR 1.10, 95%CI 0.76, 1.60).

## Overall survival - OS subgroups

<div style=\"page-break-after: always\"></div>

Due to the immaturity of the OS analysis, which was based on only 80 (3.3%) deaths in the Ptz + H + Chemo arm and 89 (3.7%) deaths in the Pla + H + Chemo arm, representing 26% of the target events for the final OS analysis, no conclusions on the exploratory analyses of OS within subgroups can be drawn.

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Summary of Efficacy for trial APHINITY

| Title: APHINITY                                                | Title: APHINITY                                                                                                                                                                                                                                             | Title: APHINITY                                                                                                                                                                                                                                             | Title: APHINITY                                                                                                                                                                                                                                             | Title: APHINITY                                                                                                                                                                                                                                             | Title: APHINITY                                                                                                                                                                                                                                             |
|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                               | BIG 4-11/BO25126/TOC4939g                                                                                                                                                                                                                                   | BIG 4-11/BO25126/TOC4939g                                                                                                                                                                                                                                   | BIG 4-11/BO25126/TOC4939g                                                                                                                                                                                                                                   | BIG 4-11/BO25126/TOC4939g                                                                                                                                                                                                                                   | BIG 4-11/BO25126/TOC4939g                                                                                                                                                                                                                                   |
| Design                                                         | A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. | A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. | A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. | A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. | A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. |
| Design                                                         | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                              | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                              | Not applicable (study is event driven) Not applicable Not applicable                                                                                                                                                                                        | Not applicable (study is event driven) Not applicable Not applicable                                                                                                                                                                                        | Not applicable (study is event driven) Not applicable Not applicable                                                                                                                                                                                        |
| Hypothesis                                                     | Superiority                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                                                                 |
| Treatments groups                                              | Chemotherapy plus trastuzumab plus placebo                                                                                                                                                                                                                  | Chemotherapy plus trastuzumab plus placebo                                                                                                                                                                                                                  | Chemotherapy (A+T 3-4 cycles each or T+C 6 cycles), 1 year of trastuzumab Q3W.                                                                                                                                                                              | Chemotherapy (A+T 3-4 cycles each or T+C 6 cycles), 1 year of trastuzumab Q3W.                                                                                                                                                                              | Chemotherapy (A+T 3-4 cycles each or T+C 6 cycles), 1 year of trastuzumab Q3W.                                                                                                                                                                              |
| Treatments groups                                              | Chemotherapy plus trastuzumab plus pertuzumab                                                                                                                                                                                                               | Chemotherapy plus trastuzumab plus pertuzumab                                                                                                                                                                                                               | Chemotherapy (A+T 3-4 cycles each or T+C 6 cycles), 1 year of trastuzumab Q3W, 1 year pertuzumab Q3W                                                                                                                                                        | Chemotherapy (A+T 3-4 cycles each or T+C 6 cycles), 1 year of trastuzumab Q3W, 1 year pertuzumab Q3W                                                                                                                                                        | Chemotherapy (A+T 3-4 cycles each or T+C 6 cycles), 1 year of trastuzumab Q3W, 1 year pertuzumab Q3W                                                                                                                                                        |
| Endpoints and definitions                                      | Primary endpoint                                                                                                                                                                                                                                            | IDFS                                                                                                                                                                                                                                                        | Invasive disease-free survival                                                                                                                                                                                                                              | Invasive disease-free survival                                                                                                                                                                                                                              | Invasive disease-free survival                                                                                                                                                                                                                              |
| Endpoints and definitions                                      | Secondary endpoint                                                                                                                                                                                                                                          | IDFS-SPNBC                                                                                                                                                                                                                                                  | IDFS including second primary non-breast cancers                                                                                                                                                                                                            | IDFS including second primary non-breast cancers                                                                                                                                                                                                            | IDFS including second primary non-breast cancers                                                                                                                                                                                                            |
| Endpoints and definitions                                      | Other Secondary endpoints                                                                                                                                                                                                                                   | DFS, OS                                                                                                                                                                                                                                                     | Disease-Free Survival, Overall Survival                                                                                                                                                                                                                     | Disease-Free Survival, Overall Survival                                                                                                                                                                                                                     | Disease-Free Survival, Overall Survival                                                                                                                                                                                                                     |
| Database lock                                                  | 19 December 2016                                                                                                                                                                                                                                            | 19 December 2016                                                                                                                                                                                                                                            | 19 December 2016                                                                                                                                                                                                                                            | 19 December 2016                                                                                                                                                                                                                                            | 19 December 2016                                                                                                                                                                                                                                            |
| Results and Analysis                                           | Results and Analysis                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                        |
| Analysis description                                           | Primary Analysis                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                            |
| and time point description Descriptive statistics and estimate | Intent to treat (all subjects) at 1 st interim analysis                                                                                                                                                                                                     | Intent to treat (all subjects) at 1 st interim analysis                                                                                                                                                                                                     | Intent to treat (all subjects) at 1 st interim analysis                                                                                                                                                                                                     | Intent to treat (all subjects) at 1 st interim analysis                                                                                                                                                                                                     | Intent to treat (all subjects) at 1 st interim analysis                                                                                                                                                                                                     |
| variability                                                    |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |
|                                                                | Treatment group Ptz + H + Chemo Pla + H + Chemo Number of subject 2400 2404 IDFS (Event-free proportion at 3 years) 94% 93%                                                                                                                                 | Treatment group Ptz + H + Chemo Pla + H + Chemo Number of subject 2400 2404 IDFS (Event-free proportion at 3 years) 94% 93%                                                                                                                                 | Treatment group Ptz + H + Chemo Pla + H + Chemo Number of subject 2400 2404 IDFS (Event-free proportion at 3 years) 94% 93%                                                                                                                                 | Treatment group Ptz + H + Chemo Pla + H + Chemo Number of subject 2400 2404 IDFS (Event-free proportion at 3 years) 94% 93%                                                                                                                                 | Treatment group Ptz + H + Chemo Pla + H + Chemo Number of subject 2400 2404 IDFS (Event-free proportion at 3 years) 94% 93%                                                                                                                                 |
|                                                                | 95%-CI                                                                                                                                                                                                                                                      | 93.09-95.03                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                             | 92.21-94.26                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                             |
|                                                                | IDFS-SPNBC (Event-free proportion years)                                                                                                                                                                                                                    | 93.5%                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                             | 92.5%                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                             |
|                                                                | at 3 95%-CI                                                                                                                                                                                                                                                 | 92.49-94.51                                                                                                                                                                                                                                                 | 91.43-93.58                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |
|                                                                | DFS                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             | 92.3%                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                             |
|                                                                |                                                                                                                                                                                                                                                             | 93.4%                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                                | 95%-CI                    | 92.40-94.43               | 91.21-93.38                |
|--------------------------------|---------------------------|---------------------------|----------------------------|
| Effect estimate per comparison | IDFS ITT population       | Comparison groups         | Ptz+H+Chemo vs Pla+H+Chemo |
| Effect estimate per comparison | IDFS ITT population       | HR                        | 0.81                       |
| Effect estimate per comparison | IDFS ITT population       | 95%-CI                    | 0.66-1.00                  |
| Effect estimate per comparison | IDFS ITT population       | P-value                   | 0.0446                     |
| Effect estimate per comparison | IDFS-SPNBC                | Comparison groups         | Ptz+H+Chemo vs Pla+H+Chemo |
| Effect estimate per comparison | IDFS-SPNBC                | HR                        | 0.82                       |
| Effect estimate per comparison | IDFS-SPNBC                | 95%-CI                    | 0.68-0.99                  |
| Effect estimate per comparison | IDFS-SPNBC                | P-value                   | 0.0430                     |
| Effect estimate per comparison | DFS                       | Comparison groups         | Ptz+H+Chemo vs Pla+H+Chemo |
| Effect estimate per comparison | DFS                       | HR                        | 0.81                       |
| Effect estimate per comparison | DFS                       | 95%-CI                    | 0.67-0.98                  |
| Effect estimate per comparison | DFS                       | P-value                   | 0.0327                     |
| Notes                          | OS not mature, 26% events | OS not mature, 26% events | OS not mature, 26% events  |

## Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable.

## Clinical studies in special populations

Not applicable.

## Supportive study(ies)

Not applicable.

## 2.4.3. Discussion on clinical efficacy

Perjeta is already authorised in the European Union (EU) for use in combination with trastuzumab and docetaxel in patients with HER2 positive metastatic breast cancer (MBC), who have not received previous anti-HER2  therapy  or  chemotherapy  for  their  metastatic  disease,  and  for  use  in  combination  with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2 -positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.

The proposed new indication (as finally agreed to be restricted) is:

## Early Breast Cancer

Perjeta is indicated for use in combination with trastuzumab and chemotherapy in:

- the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence (see section 5.1)

The proposed dose of Perjeta is unchanged.

The efficacy of adding Perjeta to standard chemotherapy and trastuzumab is supported by the APHINITY study (pivotal study).

<div style=\"page-break-after: always\"></div>

## Design and conduct of clinical studies

To support the efficacy of Perjeta in the sought indication, the MAH submitted results from one single study (APHINITY).  The  APHINITY  study  is  an  ongoing  phase  III,  prospective,  randomized,  double-blind, placebo-controlled, multicenter, two-arm clinical study in HER2-positive operable early breast cancer. The eligibility criteria were generally appropriate, although the number of possible chemotherapy regimens could have been more limited to reduce bias. Patients were randomized 1:1 to standard chemotherapy 6-8 cycles (investigator's choice) plus trastuzumab plus pertuzumab or placebo (2400 patients to the Ptz+H+Chemo arm  and  2405  patients  to  the  Pla+H+chemo  arm)  from  08  November  2011  to  31  August  2013). Trastuzumab and pertuzumab or placebo was given IV 3-weekly for 52 weeks.

The method for randomization is considered adequate. Both nodal status and hormone receptor status are prognostic factors for the primary endpoint, hence the stratification according to these factors is supported. The two different adjuvant chemotherapy regimens corresponds to potentially different time points for initiation  of  targeted  treatment  relative  to  surgery,  stratification  according  to  adjuvant  chemotherapy regimen is supported.

The study population defined by the inclusion- and exclusion criteria is generally endorsed, as it resembles the patient population, who should receive adjuvant chemotherapy and trastuzumab according to the ESMO guideline. However, due to the relatively high risk of recurrence in the HER2-positive population, even in node-negative  patients  with  tumours  &lt;1  cm,  ESMO  recommends  to  consider  anti-HER2  treatment, particularly in case of ER-negative disease. According to the inclusion criteria of the APHINITY trial, some of these patients are excluded, e.g. patients with tumor size less than 0.5 cm, probably for the purpose of including patients with higher risk of relapse. Since it is considered not to have a significant impact on the trial results, it is acceptable that patients were excluded by this criterion.

Additionally, subjects with prior malignancies within 5 years and previous chemotherapy/anti-HER2 therapy were excluded. This is endorsed, as it ensures a homogenous population with no late effects of previous cancer treatment or increased risk of recurrence or death.

It is noted, however, that following the observation that the proportion of node-negative disease patients enrolled in the first year was nearly twice that expected, the study was amended and the inclusion of patients with node-negative was stopped in order to have a population consistent with Study BCIRG 006, upon  which  assumptions  of  the  APHINITY  Study  were  based.    The  MAH  acknowledges  that  stopping recruitment of node-negative patients into the study have resulted in a patient population that may not be entirely representative of all patients with HER2-positive early breast cancer, but this choice was driven by the intention to have a population similar to BCIRG006 study, and focusing on node-positive patients that were at a higher risk of relapse and in a greater need of more effective treatments. Moreover, for these patients the  assumptions were based on a more robust evidence and a stronger treatment effect was expected. In light of the new proposed indication, this approach is no longer an issue. Adjuvant radiotherapy and/or  endocrine  therapy  was  started  after  the  end  of  chemotherapy  and  in  accordance  with  protocol recommendations.

The rather small imbalances recorded in the use of adjuvant radiotherapy and endocrine therapy in the APHINITY study across geographical regions are not considered to pose any major biases on the efficacy results of the study.

A total of 4 analyses of OS are planned. The first and the last of these are event driven, but for the second and third interim analysis, the Applicant has provided the requested details regarding the timing of the analyses.

The  primary  endpoint  was  invasive  disease-free  survival  (IDFS).  Secondary  endpoints  included  IDFS excluding  second  non-breast  malignancies  (IDFS-SPNBC);  disease-free  survival  (DFS);  overall  survival

<div style=\"page-break-after: always\"></div>

(OS);  recurrence-free  survival  (RFI);  distant  recurrence-free  interval  (DRFI);  safety  and  quality  of  life (QOL). The chosen endpoints were assessed clinically relevant and appropriate for an adjuvant breast cancer trial.

The study had 80% power to detect a hazard ratio 0.75 for IDFS with an alpha 5% (two-sided) significance level. A total enrolment of 3806 patients was initially planned (Protocol A). Patients were initially stratified according to nodal status, adjuvant chemotherapy regimen, hormone receptor status, and geographical region. A sample size reassessment was done after approximately 1900 patients had been recruited at a pace more than 50% higher than expected (September 2012); the sample size was increased from 3806 to 4800 patients (Protocol B), and on the basis of available data, the period of enrolment was reduced from 27 to 25 months and the expected time for observing 379 events was estimated to be at 46 months instead of 55 months from the date the last patient was randomized.

Analysis of IDFS stratified according to the original randomization factors of adjuvant chemotherapy, nodal status, central hormone receptor status and geographical region was consistent with the primary result.

Major protocol deviations were balanced between arms, and are not expected to have impacted the results. The analysis methods for the time to event endpoints are appropriate, and a series of relevant sensitivity analyses investigating potential for bias due to potential imbalance in assessments and follow-up time, as well as the robustness of the primary analysis are planned. Requested details have been provided regarding the start of new anti-cancer therapy and there are no considerable impact on the study outcome.  The Applicant have clarified that 15.5% (n = 372) of patients in the Perjeta arm vs. 12.6% (n = 304) of patients in the placebo arm discontinued Perjeta/placebo. There are no meaningful imbalances between the two arms, safety being the most common reason for premature discontinuation.

More than 99% of patients in each arm were female, with only 11 male patients enrolled in the study. A quarter of the patients were recruited after protocol amendment B. In order to assess the impact of the changes introduced with Protocol B, demographics and baseline characteristics summarised by Protocol Version were to be provided, as planned. Apart from a higher prevalence of Asian patients due to the differential  timings  in  the  approval  of  clinical  trial  application,  all  other  differences  (e.g.  higher  rate  of mastectomy, larger tumor size) are expected based on the decision to enroll only node-positive patients. The difference in 3-year IDFS appears to be driven by node-positive patients.

Patients received both adjuvant radiotherapy and endocrine therapy according to standard practice, and these may differ between sites, especially the radiotherapy standard practice may vary according to local practices and available equipment. The available endocrine therapies are quite uniform in their efficacy profiles and it is therefore less problematic if there are differences in the use and sequence of e.g. aromatase inhibitors,  but  the  duration  of  the  adjuvant  therapy  matters.  As  adjuvant  radiotherapy  and  endocrine therapy prevent both local and distant recurrences, these variations may present important biases. The Applicant has provided additional information about this and after a thorough review, it is agreed that the rather small imbalances recorded in the use of adjuvant radiotherapy and endocrine therapy in the APHINITY study across geographical regions are not considered to pose any major biases on the efficacy results of the study.

## Efficacy data and additional analyses

The study met its primary endpoint at the time of primary analysis with 4 years of follow-up. Treatment with  pertuzumab  plus  trastuzumab  and  standard  chemotherapy  resulted  in  a  statistically  significant improvement in IDFS, corresponding to a 19% reduction in the risk of recurrence or death, as compared to placebo plus trastuzumab and standard chemotherapy (HR 0.81, 95%CI 0.66; 1.00, p=0.0446) in the adjuvant setting of early breast cancer. The K-M IDFS curves tend to overlap up to 2 years. Estimates of IDFS event-free rates at 3 years were 94.06% vs. 93.24% in the Ptz+H+Chemo vs. Pla+H+ Chemo arms,

<div style=\"page-break-after: always\"></div>

respectively, and at 4 years were 92.28% vs. 90.58%, suggesting a sustained benefit over time after the end of treatment (1-year duration). At this point in time 171 patients (7.1%) in the pertuzumab arm versus 210 patients (8.7%) in the placebo arm have had an event. Of these patients, 112 patients (4.7%) vs. 139 patients  (5.8%)  had  a  distant  recurrence  as  the  most  frequent  IDFS  event.  This  reflects  the  fact  that adjuvant treatment of breast cancer is aimed at preventing incurable distant recurrences and these results show that local recurrence is not the major issue with this disease. Most of the distant metastases were located in the CNS, lung, and liver. Hence, a reduction of risk of invasive disease can often be translated into a clinically relevant prevention of incurable disease, only amendable for palliative treatment and ultimately resulting  in  death.  Therefore,  considering  the  low  number  of  events  so  far,  the  results  are  considered clinically meaningful. Moreover, the efficacy of the addition of pertuzumab is expected to be consistent and may be even improved over time as more events occur, because the adding of pertuzumab have shown convincing improvement of efficacy in the neoadjuvant and metastatic setting.

Another issue is the known increased risk of CNS disease in the HER2-positive population, as submitted data show that the incidence of CNS metastases was similar in the two treatment arms (1.8% vs. 1.9%), and although numbers are small, this may reflect poor CNS penetration of the adjuvant treatment including pertuzumab. To our knowledge, there are no conclusive data regarding the efficacy of pertuzumab in the CNS and therefore the activity is expected to be similar to that of trastuzumab in terms of its limited ability to cross the blood-brain barrier.  The Applicant provided further knowledge on the CNS efficacy of Perjeta, as requested. It is agreed that it may be difficult, and maybe not possible, to distinguish between the efficacy of trastuzumab and pertuzumab, when given concomitantly. It is considered encouraging that uptake of pertuzumab in CNS metastases have been observed by PET/CT in a study by Ulaner et al. 2017, however, an actual treatment benefit has not yet sufficiently been shown. It is agreed that the suggested additional 5 years of follow-up time in the APHINITY study will provide valuable information on this subject, including the Applicant's hypothesis that Perjeta may delay time to CNS metastases.

The  key secondary  endpoints were  invasive  disease-free  survival  including  second  non-breast malignancies (IDFS-SPNBC), disease-free survival (DFS), and overall survival (OS). Results for IDFS-SPNBC was similar to IDFS, and showed a clinically meaningful and statistical difference favouring the pertuzumab arm (HR 0.82, 95% CI 0.68; 0.99, p=0.0430). DFS also showed a significant benefit with the addition of pertuzumab (HR 0.81, 95% CI 0.67; 0.98, p=0.0327). Overall survival data was immature. As patients with recurrent disease have several treatment options, the overall survival is not expected to be affected before the time of the final analysis (10 years after last patient randomized), occurring in the year 2023. Moreover, it is not considered an issue with regard to the B/R assessment of the present application. Having in mind, that in the HERA trial of adjuvant trastuzumab, OS was not statistically significant until 8 years had passed, the submitted results are considered acceptable and as could be expected at this point in time. Importanty, the available data on OS and other endpoints did not raise any concerns.

The exploratory endpoints were recurrence-free interval (RFI), distant recurrence-free interval (DRFI), and breast cancer-free interval (BCFI). RFI showed a clinically significant improvement (HR 0.79, 95% CI 0.63; 0.99, p=0.0430) as well as BCFI (HR 0.77, 95% CI 0.62; 0.96, p=0.0186). The DRFI did not show a statistically  significant  difference  between  the  arms,  probably  due  to  too  few  events  (5%  vs.  6%, respectively).

Patient-reported outcome showed a considerable decline in physical function and global health status during chemotherapy and the incidence was similar in both treatment arms. This is considered to be due to the known toxicity profile of chemotherapy and is considered confirmed by the fact that scores improved and returned  to  baseline  levels  after  chemotherapy  had  ended  and  patients  only  received  HER2-targeted treatment. Diarrhoea is a known treatment-related adverse effect of both pertuzumab and taxanes, so the increased incidence of diarrhoea and the effect on PRO was expectable and does seem to be manageable in the short period of time when both therapies were given concomitantly (9 weeks). Overall, it is considered encouraging that all patients returned to or remained at baseline levels during the follow-up period (Months

<div style=\"page-break-after: always\"></div>

18, 24, and 36) according to the patient-reported treatment-related symptoms, all function scales, and global health status.

All sensitivity analyses were in favour of the pertuzumab arm, but only some were statistically significant. Many of the sensitivity analyses investigated the effect of stratification with results almost identical to the primary analysis. In addition, the effect of discontinuation, withdrawal, and start of new anti-cancer therapy were investigated in the sensitivity analyses. As new anti-cancer therapy was broadly defined, and the reasons have been clarified sufficiently by the Applicant, the previous issues regarding this has now been resolved.

Subgroup analyses were performed for the primary endpoint IDFS, however, they were not powered to detect  a  statistically  significant  effect  and  was  considered  exploratory  by  the  Applicant.  Patients  with node-positive disease (n=3005) have a high risk of recurrence and not surprisingly, there were a markedly greater benefit in this subgroup (HR 0.77, 95% CI 0.62; 0.96). This may reflect that these high-risk patients get a recurrence earlier in time than other subgroups, and results show a higher number of events in this subgroup (12% vs 9%). Patients with node-negative disease (n=1799) have a low risk of recurrence and results for this subgroup was not statistically significant (HR 1.13, 95% CI 0.68; 1.86), however, less than 4% of the patients have had an event and the confidence intervals are wide. This reflects the low risk, although it is expected that over time, this group will probably also obtain significant benefit. As HR-positive disease recur later in time compared to other subgroups, this is what may be reflected by this analysis. Hormone receptor-negative patients is another high-risk subgroup (n=1722) and appeared to have a benefit  from  the  addition  of  pertuzumab,  however,  the  differences  were  not  significant  because  the confidence intervals were very wide and included 1. The number of events was 11% vs 8%, respectively, indicating immaturity of data. However, it is important to note that in the HERA trial, as well as in BCIRG 006 trial,  based  on  which  the  assumptions  were  made,  the  benefit  from  the  addition  of  trastuzumab  was observed regardless of nodal status. Due to rate of accrual much higher than expected, and subsequent to the amendments introduced to the study design (stop of the enrolment of node-negative subjects, and increase of the sample size based on the inclusion of solely node-positive subjects), the target number of events for the primary IDFS analysis was expected to be reached earlier than initially planned. However, in practice it took longer to reach 379 events than estimated under both protocol A and protocol B. This is especially relevant for the subset of patients at lower risk of recurrence, such as node-negative patients, whose representativeness was also artificially reduced, and that experienced relatively few events compared to node-positive patients. Despite the stop of the enrolment of node-negative patients, introduced with protocol amendment of 20 November 2012 (i.e. 12 months after first patient enrolled), the median follow-up in the node-negative subgroup (48.3 months) was only slightly longer than the overall population (45.4 months), and the node-positive subgroup (44.5 months), and events were observed only in 3.5% of the patients in this subset of patients, with a rate of recurrences in node-positive subjects (10.3%) that was almost three times the one observed in node-negative patients.

In conclusion, the results observed in the overall population could appear to be driven by the node-positive subgroup that has been artificially increased with protocol amendment. It cannot be excluded that with a longer follow-up, a benefit could be shown also for node-negative patients, but this is not self-evident. Even though exploratory analyses of treatment by subgroup interaction effects did not indicate heterogeneity of treatment effect, and there are no biological explanation for assuming a lower activity of pertuzumab in node-negative  patients,  based  on  the  available  data  and  the  observed  low-risk  of  recurrence  in  this subgroup treated with standard of care chemotherapy + trastuzumab, the need and the benefit of dual anti-HER2 regimen in node-negative subjects may nevertheless be questioned. The Applicant restricted the initially  proposed  indication  to  adult  patients  with  HER2-positive  early  breast  cancer  \"at  high  risk  of recurrence\",  i.e.  to  the  protocol  pre-defined  subgroups  of  node-positive  or  hormone-receptor  negative patients, as the current results are clinically significant at this point in time due to higher risk of recurrence and therefore more events in these subgroups. A reference to section 5.1 was added, with the subgroup

<div style=\"page-break-after: always\"></div>

analyses, and a clarification that high-risk patients were defined as those with node-positive or hormone receptor-negative disease.

The rather small imbalances recorded in the use of adjuvant radiotherapy and endocrine therapy in the APHINITY study across geographical regions are not considered to pose any major biases on the efficacy results of the study.

The Applicant proposed to extend the follow-up time by additional 5 years, because it is considered that within this time frame clinically relevant information could be provided. It is considered that the extended follow-up will be very informative both with regard to the number of relapses over time (especially in the CNS) and the extent of late toxicity from the adjuvant treatment.

The data regarding HER2 protein expression levels should be interpreted cautiously due to the small sample size, the nature of an exploratory analysis, and because the analysis was not adjusted for other prognostic factors such as nodal status. However, it is noted that HER2 protein expression levels could be a clinically relevant factor, and the subgroup analysis may become relevant the time of the final analysis.

## 2.4.4. Conclusions on the clinical efficacy

Based on the results from the primary analysis of the APHINITY study, the efficacy of adding pertuzumab to standard chemotherapy and trastuzumab is not considered demonstrated in the ITT population. The study treatment reduced the risk of relapse or death by 19%, and as the majority of the observed relapses were distant, this translates into prevention of incurable disease, only amendable for palliative treatment and ultimately resulting in death. However, the borderline statistically significant benefit was not considered supported by all secondary endpoints and sensitivity analyses, and seems to be mainly driven by the highest risk  subgroups.  Hence,  the  efficacy  of  adding  pertuzumab  to  standard  chemotherapy  is  considered demonstrated  in  the  high-risk  subgroups  of  patients  with  node-positive  or  hormone-receptor-negative disease, where the efficacy has been significantly demonstrated to a clinically relevant extent. In addition, it is  considered that results in the adjuvant setting may improve over time as more events occur, in the context of pertuzumab's established efficacy in the neoadjuvant and metastatic setting of breast cancer.

In conclusion, efficacy has been demonstrated in the indication of high-risk patients with node-positive or hormone receptor-negative disease.

## 2.5. Clinical safety

## Introduction

The overall safety profile of Ptz + H + Chemo in the APHINITY study was consistent with the known safety profile of Perjeta in combination with trastuzumab and standard chemotherapy in HER2-positive metastatic or inoperable breast cancer, and no new or unexpected toxicities were reported. The frequency and nature of AEs reported were as expected for this study population, and for the treatment regimens being assessed. The overall incidence of primary cardiac events was &lt; 1% of patients in both arms.

## Patient exposure

In total, the APHINITY study provides safety data on 2364 patients exposed to Perjeta plus trastuzumab and standard  chemotherapy  (Ptz + H + Chemo)  in  the  adjuvant  setting.  Safety  data  have  previously  been submitted for more than 2000 patients treated with Perjeta alone or in combination with a range of Herceptin and/or chemotherapy regimens in registration-directed and supporting clinical trials in the neoadjuvant and

<div style=\"page-break-after: always\"></div>

metastatic settings. In addition, it is estimated that more than 160,000 patients have received Perjeta in routine clinical practice based on marketing data, and includes those treated in the EBC and metastatic breast cancer setting.

Patients were further categorized according to chemotherapy regimen received (anthracycline-based or non-anthracycline-based):

- Ptz+H+Chemo (safety population, n=2364)
- o Ptz + H + anthracycline: N=1834
- o Ptz + H + non-anthracycline: N=528
- Pla+H+Chemo (safety population, n=2405)
- o Pla + H + anthracycline: N=1894
- o Pla + H + non-anthracycline: N=510

Note  that  a  total  of  2362  patients  in  the  Ptz + H + Chemo  arm  were  categorized  as  receiving  an anthracycline-based regimen (1834 patients) or a non-anthracycline-based regimen (528 patients) but the number of patients in the Ptz+H+Chemo safety population was 2364 (a difference of 2 patients). Similarly, a total of 2404 patients in the Pla + H + Chemo arm were categorized as receiving an anthracycline-based regimen (1894 patients) or a non-anthracycline-based regimen (510 patients), but the number of patients in the Pla+H+Chemo safety population was 2405 (a difference of one patient). The reason for the difference is  because  a  total  of  three  patients  did  not  receive  any  carboplatin.  To  be  categorized  as  receiving  a non-anthracycline-based regimen, patients had to have received at least one dose of carboplatin, and have no exposure to anthracyclines. Patients who only received a taxane (regardless of whether they received Perjeta, placebo or Herceptin) could not be assigned to either the non-anthracycline or the anthracycline cohorts.

At the time of the clinical cut-off for the primary analysis (19 December 2016), 2028 patients (84.5%) in the Ptz + H + Chemo arm and 2100 patients (87.4%) in the Pla + H + Chemo arm had completed treatment. The remaining patients (372 [15.5%] in the Ptz + H + Chemo arm and 304 [12.6%] in the Pla + H + Chemo arm) did not complete, or never started, Perjeta or placebo treatment.

Overall, the median duration of study treatment (64 weeks), as well as targeted treatment (55 weeks), was the same in both treatment arms (Table 42). Note that the duration of treatment includes 28 days after the last dose of study medication representing the timing of the end of study treatment visit and the reporting period for adverse events during the treatment period.

<div style=\"page-break-after: always\"></div>

## Table 42 Overview of Treatment Duration by Treatment Regimen (Safety Population)

Overview of Treatment Duration by Treatment Regimen, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

Study Treatment Period Duration (weeks)

Anthracycline Treatment Duration (weeks)

Taxane + Targeted Treatment Duration (weeks)

Targeted Treatment Duration (weeks)

Range                                      4 - 59         4 - 70

| ______________________________________________________________________   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab + Chemotherapy (N=2405)   |
|--------------------------------------------------------------------------|----------------------------------------------------|-------------------------------------------------|
| Study Treatment Period Duration (weeks)                                  |                                                    |                                                 |
| n                                                                        | 2364                                               | 2405                                            |
| Median                                                                   | 64                                                 | 64                                              |
| Range                                                                    | 4 - 80                                             | 4 - 74                                          |
| Anthracycline Treatment Duration (weeks)                                 |                                                    |                                                 |
| n                                                                        | 1834                                               | 1894                                            |
| Median                                                                   | 11                                                 | 13                                              |
| Range                                                                    | 4 - 26                                             | 4 - 18                                          |
| Taxane + Targeted Treatment Duration (weeks)                             |                                                    |                                                 |
| n                                                                        | 2364                                               | 2338                                            |
| Median                                                                   | 55                                                 | 55                                              |
| Range                                                                    | 4 - 59                                             | 4 - 70                                          |
| Targeted Treatment Duration (weeks)                                      |                                                    |                                                 |
| n                                                                        | 2364                                               | 2335                                            |
| Median                                                                   | 55                                                 | 55                                              |
| Range                                                                    | 4 - 59                                             | 4 - 70                                          |

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ex\\_dur.sas / Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ex\\_dur\\_TRT1A\\_SE.out 21MAR2017  20:16 Page

1 of 1

## Summary of exposure to Anthracycline-based chemotherapy:

|                                                 | Ptz +H + Chemo arm (N=1834)   | Pla + H + Chemo arm (N=1894)   |
|-------------------------------------------------|-------------------------------|--------------------------------|
| Completed anthracycline                         | 1818 (99.1%)                  | 1847 (97.5%)                   |
| Completed taxane                                | 1650 (90.0%)                  | 1674 (88.4%)                   |
| Completed chemo + targeted therapy              | 1586 (86.5%)                  | 1600 (84.5%)                   |
| Completed targeted therapy but not chemotherapy | 10 (0.5%)                     | 15 (0.8%)                      |

## Summary of exposure to Non-anthracycline-based chemotherapy:

|                                          | Ptz+H+ Chemo (N=528)   | Pla+ H + Chemo (N=510)   |
|------------------------------------------|------------------------|--------------------------|
| Completed docetaxel and carboplatin (TC) | 448 (84.1%)            | 469 (91.6%)              |
| Completed TC+ targeted therapy           | 416 (78.8%)            | 448 (87.8%)              |
| Completed targeted therapy but not TC    | 37 (7.0%)              | 13 (2.5%)                |
| Median treatment duration? (range)       | 55 (4-59)              | 55 (4-59)                |

## Dose Adjustments/Delays

Perjeta/placebo dose delays or interruptions due to toxicities were permitted in APHINITY. Perjeta/placebo was administered without the need for dose adjustment/delays in 1156 patients (48.9%) vs. 1194 patients (49.6%).

<div style=\"page-break-after: always\"></div>

## Table 43

Prot0c01:BIG 4-11/B025126/T0C4939G

|                                                             | Pertuzumab Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab Chemotherapy (N=2405)   |
|-------------------------------------------------------------|--------------------------------------------------|-----------------------------------------------|
| Treatment Duration (weeks)                                  |                                                  |                                               |
| n                                                           | 2364                                             | 2335                                          |
| Median                                                      | 54                                               | 54                                            |
| Range                                                       | 3 - 58                                           | 3-69                                          |
| Number of Infusions (stat)                                  |                                                  |                                               |
| n                                                           | 2364                                             | 2335                                          |
| Median                                                      | 18                                               | 18                                            |
| Range                                                       | -22                                              | -18                                           |
| Number of Infusions (cat)                                   |                                                  |                                               |
| <12                                                         | 182 7.78)                                        | 145 6.08)                                     |
| 12 - 16                                                     | 144 6.18)                                        | 148 6.28)                                     |
| 17                                                          | 422 (17.98)                                      | 374 (15.68)                                   |
| > 17                                                        | 1616 (68.48)                                     | 1668 (69.48)                                  |
| Number（&)of Patients Completing atLeast:                    |                                                  |                                               |
| 1 infusion                                                  | 2364 (100.0%)                                    | 2335 (97.18)                                  |
| 4 infusions                                                 | 2285 96.78)                                      | 2281 (94.88) 2241                             |
| 6infusions                                                  | 2253 95.38)                                      | (93.28)                                       |
| 12 infusions                                                | 2182 92.38)                                      | 2190 (91.18)                                  |
| 17 infusions                                                | 2038 86.28)                                      | 2042 (84.98)                                  |
| Cumulative Dose (mg)                                        |                                                  |                                               |
| n                                                           | 2364                                             | 2335                                          |
| Median                                                      | 7980                                             | 0                                             |
| Range                                                       | 420 - 9660                                       | 0                                             |
| Number of Dose Adjustments/Delays (stat)                    |                                                  |                                               |
| n                                                           | 2364                                             | 2335                                          |
| Median                                                      | 1                                                | 0                                             |
| Range                                                       | 0 8                                              | 0                                             |
| Number of Dose Adjustments/Delays (cat)                     |                                                  |                                               |
| 0                                                           | 1156 (48.9%)                                     | 1194 (49.6号)                                  |
| 12                                                          | 699 (29.6号)                                      | 664 (27.6%)                                   |
|                                                             | 307 (13.0%)                                      | 303 (12.6%)                                   |
| >2                                                          | 202 (8.58)                                       | 174 (7.28)                                    |
| Number of DoseAdjustments/Delays due to AdverseEvent (stat) |                                                  |                                               |
| n                                                           | 2364                                             | 2335                                          |
| Median                                                      | 0                                                | 0                                             |
| Range                                                       | -6                                               | 0- 5                                          |
| Treatmentdurationrelates toPertuzumab/placebo.              |                                                  |                                               |

Page 1 of 1

Program:/opt/BI0sTAT/prod/cdp11450/r25126a/t\\_ex.sas/Output: /opt/BI0STAT/prod/cdl1450g/j25126a/reports/t\\_ex\\_TRT1A\\_PP\\_SE.out 24MAR20179:46

Note:11patients inthePtz+H+Chemo amreceived&gt;18cyclesofpertuzumab.

## Adverse events

<div style=\"page-break-after: always\"></div>

Table 44 Summary of Adverse Events in the APHINITY Study

|                                                         | Treatment Arm   | Treatment Arm              |
|---------------------------------------------------------|-----------------|----------------------------|
| Ptz + H + Chemo                                         | (N = 2364)      | Pla + H + Chemo (N = 2405) |
| Patients with                                           |                 |                            |
| Any AE                                                  | 99.9%           | 99.5%                      |
| Grade 3 - 5 AE                                          | 64.2%           | 57.3%                      |
| Serious AE                                              | 29.3%           | 24.3%                      |
| AE leading to treatment withdrawal a                    | 13.1%           | 11.5%                      |
| AE leading to Perjeta/placebo withdrawal                | 7.0%            | 5.8%                       |
| AE leading to any treatment interruption/modification b | 51.5%           | 44.2%                      |
| AE leading to Perjeta/placebo interruption/modification | 30.6%           | 26.3%                      |
| AEs leading to death c                                  | 0.8% d          | 0.8% d                     |
| Death due to recurrent disease                          | 2.0%            | 2.6%                       |
| Death due to other causes e                             | 0.3%            | 0.5%                       |
| Cardiac Safety                                          |                 |                            |
| Primary cardiac event f                                 | 0.7%            | 0.3%                       |
| Secondary cardiac event g                               | 2.7%            | 2.8%                       |
| Other Events to Monitor                                 |                 |                            |
| Diarrhea: All Grades                                    | 71.3%           | 45.2%                      |
| Grade ≥ 3                                               | 9.9%            | 3.7%                       |
| Rash: All Grades                                        | 51.9%           | 41.7%                      |
| Grade ≥ 3                                               | 2.5%            | 1.5%                       |
| Leukopenia: All Grades                                  | 49.8%           | 48.1%                      |
| Grade ≥ 3                                               | 37.3%           | 35.0%                      |
| Infusion-Related Reaction: All Grades                   | 54.7%           | 51.3%                      |
| Grade ≥ 3                                               | 2.7%            | 2.1%                       |
| Anaphylaxis & Hypersensitivity: All Grades              | 4.9%            | 3.6%                       |
| Grade ≥ 3                                               | 0.8%            | 0.7%                       |
| Interstitial Lung Disease: All Grades                   | 0.8%            | 0.9%                       |
| Grade ≥ 3                                               | 0.2%            | 0.2%                       |
| Mucositis: All Grades                                   | 57.0%           | 49.1%                      |
| Grade ≥ 3                                               | 4.9%            | 2.3%                       |

Source: Table 44 ; Table 55  and Table 58  in the APHNITY Primary CSR.

<div style=\"page-break-after: always\"></div>

## Table 45 Adverse Events with an Incidence Rate of at least 5% in Either Treatment Arm (Safety Population)

Most Common (&gt;=5%) Adverse Events by Treatment Regimen, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

| MedDRA Preferred Term                                                                  | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)                                       | Placebo + Trastuzumab + Chemotherapy (N=2405)   |                  |
|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------|------------------|
| ______________________________________________________________________________________ | 1632 (69.0%)                                                                           | 1575 (65.5%)                                    |                  |
| NAUSEA ALOPECIA                                                                        | 1577 (66.7%)                                                                           | 1610 (66.9%)                                    |                  |
| DIARRHOEA                                                                              | 1683 (71.2%)                                                                           | 1086 (45.2%)                                    |                  |
| FATIGUE                                                                                | 1154 (48.8%)                                                                           | 1065 (44.3%)                                    |                  |
| VOMITING                                                                               | 768 (32.5%)                                                                            | 733 (30.5%)                                     |                  |
| ARTHRALGIA                                                                             | 678 (28.7%)                                                                            | 782 (32.5%)                                     |                  |
| CONSTIPATION                                                                           | 684 (28.9%)                                                                            | 759 (31.6%)                                     |                  |
| MYALGIA                                                                                | 615 (26.0%)                                                                            | 710 (29.5%)                                     |                  |
| STOMATITIS                                                                             | 671 (28.4%)                                                                            | 573 (23.8%)                                     |                  |
| ANAEMIA                                                                                | 655 (27.7%)                                                                            | 557 (23.2%)                                     |                  |
| NEUTROPENIA                                                                            | 587 (24.8%)                                                                            | 562 (23.4%)                                     |                  |
| DYSGEUSIA                                                                              | 614 (26.0%) 609                                                                        | 518 (21.5%)                                     |                  |
| RASH HEADACHE                                                                          | (25.8%)                                                                                | 488 (20.3%)                                     |                  |
| DECREASED APPETITE                                                                     | 531 (22.5%) 565 (23.9%)                                                                | 563 (23.4%) 478 (19.9%)                         |                  |
| ASTHENIA                                                                               | 505 (21.4%)                                                                            |                                                 |                  |
|                                                                                        |                                                                                        | 500 (20.8%)                                     |                  |
| MUCOSAL INFLAMMATION HOT FLUSH                                                         | 552 (23.4%) 482 (20.4%)                                                                | 448 (18.6%) (21.2%)                             |                  |
| PYREXIA                                                                                | 473 (20.0%)                                                                            | 509 469 (19.5%)                                 |                  |
| OEDEMA PERIPHERAL                                                                      |                                                                                        |                                                 |                  |
| PERIPHERAL SENSORY NEUROPATHY                                                          | 405 (17.1%) 427 (18.1%)                                                                | 483 (20.1%) 422 (17.5%)                         |                  |
| INSOMNIA                                                                               | 404 (17.1%)                                                                            | 400 (16.6%)                                     |                  |
| EPISTAXIS                                                                              | 430 (18.2%)                                                                            | 326 (13.6%)                                     |                  |
| NEUROPATHY PERIPHERAL                                                                  | 366 (15.5%)                                                                            | 369 (15.3%)                                     |                  |
| COUGH DYSPEPSIA                                                                        | 374 (15.8%)                                                                            | 351 (14.6%) 341                                 |                  |
| NEUTROPHIL                                                                             | 325 (13.7%)                                                                            | (14.2%)                                         |                  |
| COUNT DECREASED LACRIMATION INCREASED                                                  | 327 (13.8%) 310 (13.1%)                                                                | 330 (13.7%) 322 (13.4%)                         |                  |
| NASOPHARYNGITIS                                                                        |                                                                                        | 284 (11.8%)                                     |                  |
| DRY SKIN                                                                               | 316 (13.4%) 311 (13.2%)                                                                | 268 (11.1%)                                     |                  |
| NAIL DISORDER                                                                          | 280 (11.8%)                                                                            | 284 (11.8%)                                     |                  |
| RADIATION SKIN INJURY DYSPNOEA                                                         | 298 (12.6%)                                                                            | 266 (11.1%) g                                   |                  |
| FEBRILE NEUTROPENIA                                                                    | 281 (11.9%)                                                                            | 277 (11.5%) 266 (11.1%)                         |                  |
| ABDOMINAL PAIN                                                                         | 287 (12.1%) 287 (12.1%)                                                                | 262 (10.9%) (                                   |                  |
| PRURITUS                                                                               | 331 (14.0%)                                                                            | 217 9.0%) 275 (11.4%)                           |                  |
| DIZZINESS                                                                              | 270 (11.4%)                                                                            |                                                 |                  |
| PARAESTHESIA PAIN IN                                                                   | 278 (11.8%) (10.0%)                                                                    | 240 (10.0%) (10.5%)                             |                  |
| EXTREMITY BONE PAIN                                                                    | 236 223 ( 9.4%)                                                                        | 252 256 (10.6%) 244                             |                  |
| ALANINE AMINOTRANSFERASE INCREASED ABDOMINAL PAIN UPPER                                | 221 ( 9.3%) 245                                                                        | (10.1%) 218 ( 214 (                             |                  |
| ERYTHEMA                                                                               | (10.4%) 235 ( 9.9%)                                                                    | 9.1%) 8.9%) 238 ( 9.9%)                         |                  |
|                                                                                        | 207 ( 8.8%)                                                                            |                                                 |                  |
| BACK PAIN WHITE BLOOD CELL DECREASED                                                   | 234 ( 9.9%)                                                                            | 206 ( 8.6%) 222 ( 9.2%)                         |                  |
| COUNT LEUKOPENIA MUSCULOSKELETAL PAIN                                                  | 216 ( 9.1%)                                                                            | 216 (                                           |                  |
| OROPHARYNGEAL PAIN PALMAR-PLANTAR ERYTHRODYSAESTHESIA                                  | 201 ( 8.5%) 216 ( 217 (                                                                | 9.0%) 175 ( 158 (                               |                  |
| SYNDROME UPPER RESPIRATORY TRACT INFECTION                                             | 9.1%) 191 (                                                                            | 7.3%) 177 (                                     |                  |
| NAIL DISCOLOURATION                                                                    | 9.2%) 8.1%) 175 ( 7.4%)                                                                | 6.6%) 7.4%) 178 (                               |                  |
|                                                                                        | Pertuzumab + Trastuzumab                                                               | 7.4%) Placebo + Trastuzumab                     |                  |
|                                                                                        | + Chemotherapy (N=2364)                                                                | (N=2405)                                        |                  |
| MedDRA Preferred Term                                                                  | ______________________________________________________________________________________ | + Chemotherapy                                  |                  |
|                                                                                        | 187 ( 7.9%) 217 ( 9.2%)                                                                | 163 ( 6.8%) 123 ( 5.1%) 135 ( 5.6%)             |                  |
| URINARY TRACT INFECTION MUSCLE SPASMS                                                  | 191 ( 8.1%) 157 ( 6.6%)                                                                |                                                 |                  |
| HAEMORRHOIDS ASPARTATE AMINOTRANSFERASE LYMPHOEDEMA                                    | 185 ( 7.8%) 145 ( 6.1%) 134 ( 5.7%) 139 ( 5.9%) 148 ( 6.3%) 147 (                      | 165 ( 6.9%) 125 ( 5.2%) 162 ( 6.7%) 161 ( 6.7%) |                  |
| OEDEMA DRY MOUTH                                                                       | 124 (                                                                                  | 156 ( 6.5%) 136 ( 5.7%)                         |                  |
| INCREASED                                                                              |                                                                                        |                                                 |                  |
|                                                                                        |                                                                                        | 124 ( 147 (                                     |                  |
| CONJUNCTIVITIS EJECTION                                                                |                                                                                        | 5.2%) 6.1%) 76 ( 3.2%)                          |                  |
| FRACTION DECREASED WEIGHT DECREASED                                                    | 6.2%) 192 ( 151 (                                                                      | 110 ( 4.6%)                                     |                  |
| ANXIETY                                                                                | 5.2%) 8.1%) 6.4%) 141 ( 6.0%)                                                          | 116 ( 4.8%)                                     |                  |
| RHINITIS                                                                               | 154 (                                                                                  | 99 ( 4.1%)                                      |                  |
| HYPOKALAEMIA                                                                           |                                                                                        | 112 ( 4.7%)                                     |                  |
| DRY EYE                                                                                | 140 ( 127 (                                                                            | 120 (                                           |                  |
| INFLUENZA LIKE                                                                         | 6.5%) 5.9%)                                                                            | 5.0%)                                           |                  |
| ILLNESS GASTROOESOPHAGEAL REFLUX                                                       | 121 (                                                                                  | 108 ( 4.5%) 79 ( 3.3%)                          |                  |
|                                                                                        | 150 (                                                                                  |                                                 |                  |
| HYPOMAGNESAEMIA                                                                        | 92 (                                                                                   | 126 ( 5.2%)                                     |                  |
| HYPERTENSION                                                                           |                                                                                        | 5.4%)                                           |                  |
| WEIGHT INCREASED                                                                       | (                                                                                      | 130 (                                           |                  |
|                                                                                        | 59                                                                                     |                                                 |                  |
| ______________________________________________________________________________________ |                                                                                        |                                                 |                  |
|                                                                                        | 2.5%)                                                                                  |                                                 |                  |
|                                                                                        |                                                                                        | 6.3%) 3.9%)                                     |                  |
|                                                                                        |                                                                                        | 5.1%)                                           |                  |
|                                                                                        |                                                                                        | 5.4%)                                           |                  |
|                                                                                        |                                                                                        | DISEASE                                         |                  |
|                                                                                        |                                                                                        |                                                 | RHINORRHOEA PAIN |

<div style=\"page-break-after: always\"></div>

Investigator text for AEs encoded using MedDRA v19.1 . Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. Table includes AEs with onset from first dose of any study treatment through 28 days after last dose of study treatment.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ae\\_pt.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ae\\_pt\\_TRT1A\\_SE.out 21MAR2017 20:00                                                                   Page 2 of 2

## Serious adverse event/deaths/other significant events

## Grade 3-5 adverse events

## Table 46 Most Common ( ≥ 5%) NCI-CTCAE Grade 3 - 5 Adverse Events By Treatment Regimen (Safety Population)

Most Common (&gt;=5%) NCI-CTCAE Grade &gt;=3 Adverse Events by Treatment Regimen, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

| MedDRA Preferred Term      | Pertuzumab + Trastuzumab + Chemotherapy (N=2364) ______________________________________________________________________________________   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364) ______________________________________________________________________________________   |   Placebo + Trastuzumab + Chemotherapy (N=2405) | Placebo + Trastuzumab + Chemotherapy (N=2405)   |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| NEUTROPENIA                | 385                                                                                                                                       | (16.3%)                                                                                                                                   |                                             377 | (15.7%)                                         |
| FEBRILE NEUTROPENIA        | 287                                                                                                                                       | (12.1%)                                                                                                                                   |                                             266 | (11.1%)                                         |
| NEUTROPHIL COUNT DECREASED | 228                                                                                                                                       | ( 9.6%)                                                                                                                                   |                                             230 | ( 9.6%)                                         |
| DIARRHOEA                  | 232                                                                                                                                       | ( 9.8%)                                                                                                                                   |                                              90 | 3.7%)                                           |
| ANAEMIA                    | 163 ______________________________________________________________________________________                                                | ( 6.9%)                                                                                                                                   |                                             113 | ( ( 4.7%)                                       |

Investigator text for AEs encoded using MedDRA v19.1 .

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Percentages are based on N in the column headings.

For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. Table includes AEs with onset from first dose of any study treatment through 28 days after last dose of study treatment.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ae\\_pt.sas

21MAR2017 20:01                                                                   Page 1 of 1

Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ae\\_pt\\_TRT1A\\_CTC3\\_SE.out

## Adverse events leading to death

The same proportion of patients in each treatment arm died during the study due to AEs, 18 patients (0.8%) vs. 20 patients (0.8%).A total of 39 SAEs in 38 patients resulted in death, of which two (one in each treatment arm) were considered related to study treatment by the investigator, as summarized below (see also Table 47):

- Patient 2438280008 (Ptz + H + Chemo): this 58-year old woman died of a malignant tongue neoplasm on Study Day 685. The onset of this event and the fatal outcome occurred during the post-treatment phase of the study. The SAE was assessed by the investigator as related to HER2-targeted therapy because the patient had no other apparent predisposing factors for this malignancy.
- Patient 2314490002 (Pla + H + Chemo): a 58-year old woman who died suddenly of cardiac failure. She received four cycles of epirubicin (90 mg/m2) and cyclophosphamide, and radiotherapy to the left chest wall from Study Day 201 to Study Day 240. She experienced Grade 3 (NYHA III) cardiac failure starting approximately 2 months after completing placebo and Herceptin but recovered. This event was reported as an SAE of cardiac failure but did not meet the LVEF criteria for a primary or secondary cardiac event. The patient died suddenly of cardiac failure on Study Day 1373 (during the post-treatment phase of the study). The fatal SAE was assessed by the investigator as related to HER2-targeted therapy, and unrelated to chemotherapy. However, the investigator commented, 'cardiogenic shock with sudden cardiac death (known chemotherapy induced dilated cardiomyopathy)'.

<div style=\"page-break-after: always\"></div>

## Table 47 Adverse Events Resulting in Death by Treatment Regimen (Safety Population)

Adverse\\_Events Resulting\\_in Death by Treatment Regimen, Safety Evaluated Population Protoco1:BIG 4-11/B025126/T0C4939G

<!-- image -->

## Other serious adverse events

The incidence of SAEs was higher in the pertuzumab arm. A total of 692 patients (29.3%) in the pertuzumab arm experienced 1073 SAEs, and 585 patients (24.3%) in the placebo arm experienced 883 SAEs (Table 48).

SAEs were reported most frequently in the following SOCs:

- Blood and Lymphatic System Disorders:  11.0% vs. 10.5%.

- Infections and Infestations: 6.8% vs. 5.8%.

- Gastrointestinal disorders:  5.2% vs. 3.3%.

<div style=\"page-break-after: always\"></div>

## Table 48 Serious Adverse Events ( ≥ 1%) (Safety Population)

Serious Adverse Events by Treatment Regimen, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

| MedDRA System Organ Class MedDRA Preferred Term          | Pertuzumab + Trastuzumab + Chemotherapy (N=2364) ___________________________________________________________________________________________   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364) ___________________________________________________________________________________________   | Placebo + Trastuzumab + Chemotherapy (N=2405)   |
|----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| Total number of patients with at least one adverse event | 692                                                                                                                                            | (29.3%)                                                                                                                                        | 585 (24.3%)                                     |
| Overall total number of events                           | 1073                                                                                                                                           | 1073                                                                                                                                           | 883                                             |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                     |                                                                                                                                                |                                                                                                                                                |                                                 |
| Total number of patients with at least one adverse event | 259                                                                                                                                            | (11.0%)                                                                                                                                        | 252 (10.5%)                                     |
| FEBRILE NEUTROPENIA                                      | 208                                                                                                                                            | ( 8.8%)                                                                                                                                        | 196 ( 8.1%)                                     |
| Total number of events                                   |                                                                                                                                                | 298                                                                                                                                            | 286                                             |
| GASTROINTESTINAL DISORDERS                               |                                                                                                                                                |                                                                                                                                                |                                                 |
| Total number of patients with at least one adverse event | 124                                                                                                                                            | ( 5.2%)                                                                                                                                        | 79 ( 3.3%)                                      |
| DIARRHOEA                                                | 58                                                                                                                                             | ( 2.5%)                                                                                                                                        | 18 ( 0.7%)                                      |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS     |                                                                                                                                                |                                                                                                                                                |                                                 |
| Total number of patients with at least one adverse event | 69                                                                                                                                             | ( 2.9%)                                                                                                                                        | 68 ( 2.8%)                                      |
| PYREXIA                                                  | 39                                                                                                                                             | ( 1.6%)                                                                                                                                        | 45 ( 1.9%)                                      |
| Total number of events                                   |                                                                                                                                                | 77                                                                                                                                             | 80                                              |

Total number of events                                            77             80

Investigator text for AEs encoded using MedDRA v19.1 .

Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once.  For frequency counts of 'Total number of events' rows, multiple occurrences of the same AE in an individual are counted separately. Table includes AEs with onset from first dose of any study treatment through 28 days after last dose of study treatment.

Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ae\\_TRT1A\\_SER\\_SE.out

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ae.sas

21MAR2017 19:32                                                Page 1 of 1

## Other significant events

## Cardiac events

A primary cardiac event was defined as either:

- Heart Failure (NYHA Class III or IV) and a drop in LVEF of at least 10 EF points from baseline AND to below 50%

or

- Cardiac Death

<div style=\"page-break-after: always\"></div>

## Table 49 Summary of Cardiac Events (Safety Population)

Cardiac Safety SurmarybyTreatment Regimen,Safety Evaluated Fopulation Protoco1:BIG4-11/B025126/T0C4939G

|                                                                          | Pertuzumab + Trastuzumab+ Chemotherapy (N=2364)   | Placebo+ Trastuzumab + Chenotherapy (N=2405)   |
|--------------------------------------------------------------------------|---------------------------------------------------|------------------------------------------------|
| Primary Cardiac Event                                                    | 17(0.75)                                          | 8 (0.35)                                       |
| 95%CI*                                                                   | 0.4 (0.0,0.8)                                     | 0.4 (0.0,0.8)                                  |
| Heart Failure (NYHA III or IV)_and LvEF deeline                          | 15(0.6)                                           | 6(0.2) 2 (<0.14)                               |
| Cardiac death (definite or probable)                                     | 2(<0.1)                                           | 67 (2.8%)                                      |
| Secondlary Cardiac Event Treatment differenee (pertuzumab-placebo) +1096 | 64 (2.76)                                         |                                                |
|                                                                          | 50(2.1)                                           | 47 (2.0%) 20(0.8号)                             |
| Identified automatically from LVEF assessments Identified by CAB         | 14 (0.6)                                          |                                                |

Primary cardiac events are counted over the whole study period,including post-treatment follow-up.

Peroentages axe based on N in the column headings.

Secondary cardiac events are counted up to the date of recurrence or end of post-treatment follow-up, whichever occurs earlier.

Sigmificant LvEF decline defined as a decline of&gt;=10 points to a value &lt;50%.

Secondary cardiae events are only counted for patients who have not experieneed a primary cardiae event.

g5s confidence interval with Hauck=Anderson correction.

25FEB2017 12:20

LvEF decline of at least 10 Ejectlion Fractlon polnts from baseline AND to below 50%.

Page l of 1

The CAB were sent cases where a patient experienced an LVEF drop to &lt;50% and where the drop was ≥10% points from baseline but where there was no repeat LVEF assessment within 7 to 35 days or where there was no subsequent LVEF assessment after a significant drop.

A total of 25 patients met the criteria for a primary cardiac event: 17 patients (0.7%) vs. 8 patients (0.3%) (Table 49). Heart failure (NYHA III or IV) with an LVEF decline was reported in 15 patients (0.6%) versus 7 patients  (0.3%).  Cardiac  death  (death  with  a  definite  or  probable  cardiac  cause)  was  reported  in 4 patients: 2 patients ( &lt; 0.1%) vs. 2 patients ( &lt; 0.1%).

All cardiac deaths occurred in patients who received anthracycline-based chemotherapy. One cardiac death, which occurred in the placebo arm, was assessed by the investigator as related to HER2-targeted therapy. Cardiac deaths are presented below:

## Ptz + H + Chemo arm

Patient 2323350003 experienced two primary cardiac events (one fatal) but no preceding asymptomatic or mildly symptomatic LVEF decline. This 77 year old woman had pre-existing hypertension and mitral valve disease. She received three cycles of fluorouracil (500 mg/m 2 ), epirubicin (100 mg/m 2 ) and cyclophosphamide (500 mg/m 2 ), and radiotherapy to the left breast and supraclavicular area (Study Day 134 to 172). She experienced heart failure on Study Day 186, which resulted in permanent discontinuation of HER2-targeted therapy. She subsequently died on Study Day 1334 (during the post-treatment phase of the  study)  due  to  worsening  mitral  value  disease.  The  fatal  SAE  was  assessed  by  the  investigator  as unrelated to HER2-targeted therapy, and related to the patient's medical history of mitral value disease.

Patient 2316620009: This 80 year old woman died from cardiogenic shock on Study Day 453.  The patient received four cycles of epirubicin (90 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ), and radiotherapy to the left breast, left supraclavicular area, left axilla and left tumor bed (from Study Day 209 to 273). Treatment with HER2-targeted therapy and paclitaxel was permanently discontinued due to the physician's decision, with the last doses administered on Study Day 107 and Study Day 121, respectively. The fatal SAE was assessed by the investigator as unrelated to HER2-targeted therapy, and related to the patient's medical history of mammary cancer. However, on an unspecified date, the patient's electrocardiogram was noted to show acute elevation of myocardial infarction in the region of the rear wall.

## Pla + H + Chemo arm:

Patient  2314490002:  This  58-year  old  woman  received  four  cycles  of  epirubicin  (90 mg/m 2 )  and cyclophosphamide, and radiotherapy to the left chest wall from Study Day 201 to Study Day 240.  She experienced Grade 3 (NYHA III) cardiac failure starting approximately 2 months after completing placebo

<div style=\"page-break-after: always\"></div>

and Herceptin but recovered. This event was reported as an SAE of cardiac failure but did not meet the LVEF criteria for a primary or secondary cardiac event. The patient died suddenly of cardiac failure on Study Day 1373 (during the post-treatment phase of the study). The fatal SAE was assessed by the investigator as related to HER2-targeted therapy, and unrelated to chemotherapy. However, the investigator commented, 'cardiogenic shock with sudden cardiac death (known chemotherapy induced dilated cardiomyopathy)'.

Patient 2324510001: This 66-year old woman died of acute myocardial infarction on Study Day 1636 (during the post-treatment phase of the study). The patient completed HER2-targeted therapy on Study Day 442 (18 cycles). Additionally, the patient received four cycles of doxorubicin (60 mg/m 2  and cyclophosphamide, and radiotherapy to the left breast from Study Day 220 to Study Day 255. The fatal SAE was assessed by the investigator as unrelated to HER2-targeted therapy.

## Timing of primary cardiac events

Almost all of the primary cardiac events (16/17 events in the Ptz + H + Chemo arm, and 7/8 events in the Pla + H + Chemo arm) were reported during the first 2 years from randomization. Two events were reported &gt; 2 years from randomization: one event in the Ptz + H + Chemo arm was reported approximately 3.5 years after randomization,  and  one  event  in  the  Pla + H + Chemo  arm  was  reported  approximately  4.5  years  after randomization.

Importantly, of the 25 primary cardiac events that occurred during the APHINTY study, one occurred during the anthracycline treatment phase (before commencement of HER2-targeted therapy). This patient (Patient 2327600002) was randomized to the Ptz + H + Chemo arm but since she was unable to start Perjeta treatment due  to  the  cardiac  event,  she  was  analyzed  in  the  Pla + H + Chemo  arm.  All  of  the  other  patients  who experienced primary cardiac events were analyzed in the treatment arm to which they were randomized.

<div style=\"page-break-after: always\"></div>

## Recovery from primary cardiac events

## Table 50 Overview of Recovery from Primary Cardiac Events

| Patient No.     | Recovery based on LVEF criteria alone a   | Investigator Reported Outcome   |
|-----------------|-------------------------------------------|---------------------------------|
| Ptz + H + Chemo |                                           |                                 |
| 2316620009 b    | No                                        | Fatal                           |
| 2323350003 c    | No                                        | Fatal                           |
| 2323350003 c    | No                                        | Resolved with sequelae          |
| 2089210003      | Yes                                       | Not resolved as of CCOD         |
| 2316300030      | No                                        | Not resolved as of CCOD         |
| 2316340006      | No                                        | Not resolved as of CCOD         |
| 2326770011      | No                                        | Not resolved as of CCOD         |
| 2333880002      | No                                        | Not resolved as of CCOD         |
| 2392330008      | No                                        | Not resolved as of CCOD         |
| 2312870022      | No d                                      | Resolved with sequelae          |
| 2314110015      | Yes                                       | Resolved with sequelae          |
| 2308140005      | Yes                                       | Resolved                        |
| 2308670010      | Yes                                       | Resolved                        |
| 2318390008      | Yes                                       | Resolved                        |
| 2323420001      | Yes                                       | Resolved                        |
| 2326380006      | Yes                                       | Resolved                        |
| 2326560005      | No e,f                                    | Resolved                        |
| 2372890028      | No g                                      | Resolved                        |
| Pla + H + Chemo |                                           |                                 |
| 2314490002 h    | No                                        | Fatal                           |
| 2324510001      | No                                        | Fatal                           |
| 2320970012      | Yes i                                     | Not resolved as of CCOD         |
| 2327600002 j    | No                                        | Resolved with sequelae          |
| 2102670020      | Yes                                       | Resolved                        |
| 2308040004      | Yes                                       | Resolved                        |
| 2314840001      | Yes                                       | Resolved                        |
| 2439730008      | No                                        | Resolved                        |

CCOD = clinical cut-off date, chemo = chemotherapy, H = Herceptin, INV = investigator, LVEF = left ventricular ejection fraction, N/A = not applicable, Ptz = pertuzumab, Pla = placebo.  Source:  Table 59 in Primary APHINITY CSR.

a  Defined as two consecutive LVEF assessments &gt; 50%.

b  PT reported was cardiogenic shock.

c  Patient had two primary cardiac events:  heart failure (resolved with sequelae) but subsequently died due to a second primary cardiac event (worsening of mitral valve disease).

d  Single drop (Study Day 337), then single recovery (Study Day 771).

e  Two events of heart failure (one during treatment and one in follow-up; both resolved).

f  Single drop (Study Day 198), then single recovery (Study Day 1166), then single drop (Study Day 1356), then single recovery (Study Day 1500).

g  Single drop (Study Day 172), then single recovery (Study Day 259).

h Prior to the fatal event, the patient had a serious cardiac event with documented ventricular abnormalities but this did not meet the LVEF criteria for a primary or secondary cardiac event.

i  Single drop (Study Day 176), then single recovery (Study Day 253), further drop (Study Day 590), single recovery (Study Day 956).

j This patient was randomized to the Ptz + H + Chemo arm, but was analyzed for safety in the Pla + H + Chemo arm because the patient developed an acute myocardial infarction with associated LVEF decline (meeting the criteria for a primary cardiac event) during the anthracycline period and was withdrawn from treatment prior to receiving Perjeta.

## Updated data with cut-off date 15 may 2017

Overall, a total of 25 patients met the criteria for a primary cardiac event: 17 patients in the pertuzumab arm and 8 patients in the Placebo arm. At the time of primary data cutoff (19 December 2016), 2 patients in each arm had experienced a fatal cardiac event. Of the remaining 15 patients in the pertuzumab arm and 6 patients in the Placebo arm, 7 and 4 patients, respectively, had achieved LVEF recovery (defined as two consecutive LVEFs ≥ 50%). No additional patients had experienced a primary cardiac event and there was no change in the recovery rates, compared to the primary data cutoff. Therefore, 8 patients remained in the pertuzumab arm and 2 patients in the Placebo arm who had not died or recovered at the time of the most recent data cutoff (15 May 2017). Of these 8 patients, no further data is expected for 4 patients: 2 patients have died due to second primary cancers (Patients 23163000030 and 2316340006) and 2 have completely

<div style=\"page-break-after: always\"></div>

withdrawn from the study (Patients 2326560005 and 2372890028). Further follow-up data may become available  for  4  patients  (Patients  2392330008,  2326770011,  2333880002  and  2312870022)  in  the pertuzumab arm. Of these 4 patients, an additional LVEF assessment (53%) has been reported for Patient 2392330008, which meets the criteria for acute recovery. Of the 2 remaining patients in the Placebo arm who had not recovered at the most recent data cutoff, further follow-up data may become available for one patient (Patient 2439730008). The other patient (Patient 2327600002) has withdrawn from the study and no further follow-up data will be received.

Table 51 Recovery from Cardiac Events (Safety Population)

Acute Recovery from Cardiac Events by Treatment Regimen, Safety Evaluated Population Prot0col: BIG 4-11/B025126/10C4939G Clinical cut-off date: 15MAY2017 Snapshot date:19JuL2017

|                                                                                  | Pertuzumab+ Trastuzumab Chemotherapy (N=2364)   | Placebo+ Trastuzumab Chemotherapy (N=2405)   |
|----------------------------------------------------------------------------------|-------------------------------------------------|----------------------------------------------|
| Number of Patients with a non-death Primary Cardiac Event                        | 15 ( 0.66)                                      | 6 ( 0.26)                                    |
| Acute recovery achieved* n Yes No                                                | 15 7(46.76) 8(53.34)                            | 6 4(66.76) 2(33.3%)                          |
| Time to acute recovery (weeks) n Vedian                                          |                                                 |                                              |
|                                                                                  | 7 27.00 3.1 - 52.4                              | 4 16.29 11.0 - 30.1                          |
| Range Number of Patients with a Secondary Cardiac Event Aeute reeovery achieved* | 66( 2.8%)                                       | 67( 2.8%)                                    |
| n Yes No                                                                         | 70 54(77.1%) 16 (22.94)                         | 67 55 (82.16) 12 (17.9%)                     |
| Time to acute recovery (weeks) n Median                                          | 54 18.07                                        | 55 23.29                                     |
| Range                                                                            |                                                 |                                              |
|                                                                                  | 4.4 - 129.7                                     | 1.7-113.9                                    |

Program:/opt/B1osrAr/prod/edp11450/r25126a/t\\_saf\\_ar.sas/ Output:/opt/B1osTAT/prod/ed11450g/j2512e 27JUL2017 10:51

## Risk factors for primary cardiac events

Pre-defined baseline characteristics considered to be possible risk factors for a primary cardiac event were evaluated in the individual patients who developed a primary cardiac event, and included anthracycline exposure, trastuzumab exposure, radiation exposure, age, smoking status, diabetes mellitus, hypertension and other cardiac conditions or medication. All of the patients who developed a primary cardiac event had at least one of these potential risk factors. Most patients had received anthracyclines or radiotherapy or both. Only one patient (Patient 2372890028) had not received prior anthracyclines or chest radiotherapy. The other identified risk factors in this particular patient were smoking history and coronary artery disease.

## Anthracycline exposure

<div style=\"page-break-after: always\"></div>

Table 52 Cardiac Safety Summary by Chemotherapy Regimen

|                                         | Ptz+H+Anthracycline       | Ptz+H+Anthracycline   | Ptz+H+Anthracycline      | Pla+H+Anthracycllne       | Pla+H+Anthracycllne   | Pla+H+Anthracycllne      | Plz +H + Non- Anthracycline   | Pla + H + Non- Anthracycline   |
|-----------------------------------------|---------------------------|-----------------------|--------------------------|---------------------------|-----------------------|--------------------------|-------------------------------|--------------------------------|
|                                         | Total Patients (N = 1834) | Dose Dense (N = 136)  | Non-dose dense (N= 1698) | Total Patients (N = 1894) | Dose Dense (N = 124)  | Non-dose dense (N= 1770) | Total Patients (N =528)       | Total Patients (N=510)         |
| Primary cardiac event                   | 15 (0.8%)                 | 1 (0.7%)              | 14 (0.8%)                | 7 (0.4%)                  | 1 (0.8%)              | 6 (0.3%)                 | 2 (0.4%)                      | 1 (0.2%)                       |
| Heart failure (NYHA III or IV) and LVEF | 13 (0.7%)                 | 1 (0.7%)              | 12 (0.7%)                | 5 (0.3%)                  | 1 (0.8%)              | 4 (0.2%)                 | 2 (0.4%)                      | 1 (0.2%)                       |
| Cardiac death                           | 2 (0.1%)                  | 0                     | 2 (0.1%)                 | 2 (0.1%)                  | 0                     | 2 (0.1%)                 | 0                             | 0                              |
| Secondarycardiacevent                   | 55 (3.0%)                 | 8 (5.9%)              | 47 (2.8%)                | 60 (3.2%)                 | 6 (4.8%)              | 54 (3.1%)                | 9 (1.7%)                      | 7 (1.4%)                       |
| Identified from LVEF assessments        | 46 (2.5%)                 | 8 (5.9%)              | 38 (2.2%)                | 44 (2.3%)                 | 4 (3.2%)              | 40 (2.3%)                | 4 (0.8%)                      | 3 (0.6%)                       |
| Identified by CAB b                     | 9 (0.5%)                  | 0                     | 9 (0.5%)                 | 16 (0.8%)                 | 2 (1.6%)              | 14 (0.8%)                | 5 (0.9%)                      | 4 (0.8%)                       |

CAB=Cardiac Advisory Board, H = Herceptin,LVEF=left ventricular ejection fraction, NYHA=New York Heart Association=,Pla = placebo, Ptz = Perjeta.

LVEF decine of at least 10 EjectionFraction points from baseline AND to below50%

The CAB were sent cases where a patient experienced an LVEF drop to &lt;50% and where the drop was ≥10% points from baseline but where there was no repeat LVEF assessment within 7 to 35 days or where there was no subsequent LVEF assessment after a slgnificant drop.

SoUrCe:\\_Saf\\_CS\\_TRT2A\\_ANTH\\_SE.t\\_Sa\\_CS\\_TRT3A\\_DDAN\\_SE.\\_Saf\\_CS\\_TRT3A\\_NDDA\\_SE.t\\_Saf\\_CS\\_TRT2A\\_NACO\\_SE

<!-- image -->

Most of the primary cardiac events were reported in patients who received anthracycline-based treatment (Table 52):

- Of the 17 patients in the Ptz + H + Chemo arm who experienced a primary cardiac event, 15 patients received anthracycline-based chemotherapy (88.2%), and 2 patients received non-anthracycline-based chemotherapy (11.8%).
- Of the 8 patients in the Pla + H + Chemo arm who experienced a primary cardiac event, 7 patients received anthracycline-based chemotherapy (87.5%), and 1 patient received non-anthracycline-based chemotherapy (12.5%).

The  great  majority  of  patients  who  received  anthracycline-based  chemotherapy  did  not  experience  a primary cardiac event (0.8% vs. 0.4%). Although anthracycline exposure appears to be a clear risk factor for a primary cardiac event, the incidence of primary cardiac events was not much greater in absolute terms than that observed in patients treated with non-anthracycline-based chemotherapy (0.4% vs. 0.2%).

## Asymptomatic or mildly symptomatic LVEF declines

Eight patients experienced both a primary cardiac event and an asymptomatic or mildly symptomatic LVEF decline, i.e., an event that would have been counted as a secondary cardiac event had the patient not also experienced a primary cardiac event: 6 patients (0.3%] in the Ptz + H + Chemo arm vs. 2 patients (&lt;0.1%] in the Pla + H + Chemo arm. In 5 of these 8 patients (4 patients in the Ptz + H + Chemo arm vs. 1 patient in the Pla + H + Chemo arm), the significant LVEF decline occurred prior to the primary cardiac event. The remaining 3 patients had no such event preceding the primary cardiac event (2 patients in the Ptz + H + Chemo arm and 1 patient in the Pla + H + Chemo arm).

## Secondary cardiac events

A secondary cardiac event was defined as:

- Asymptomatic or mildly symptomatic (NYHA Class II) significant drop in LVEF defined as an absolute decrease of at least 10 EF points from baseline AND to below 50%, confirmed by a second LVEF assessment within approximately three weeks of the first significant LVEF assessment or confirmed by the CAB.

A total of 131 patients experienced a secondary cardiac event (see Table 52: 64 patients (2.7%) vs. 67 patients (2.8%).

- 97 patients were identified automatically from LVEF assessments: 50 patients (2.1%) vs. 47 patients (2.0%).

<div style=\"page-break-after: always\"></div>

- 34 patients were identified by the CAB: 14 patients (0.6%) vs. 20 patients (0.8%).

## Other cardiac events

Other cardiac events are defined as:

- Acute coronary syndrome
- Acute myocardial infarction
- Severe rhythm disturbances requiring treatment

## Table 53 Other Cardiac Events by Treatment Regimen (Safety Population)

Other Cardiac Events by Treatment Regimen, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

| ______________________________________________________________________________   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab + Chemotherapy (N=2405)   |
|----------------------------------------------------------------------------------|----------------------------------------------------|-------------------------------------------------|
| Any other cardiac events Total number of events                                  | 63 (2.7%) 72                                       | 58 ( 2.4%) 65                                   |
| Acute Coronary Syndrome (PT)                                                     | 0                                                  | 2 (<0.1%)                                       |
| Acute myocardial infarction                                                      | 4 (0.2%)                                           | 4 ( 0.2%)                                       |
| Severe rhythm disturbances requiring treatment                                   | 60 (2.5%)                                          | 52 ( 2.2%)                                      |

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_saf\\_oce.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_saf\\_oce\\_TRT1A\\_SE.out 21MAR2017 20:29                                                      Page 1 of 1

The most frequently reported severe rhythm disturbances requiring treatment included tachycardia (12 patients [0.5%] in the Ptz + H + Chemo arm vs. 14 patients [0.6%] in the Pla + H + Chemo), atrial fibrillation (8 patients [0.3%] vs. 10 patients [0.4%], respectively), syncope (9 patients [0.4%] vs. 3 patients [0.1%], respectively), and palpitations (6 patients [0.3%] vs. 8 patients [0.3%], respectively). The majority of the severe rhythm disturbances requiring treatment occurred in patients treated with an anthracycline-based regimen.

## Table 54 Timing of Onset of Syncope

a  One patient in each treatment arm experienced separate syncope events in both the targeted therapy + chemotherapy period and the targeted therapy post-chemotherapy period

| Timing of Syncope Events                                         | Treatment       | Treatment       |
|------------------------------------------------------------------|-----------------|-----------------|
| Timing of Syncope Events                                         | Ptz + H + Chemo | Pla + H + Chemo |
| Number of Patients                                               | (n = 1834)      | (n = 1894)      |
| During Anthracycline Treatment                                   | 7 (0.4%)        | 7 (0.4%)        |
| Number of Patients                                               | (n = 2364)      | (n = 2405)      |
| During the Targeted Therapy + Chemotherapy Treatment Period a    | 20 (0.8%)       | 15 (0.6%)       |
| Number of Patients                                               | (n = 2364)      | (n = 2405)      |
| During the Targeted Therapy Post-Chemotherapy Treatment Period a | 10 (0.4%)       | 5 (0.2%)        |

Source: t\\_ae\\_TRT2A\\_AEAN\\_SE; t\\_ae\\_TRT1A\\_TACH\\_SE; t\\_ae\\_TRT1A \\_TAPO\\_SE.

The incidence of syncopal events considered by the Investigator to be related to HER2-targeted treatment was very low in both treatment arms in both treatment arms (see Table 55).

<div style=\"page-break-after: always\"></div>

Table 55 Syncope Events Considered Related to HER-2 Targeted Treatment by Investigator

| Preferred term   | All Grades                 | All Grades                 | ≥ Grade 3                  | ≥ Grade 3                  |
|------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                  | Ptz + H + Chemo (n = 2364) | Pla + H + Chemo (n = 2405) | Ptz + H + Chemo (n = 2364) | Pla + H + Chemo (n = 2405) |
| Syncope          | 4 (0.2%)                   | 3 (0.1%)                   | 3 (0.1%)                   | 3 (0.1%)                   |

Source: t\\_ae\\_TRT1A\\_REL\\_SEIDM:/Authoring Repository/RO4368451/Clinical/Study BO25126/CSR Documents &amp; Data Outputs/Primary CSR, Study BO25126 (APHINITY),  , Data Output/t\\_ae\\_TRT1A\\_REL\\_SE or page 186 of the full CSR; t\\_ae\\_TRT1A\\_REL3\\_SE. page 10023 primary

The incidence of all syncope events regardless of requirement for treatment showed a very small difference between arms, even smaller for ≥ Grade 3. Of the patients requiring treatment for syncope, for the majority of  patients  (8  out  of  9  patients)  in  the  pertuzumab  arm,  the  syncopal  event  appeared  to  have  been associated  with  intravascular  volume  depletion  (diarrhea,  nausea,  vomiting,  dehydration,  hypotension and/or anaemia), and occurred during concomitant chemotherapy. None of the syncope events requiring treatment led to study therapy withdrawal.Withdrawal of any study medication due to other cardiac events occurred in 9 patients in the Ptz + H + Chemo arm (0.4%) vs. 8 patients [0.3%] in the Pla + H + Chemo arm. These  figures  include  3  patients  who  withdrew  from  study  medication  before  commencement  of HER2-targeted therapy. Withdrawal of Ptz/Pla due to other cardiac events occurred in 5 patients in each arm, mainly due to myocardial infarction (2 patients in each arm).

## Changes in LVEF

Patients had to have an LVEF of at least 55% (measured by ECHO [preferred] or MUGA scan) to enter the study. At baseline, the mean LVEF was 65.2% in the Ptz + H + Chemo arm, and 65.3% in the Pla + H + Chemo arm. Table 56 summarizes the worst on-study LVEF measurements. The worst on-study LVEF was a mean of 7.5% lower than baseline in the Ptz + H + Chemo arm, and 7.6% lower than baseline in the Pla + H + Chemo arm.

LVEF drops to &lt;40% during the study occurred in 34 patients (1.4%) vs. 32 patients (1.3%). The majority of these patients were treated with an anthracycline-based regimen (27 vs. 30 patients). The remaining patients (7 vs. 2 patients) received a non-anthracycline chemotherapy regimen.

A total of 133 patients (5.7%) in the Ptz + H + Chemo arm experienced at least one significant LVEF drop (defined as a drop in LVEF of at least 10 EF points from baseline and to below 50%) during the study compared with 165 patients (7.0%) in Pla + H + Chemo arm.

Table 56 Summary of Maximum Decrease in LVEF Measures by Treatment Regimen (Safety Population)

Summary of Maximum Decrease in LVEF Measures by Treatment Regimen, Safety Evaluated Population

<!-- image -->

| Protocol: BIG 4-11/BO25126/TOC4939G   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab + Chemotherapy (N=2405)   |
|---------------------------------------|----------------------------------------------------|-------------------------------------------------|
| Baseline LVEF (%)                     |                                                    |                                                 |
| n                                     | 2363                                               | 2401                                            |
| Mean (SD)                             | 65.2 (5.9)                                         | 65.3 (6.1)                                      |
| Median                                | 65.0                                               | 65.0                                            |
| Range                                 | 51 - 90                                            | 50 - 92                                         |
| Change from Baseline to Worst Value   |                                                    |                                                 |
| n                                     | 2348                                               | 2351                                            |
| Mean (SD)                             | -7.5 (6.6)                                         | -7.6 (6.7)                                      |
| Median                                | -7.0                                               | -7.0                                            |
| Range                                 | -49 - 11                                           | -54 - 14                                        |
| Treatment difference* 95% C.I.        | 0.1                                                |                                                 |
| Worst value <40%                      | (-0.3, 0.5)                                        | 32 (1.3%)                                       |
| Yes No                                | 34 (1.4%) 2330 (98.6%)                             | 2373 (98.7%)                                    |

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_saf\\_lvefm.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_saf\\_lvefm\\_TRT1A\\_SE.out 21MAR2017 20:37                                                                   Page 1 of 1

## Diarrhea

<div style=\"page-break-after: always\"></div>

In both treatment arms, the majority of diarrhea events (all Grades) that started during targeted treatment (63.7% vs. 66.2% of events) occurred in the first 3 cycles of treatment. Less than 10% of patients in either treatment arm experienced diarrhea from Cycle 4 onwards, and &lt;3% of patients from Cycle 7 onwards. The majority of Grade ≥ 3 events of diarrhea that started during targeted treatment also occurred in the first three cycles of treatment (84.4% of Grade ≥ 3 events vs. 84.1% of Grade ≥ 3 events).

The median time from first targeted treatment to onset of a diarrhea event was 7 days vs. 10 days. On average, events of diarrhea lasted longer in the pertuzumab arm, median 8 days vs. median 6 days; the median duration of the longest event was 35 days vs. 13 days.

The median time from first targeted treatment to onset of Grade ≥ 3 diarrhea was 8 days in both treatment arms. On average, Grade ≥ 3 diarrhea events lasted longer in the Ptz + H + Chemo arm (median 20 days vs. median 8 days); the median duration of the longest event was 22 days vs. 8 days.

## Table 57 Summary of Diarrhea Adverse Events (Safety Population)

Summary of Diarrhoea Adverse Events, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

| MedDRA System Organ Class MedDRA Preferred Term          | Pertuzumab + Trastuzumab + Chemotherapy (N=2364) ________________________________________________________________________________________   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364) ________________________________________________________________________________________   | Placebo + Trastuzumab + Chemotherapy (N=2405)   |
|----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| Total number of patients with at least one adverse event | 1685                                                                                                                                        | (71.3%)                                                                                                                                     | 1086 (45.2%)                                    |
| Overall total number of events                           | 3415                                                                                                                                        | 3415                                                                                                                                        | 1792                                            |
| GASTROINTESTINAL DISORDERS                               |                                                                                                                                             |                                                                                                                                             |                                                 |
| Total number of patients with at least one adverse event | 1683                                                                                                                                        | (71.2%)                                                                                                                                     | 1086 (45.2%)                                    |
| DIARRHOEA                                                | 1683                                                                                                                                        | (71.2%)                                                                                                                                     | 1086 (45.2%)                                    |
| DIARRHOEA HAEMORRHAGIC                                   | 0                                                                                                                                           |                                                                                                                                             | 1 (<0.1%)                                       |
| Total number of events                                   | 3411                                                                                                                                        | 3411                                                                                                                                        | 1791                                            |
| INFECTIONS AND INFESTATIONS                              |                                                                                                                                             |                                                                                                                                             |                                                 |
| Total number of patients with at least one adverse event | 4                                                                                                                                           | ( 0.2%)                                                                                                                                     | 1 (<0.1%)                                       |
| DIARRHOEA INFECTIOUS                                     | 4                                                                                                                                           | ( 0.2%)                                                                                                                                     | 1 (<0.1%)                                       |
| Total number of events                                   |                                                                                                                                             | 4                                                                                                                                           | 1                                               |

Investigator text for AEs encoded using MedDRA v19.1 .

For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once.  For frequency counts of 'Total number of events' rows, multiple occurrences of the same AE in an individual are counted separately. Table includes AEs with onset from first dose of any study treatment through 28 days after last dose of study treatment.

Percentages are based on N in the column headings.

Diarrhoea events identified from the PT 'DIARRHOEA INFECTIOUS', 'DIARRHOEA', 'DIARRHOEA HAEMORRHAGIC', 'DIARRHOEA NEONATAL' or 'POST PROCEDURAL DIARRHOEA'.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ae.sas

23MAR2017 18:34                                                                   Page 1 of 1

Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ae\\_TRT1A\\_DIA\\_SE.out

The  highest  incidence  of  diarrhea  was  reported  during  the  TTTC  (taxane  treatment)  period  (61.4%  of patients vs. 33.8% of patients, respectively), with a decrease observed upon chemotherapy cessation in the PCTT (pertuzumab treatment) period (18.1% vs. 9.2% of patients, respectively). During the anthracycline period, diarrhea was reported in 16.1% vs. 14.7% of patients. The highest incidence of Grade ≥ 3 diarrhea was  also  reported  during  the  TTTC  period  (8.4%  vs.  2.5%  of  patients,  respectively),  followed  by  the anthracycline  period  (1.2%  vs.  1.3%,  respectively),  and  the  PCTT  period  (0.5%  vs.  0.2%  of  patients, respectively).

For patients who experienced diarrhea, guidance per the study protocol and Perjeta label recommended early intervention with loperamide as well as fluid and electrolyte replacement. For the treatment of diarrhea AEs, loperamide was administered to 842 patients (35.6%) in the Ptz + H + Chemo arm, and 356 patients (14.8%) in the Pla + H + Chemo arm.

<div style=\"page-break-after: always\"></div>

Table 58 Selected Treatments for Diarrhea AEs by Treatment Regimen (0.1%)

| Treatment                                                                                     | Ptz + H + Chemo (n = 2364)   | Pla + H+Chemo (n = 2405)   |
|-----------------------------------------------------------------------------------------------|------------------------------|----------------------------|
| Patients treated with Antidiarrhoeals                                                         |                              |                            |
| Loperamide                                                                                    | 842 (35.6%)                  | 356 (14.8%)                |
| Patients treated with Electrolytes                                                            |                              |                            |
| Sodium Chloride                                                                               | 29 (1.2%)                    | 19 (0.8%)                  |
| Fluid Replacement                                                                             | 23 (1.0%)                    | 10 (0.4%)                  |
| Potassium Chloride                                                                            | 6 (0.3%)                     | 5 (0.2%)                   |
| Glucose/Sodium Chloride                                                                       | 6 (0.3%)                     | 2 ( < 0.1%)                |
| Electrolytes                                                                                  | 5 (0.2%)                     | 3 (0.1%)                   |
| Potassium Chloride/Sodium Chloride                                                            | 4 (0.2%)                     | 0 4 ( < 0.1%)              |
| Other Fluid Replacement                                                                       | 4 (0.2%)                     | 2 ( < 0.1%)                |
| Citric Acid/Glucose/Potassium Chloride/Sodium Bicarbonate/Sodium Chloride/Sodium Citrate Acid | 1 ( < 0.1%)                  | 3 (0.1%)                   |

Source: t\\_cm\\_DIA\\_SE.link to page 10 of the Primary CSR Part B

## Rash

## Table 59 Summary of Rash (AEGT) Adverse Events (Safety Population)

Summary of Rash (AEGT) Adverse Events, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

| MedDRA System Organ Class MedDRA Preferred Term          | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab + Chemotherapy (N=2405) ________________________________________________________________________________________   | Placebo + Trastuzumab + Chemotherapy (N=2405) ________________________________________________________________________________________   |
|----------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Total number of patients with at least one adverse event | 1226 (51.9%)                                       | 1226 (51.9%)                                       | 1002 (41.7%)                                                                                                                             | 1002 (41.7%)                                                                                                                             |
| Overall total number of events                           | 2008                                               | 2008                                               | 1588                                                                                                                                     | 1588                                                                                                                                     |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                   |                                                    |                                                    |                                                                                                                                          |                                                                                                                                          |
| Total number of patients with at least one adverse event | 1199                                               | (50.7%)                                            | 978                                                                                                                                      | (40.7%)                                                                                                                                  |
| RASH                                                     | 609                                                | (25.8%)                                            | 488                                                                                                                                      | (20.3%)                                                                                                                                  |
| ERYTHEMA                                                 | 235 (                                              | 9.9%)                                              | 214                                                                                                                                      | ( 8.9%)                                                                                                                                  |
| PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME              | 217 (                                              | 9.2%)                                              | 158                                                                                                                                      | ( 6.6%)                                                                                                                                  |
| DERMATITIS                                               | 108 (                                              | 4.6%)                                              | 92                                                                                                                                       | ( 3.8%)                                                                                                                                  |
| RASH MACULO-PAPULAR                                      | 81 (                                               | 3.4%)                                              | 57                                                                                                                                       | 2.4%)                                                                                                                                    |
| DERMATITIS ACNEIFORM                                     | 88 (                                               | 3.7%)                                              | 49                                                                                                                                       | ( ( 2.0%)                                                                                                                                |
| SKIN EXFOLIATION                                         | 43 (                                               | 1.8%)                                              | 32                                                                                                                                       | ( 1.3%)                                                                                                                                  |
| ECZEMA                                                   | 43 (                                               | 1.8%)                                              | 25                                                                                                                                       | ( 1.0%)                                                                                                                                  |
| ACNE                                                     | 32 (                                               | 1.4%)                                              | 30                                                                                                                                       | ( 1.2%)                                                                                                                                  |
| SKIN TOXICITY                                            | 21 (                                               | 0.9%)                                              | 19                                                                                                                                       | ( 0.8%)                                                                                                                                  |
| RASH PRURITIC                                            | 17 (                                               | 0.7%)                                              | 21                                                                                                                                       | ( 0.9%)                                                                                                                                  |
| SKIN ULCER                                               | 21 (                                               | 0.9%)                                              | 11                                                                                                                                       | ( 0.5%)                                                                                                                                  |
| DERMATITIS ALLERGIC                                      | 14 (                                               | 0.6%)                                              | 13                                                                                                                                       | ( 0.5%)                                                                                                                                  |
| RASH MACULAR                                             | 16 (                                               | 0.7%)                                              | 11                                                                                                                                       | ( 0.5%)                                                                                                                                  |
| RASH PAPULAR                                             | 9 (                                                | 0.4%)                                              | 6                                                                                                                                        | ( 0.2%)                                                                                                                                  |
| DERMATITIS BULLOUS                                       | 6                                                  | 0.3%)                                              |                                                                                                                                          | ( 0.3%)                                                                                                                                  |
| RASH ERYTHEMATOUS                                        | 6                                                  | ( ( 0.3%)                                          | 8                                                                                                                                        | ( 0.2%)                                                                                                                                  |
| DERMATITIS EXFOLIATIVE                                   | 7                                                  | 0.3%)                                              | 6                                                                                                                                        | ( 0.2%)                                                                                                                                  |
| DRUG ERUPTION                                            | 6                                                  | ( ( 0.3%)                                          | 4 5                                                                                                                                      | ( 0.2%)                                                                                                                                  |
| RASH GENERALISED                                         | 7                                                  | 0.3%)                                              | 4                                                                                                                                        | ( 0.2%)                                                                                                                                  |
| ERYTHEMA MULTIFORME                                      | 4                                                  | ( ( 0.2%)                                          | 2                                                                                                                                        | (<0.1%)                                                                                                                                  |
| EXFOLIATIVE RASH                                         | 5                                                  | 0.2%)                                              | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| TOXIC SKIN ERUPTION                                      | 2                                                  | ( (<0.1%)                                          | 2                                                                                                                                        | (<0.1%)                                                                                                                                  |
| GENERALISED ERYTHEMA                                     | 2                                                  | (<0.1%)                                            | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| SEBORRHOEIC DERMATITIS                                   | 2                                                  | (<0.1%)                                            | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| RASH FOLLICULAR                                          | 0                                                  |                                                    | 2                                                                                                                                        | (<0.1%)                                                                                                                                  |
| RASH VESICULAR                                           | 1                                                  | (<0.1%)                                            | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| BUTTERFLY RASH                                           | 0                                                  |                                                    | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| NODULAR RASH                                             | 0                                                  |                                                    |                                                                                                                                          | 1 (<0.1%)                                                                                                                                |
| TOXIC EPIDERMAL NECROLYSIS                               | 1                                                  | (<0.1%)                                            |                                                                                                                                          | 0                                                                                                                                        |
| Total number of events                                   |                                                    | 1912                                               |                                                                                                                                          | 1524                                                                                                                                     |
| INFECTIONS AND INFESTATIONS                              |                                                    |                                                    |                                                                                                                                          |                                                                                                                                          |
| Total number of patients with at least one adverse event | 81                                                 | ( 3.4%)                                            | 57                                                                                                                                       | ( 2.4%)                                                                                                                                  |
| FOLLICULITIS                                             | 39                                                 | ( 1.6%)                                            | 21                                                                                                                                       | ( 0.9%)                                                                                                                                  |
| RASH PUSTULAR                                            | 33                                                 | ( 1.4%)                                            | 20                                                                                                                                       | ( 0.8%)                                                                                                                                  |
| FURUNCLE                                                 | 8                                                  | 0.3%)                                              | 13                                                                                                                                       | ( 0.5%)                                                                                                                                  |
| DERMATITIS INFECTED                                      | 1                                                  | ( (<0.1%)                                          | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| ACNE PUSTULAR                                            | 0                                                  |                                                    | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| EYELID FOLLICULITIS                                      | 0                                                  |                                                    | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| Total number of events                                   |                                                    | 93                                                 |                                                                                                                                          | 63                                                                                                                                       |
| EYE DISORDERS                                            |                                                    |                                                    |                                                                                                                                          |                                                                                                                                          |
| Total number of patients with at least one adverse event | 3                                                  | ( 0.1%)                                            | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| ERYTHEMA OF EYELID                                       | 3                                                  | ( 0.1%)                                            | 0                                                                                                                                        |                                                                                                                                          |
| EYELID RASH                                              | 0                                                  |                                                    | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

Total number of events                                          3              1

Investigator text for AEs encoded using MedDRA v19.1 .

For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once.  For frequency counts of 'Total number of events' rows, multiple occurrences of the same AE in an individual are counted separately. Table includes AEs with onset from first dose of any study treatment through 28 days after last dose of study treatment.

Percentages are based on N in the column headings.

Rash events identified from the Roche Standard AEGT 'EGFR Associated rash'.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ae.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ae\\_TRT1A\\_RASH\\_SE.out 21MAR2017 19:39                                                Page 1 of 1

## Leucopenia

## Table 60 Summary of Leukopenia (SMQ) Adverse Events (Safety Population)

| of Leukopenia (SMQ) Adverse Events, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G                                      | of Leukopenia (SMQ) Adverse Events, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G   | of Leukopenia (SMQ) Adverse Events, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G   | of Leukopenia (SMQ) Adverse Events, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G   | of Leukopenia (SMQ) Adverse Events, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G   |
|------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| MedDRA System Organ Class MedDRA Preferred Term ________________________________________________________________________________________ | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)                                                      | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)                                                      | Placebo + Trastuzumab + Chemotherapy (N=2405)                                                         | Placebo + Trastuzumab + Chemotherapy (N=2405)                                                         |
| Total number of patients with at least one adverse event                                                                                 | 1178                                                                                                  | (49.8%)                                                                                               | 1158                                                                                                  | (48.1%)                                                                                               |
| Overall total number of events                                                                                                           | 3149                                                                                                  | 3149                                                                                                  | 3008                                                                                                  | 3008                                                                                                  |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS                                                                                                     |                                                                                                       |                                                                                                       |                                                                                                       |                                                                                                       |
| Total number of patients with at least one adverse event                                                                                 | 871                                                                                                   | (36.8%)                                                                                               | 853                                                                                                   | (35.5%)                                                                                               |
| NEUTROPENIA                                                                                                                              | 587                                                                                                   | (24.8%)                                                                                               | 562                                                                                                   | (23.4%)                                                                                               |
| FEBRILE NEUTROPENIA                                                                                                                      | 287                                                                                                   | (12.1%)                                                                                               | 266                                                                                                   | (11.1%)                                                                                               |
| LEUKOPENIA                                                                                                                               | 216                                                                                                   | ( 9.1%)                                                                                               | 222                                                                                                   | ( 9.2%)                                                                                               |
| GRANULOCYTOPENIA                                                                                                                         | 19                                                                                                    | 0.8%)                                                                                                 | 23                                                                                                    | ( 1.0%)                                                                                               |
| LYMPHOPENIA                                                                                                                              | 13                                                                                                    | ( ( 0.5%)                                                                                             | 14                                                                                                    | ( 0.6%)                                                                                               |
| AGRANULOCYTOSIS                                                                                                                          | 3                                                                                                     | 0.1%)                                                                                                 | 3                                                                                                     | ( 0.1%)                                                                                               |
| Total number of events                                                                                                                   | ( 1843                                                                                                | ( 1843                                                                                                | 1806                                                                                                  | 1806                                                                                                  |
| INVESTIGATIONS                                                                                                                           |                                                                                                       |                                                                                                       |                                                                                                       |                                                                                                       |
| Total number of patients with at least one adverse event                                                                                 | 433                                                                                                   | (18.3%)                                                                                               | 428                                                                                                   | (17.8%)                                                                                               |
| NEUTROPHIL COUNT DECREASED                                                                                                               | 327                                                                                                   | (13.8%)                                                                                               | 330                                                                                                   | (13.7%)                                                                                               |
| WHITE BLOOD CELL COUNT DECREASED                                                                                                         | 234                                                                                                   | ( 9.9%)                                                                                               | 206                                                                                                   | ( 8.6%)                                                                                               |
| LYMPHOCYTE COUNT DECREASED                                                                                                               | 20                                                                                                    | ( 0.8%)                                                                                               | 10                                                                                                    | ( 0.4%)                                                                                               |
| METAMYELOCYTE COUNT DECREASED                                                                                                            | 1                                                                                                     | (<0.1%)                                                                                               | 0                                                                                                     | 0                                                                                                     |
| Total number of events                                                                                                                   | 1294                                                                                                  | 1294                                                                                                  | 1196                                                                                                  | 1196                                                                                                  |
| INFECTIONS AND INFESTATIONS                                                                                                              |                                                                                                       |                                                                                                       |                                                                                                       |                                                                                                       |
| Total number of patients with at least one adverse event                                                                                 | 11                                                                                                    | ( 0.5%)                                                                                               | 6                                                                                                     | ( 0.2%)                                                                                               |
| NEUTROPENIC SEPSIS                                                                                                                       | 10                                                                                                    | ( 0.4%)                                                                                               | 4                                                                                                     | ( 0.2%)                                                                                               |
| NEUTROPENIC INFECTION                                                                                                                    | 1                                                                                                     | (<0.1%)                                                                                               | 2                                                                                                     | (<0.1%)                                                                                               |
| Total number of events                                                                                                                   |                                                                                                       | 12                                                                                                    |                                                                                                       | 6                                                                                                     |

Investigator text for AEs encoded using MedDRA v19.1 .

For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once.  For frequency counts of 'Total number of events' rows, multiple occurrences of the same AE in an individual are counted separately. Table includes AEs with onset from first dose of any study treatment through 28 days after last dose of study treatment.

Percentages are based on N in the column headings.

Leukopenia events identified from the SMQ (narrow) 'Haematopoietic Leukopenia'.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ae.sas

21MAR2017 19:39                                                                   Page 1 of 1

Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ae\\_TRT1A\\_LEUK\\_SE.out

## Infusion-related reactions (IRR)

Overall, IRRs were experienced in 1293 patients (54.7%) vs. 1199 patients (51.3%). Grade 1 -2 IRRs were reported in 53.1% vs 50.1% of the patients and grade ≥ 3 events were reported in 65 patients (2.7%) vs. 49 patients  (2.1%);  there  were  no  fatal  events.  The  most  common  ( ≥ 5%)  IRRs  starting  on  the  day  of Perjeta/placebo infusion were fatigue (218 patients [9.2%] vs. 194 patients [8.3%], respectively), followed by  arthralgia  (182 patients  [7.7%]  vs.  213  patients  [9.1%]),  hot  flush  (157  patients  [6.6%]  vs. 148 patients [6.3%]), myalgia (120 patients [5.1%] vs. 144 patients [6.2%]), and dysgeusia (119 patients [5.0%] vs. 100 patients [4.3%]).

In Cycle 1, the incidence of IRRs (all Grades) starting on the day of Perjeta/placebo infusion was similar between the treatment arms (495 patients [20.9%] vs. 420 patients [18.0%]). Grade ≥ 3  events were

<div style=\"page-break-after: always\"></div>

reported  in  1.2%  vs.  0.7%.  In  Cycle  2,  the  incidence  of  IRRs  (all  Grades)  starting  on  the  day  of Perjeta/placebo infusion was lower and also similar between the treatment arms, 13.3% vs. 12.6%. Grade ≥ 3 events were reported in 0.3% vs. 0.4% of the patients, respectively. Serious IRR events were reported in 3 patients (0.1%) in the Ptz + H + Chemo arm, and 1 patient ( &lt; 0.1%) in the Pla + H + Chemo arm.

## Anaphylaxis and hypersensitivity

The most common events were hypersensitivity (3.4% vs. 2.9%) followed by drug hypersensitivity (1.3% vs. 0.5%). The majority of events were Grade 1 or 2 in severity. Grade ≥ 3 events were reported in 18 patients (0.8%) vs. 17 patients (0.7%); there were no fatal events. The highest incidence of anaphylaxis and hypersensitivity AEs was reported during the TTTC period, i.e. hypersensitivity (62 patients [2.6%] vs. 50 patients [2.1%]), followed by drug hypersensitivity (22 patients [0.9%] vs. 8 patients [0.3%]).

Serious events were reported in 15 patients (0.6%) vs. 8 patients (0.3%) and most frequently reported was hypersensitivity (11 patients [0.5%] vs. 3 patients [0.1%]).

## Table 61 Summary of Anaphylaxis &amp; Hypersensitivity (AEGT) Adverse Events (Safety Population)

Summary of Anaphylaxis &amp; Hypersensitivity(AEGT) Adverse Events, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

| MedDRA System Organ Class MedDRA Preferred Term ________________________________________________________________________________________   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab + Chemotherapy (N=2405)   |
|--------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|-------------------------------------------------|
| Total number of patients with at least one adverse event                                                                                   | 116 ( 4.9%)                                        | 86 ( 3.6%)                                      |
| Overall total number of events                                                                                                             | 138                                                | 118                                             |
| IMMUNE SYSTEM DISORDERS                                                                                                                    |                                                    |                                                 |
| Total number of patients with at least one adverse event                                                                                   | 113 ( 4.8%)                                        | 86 ( 3.6%)                                      |
| HYPERSENSITIVITY                                                                                                                           | 80 ( 3.4%)                                         | 70 ( 2.9%)                                      |
| DRUG HYPERSENSITIVITY                                                                                                                      | 30 ( 1.3%)                                         | 12 ( 0.5%)                                      |
| ANAPHYLACTIC REACTION                                                                                                                      | 2 (<0.1%)                                          | 5 ( 0.2%)                                       |
| ANAPHYLACTIC SHOCK                                                                                                                         | 1 (<0.1%)                                          | 2 (<0.1%)                                       |
| Total number of events                                                                                                                     | 135                                                | 118                                             |
| VASCULAR DISORDERS                                                                                                                         |                                                    |                                                 |
| Total number of patients with at least one adverse event                                                                                   | 2 (<0.1%)                                          | 0                                               |
| CIRCULATORY COLLAPSE                                                                                                                       | 2 (<0.1%)                                          | 0                                               |
| Total number of events                                                                                                                     | 2                                                  | 0                                               |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                                       |                                                    |                                                 |
| Total number of patients with at least one adverse event                                                                                   | 1 (<0.1%)                                          | 0                                               |
| INJECTION SITE HYPERSENSITIVITY                                                                                                            | 1 (<0.1%)                                          | 0                                               |
| Total number of events                                                                                                                     | 1                                                  | 0                                               |

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Percentages are based on N in the column headings.

Investigator text for AEs encoded using MedDRA v19.1 .

For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once.  For frequency counts of 'Total number of events' rows, multiple occurrences of the same AE in an individual are counted separately. Table includes AEs with onset from first dose of any study treatment through 28 days after last dose of study treatment.

Anaphylaxis and hypersensitivity events identified from the Roche Standard AEGT 'Anaphylaxis and Hypersensitivity'.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ae.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ae\\_TRT1A\\_ANHY\\_SE.out 21MAR2017 19:40                                                                   Page 1 of 1

## Interstitial lung disease

The  most  commonly  reported  AEs  were  pneumonitis  and  radiation  pneumonitis  (both  0.3%  vs.  0.2%, respectively). Grade ≥ 3 events were reported in 5 patients (0.2%) vs. 4 patients (0.2%).

AEs were reported most frequently during the PCTT period (when radiotherapy was given, if indicated): radiation pneumonitis (7 patients [0.3%] vs. 5 patients [0.2%]), and pneumonitis (2 patients [&lt;0.1%] vs. 1 patient [&lt;0.1%], respectively).

<div style=\"page-break-after: always\"></div>

There were 13 SAEs reported (4 SAEs vs. 9 SAEs); two SAEs resulted in death. The most frequently reported were pneumonitis (2 patients  [ &lt; 0.1%] vs. 4 patients  [0.2%],  respectively),  followed  by  ILD  (1  patient [ &lt; 0.1%] vs. 2 patients [ &lt; 0.1%], respectively).

## Table 62 Summary of Interstitial Lung Disease AEs (Safety Population)

Summary of Interstitial Lung Disease (SMQ) Adverse Events, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

| MedDRA System Organ Class MedDRA Preferred Term ________________________________________________________________________________________   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab + Chemotherapy (N=2405)   |
|--------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|-------------------------------------------------|
| Total number of patients with at least one adverse event                                                                                   | 19 ( 0.8%)                                         | 22 ( 0.9%)                                      |
| Overall total number of events                                                                                                             | 19                                                 | 22                                              |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS                                                                                            |                                                    |                                                 |
| Total number of patients with at least one adverse event                                                                                   | 11 ( 0.5%)                                         | 11 ( 0.5%)                                      |
| PNEUMONITIS                                                                                                                                | 8 ( 0.3%)                                          | 6 ( 0.2%)                                       |
| INTERSTITIAL LUNG DISEASE                                                                                                                  | 2 (<0.1%)                                          | 3 ( 0.1%)                                       |
| PULMONARY FIBROSIS                                                                                                                         | 1 (<0.1%)                                          | 1 (<0.1%)                                       |
| LUNG INFILTRATION                                                                                                                          | 0                                                  | 1 (<0.1%)                                       |
| Total number of events                                                                                                                     | 11                                                 | 11                                              |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS                                                                                             |                                                    |                                                 |
| Total number of patients with at least one adverse event                                                                                   | 7 ( 0.3%)                                          | 10 ( 0.4%)                                      |
| RADIATION PNEUMONITIS                                                                                                                      | 7 ( 0.3%)                                          | 5 ( 0.2%)                                       |
| PULMONARY RADIATION INJURY                                                                                                                 | 0                                                  | 5 ( 0.2%)                                       |
| Total number of events                                                                                                                     | 7                                                  | 10                                              |
| INFECTIONS AND INFESTATIONS                                                                                                                |                                                    |                                                 |
| Total number of patients with at least one adverse event                                                                                   | 1 (<0.1%)                                          | 1 (<0.1%)                                       |
| BRONCHIOLITIS                                                                                                                              | 1 (<0.1%)                                          | 1 (<0.1%)                                       |
| Total number of events                                                                                                                     | 1                                                  | 1                                               |

Investigator text for AEs encoded using MedDRA v19.1 .

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Percentages are based on N in the column headings.

ILD events identified from the SMQ (narrow) 'Interstitial Lung Disease'.

For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once.  For frequency counts of 'Total number of events' rows, multiple occurrences of the same AE in an individual are counted separately. Table includes AEs with onset from first dose of any study treatment through 28 days after last dose of study treatment.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ae.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ae\\_TRT1A\\_ILD\\_SE.out 21MAR2017 19:41                                                                   Page 1 of 1

## Mucositis

The most frequently reported events were stomatitis (28.4% vs. 23.8%), mucosal inflammation (23.4% vs. 18.6%), pharyngitis (4.2% vs. 3.5%), and mouth ulceration (2.9% vs. 3.1%). Grade ≥ 3  events were reported in 115 patients (4.9%) vs. 55 patients (2.3%). None of the events had a fatal outcome.

AEs of mucositis were more frequently reported during the TTTC period (stomatitis: 17.3% vs. 13.1%; mucosal inflammation: 14.8% vs. 10.9%), followed by the anthracycline treatment period (stomatitis: 17.3% vs. 15.9%; mucosal inflammation: 13.1% vs. 11.0%, respectively). During the PCTT period the incidence of stomatitis had fallen to approximately 2% in each arm. In the post-treatment follow-up period, only one event of stomatitis was reported in the placebo arm.

Mucositis AEs which led to withdrawal from any study treatment included stomatitis (6 patients [0.3%] vs. 1 patient  ( &lt; 0.1%)),  followed  by  mucosal  inflammation  (2 patients  [&lt;0.1%]  vs.  1 patients  [&lt;0.1%]. Stomatitis led to withdrawal from Perjeta in 2 patients (&lt;0.1%) in the pertuzumab arm only.

The most frequently reported mucositis SAEs were gastroenteritis (8 patients [0.3%] vs. 3 patient [0.1%]), stomatitis (7 patients [0.3%] vs. 1 patient [ &lt; 0.1%], respectively), and mucosal inflammation (4 patients [0.2%] vs. 1 patient [ &lt; 0.1%], respectively). None of the SAEs resulted in death.

<div style=\"page-break-after: always\"></div>

Table 63 Summary of Mucositis AEs (Safety Population)

Summary of Mucositis (AEGT) Adverse Events, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

| MedDRA System Organ Class MedDRA Preferred Term          | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab + Chemotherapy (N=2405) ________________________________________________________________________________________   | Placebo + Trastuzumab + Chemotherapy (N=2405) ________________________________________________________________________________________   |
|----------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Total number of patients with at least one adverse event | 1348 (57.0%)                                       | 1348 (57.0%)                                       | 1180 (49.1%)                                                                                                                             | 1180 (49.1%)                                                                                                                             |
| Overall total number of events                           | 2328                                               | 2328                                               | 1917                                                                                                                                     | 1917                                                                                                                                     |
| GASTROINTESTINAL DISORDERS                               |                                                    |                                                    |                                                                                                                                          |                                                                                                                                          |
| Total number of patients with at least one adverse event | 848                                                | (35.9%)                                            | 732                                                                                                                                      | (30.4%)                                                                                                                                  |
| STOMATITIS                                               | 671                                                | (28.4%)                                            | 573                                                                                                                                      | (23.8%)                                                                                                                                  |
| MOUTH ULCERATION                                         | 69                                                 | ( 2.9%)                                            | 75                                                                                                                                       | ( 3.1%)                                                                                                                                  |
| GASTRITIS                                                | 58                                                 | ( 2.5%)                                            | 46                                                                                                                                       | ( 1.9%)                                                                                                                                  |
| APHTHOUS ULCER                                           | 35                                                 | ( 1.5%)                                            | 23                                                                                                                                       | ( 1.0%)                                                                                                                                  |
| OESOPHAGITIS                                             | 30 (                                               | 1.3%)                                              | 23                                                                                                                                       | ( 1.0%)                                                                                                                                  |
| GLOSSITIS                                                | 8 (                                                | 0.3%)                                              | 14                                                                                                                                       | ( 0.6%)                                                                                                                                  |
| ANAL INFLAMMATION                                        | 13 (                                               | 0.5%)                                              | 8                                                                                                                                        | ( 0.3%)                                                                                                                                  |
| COLITIS                                                  | 9 (                                                | 0.4%)                                              | 10                                                                                                                                       | ( 0.4%)                                                                                                                                  |
| CHEILITIS                                                | 6                                                  | 0.3%)                                              | 9                                                                                                                                        | ( 0.4%)                                                                                                                                  |
| PROCTITIS                                                | 10                                                 | ( ( 0.4%)                                          | 5                                                                                                                                        | ( 0.2%)                                                                                                                                  |
| GINGIVAL ULCERATION                                      | 5                                                  | 0.2%)                                              | 9                                                                                                                                        | ( 0.4%)                                                                                                                                  |
| CHRONIC GASTRITIS                                        | 5                                                  | ( ( 0.2%)                                          | 2                                                                                                                                        | (<0.1%)                                                                                                                                  |
| GASTRITIS EROSIVE                                        | 3                                                  | ( 0.1%)                                            | 2                                                                                                                                        | (<0.1%)                                                                                                                                  |
| ENTEROCOLITIS                                            | 2                                                  | (<0.1%)                                            | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| GASTROINTESTINAL INFLAMMATION                            | 3                                                  | ( 0.1%)                                            | 0                                                                                                                                        |                                                                                                                                          |
| DUODENITIS                                               | 1                                                  | (<0.1%)                                            | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| COLITIS ULCERATIVE                                       | 1                                                  | (<0.1%)                                            | 0                                                                                                                                        | 0                                                                                                                                        |
| DIARRHOEA HAEMORRHAGIC                                   | 0                                                  |                                                    | 1 (<0.1%)                                                                                                                                | 1 (<0.1%)                                                                                                                                |
| NONINFECTIVE GINGIVITIS                                  | 1                                                  | (<0.1%)                                            | 0                                                                                                                                        | 0                                                                                                                                        |
| Total number of events                                   | 1313                                               | 1313                                               | 1080                                                                                                                                     | 1080                                                                                                                                     |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS     |                                                    |                                                    |                                                                                                                                          |                                                                                                                                          |
| Total number of patients with at least one adverse event | 554                                                | (23.4%)                                            | 449                                                                                                                                      | (18.7%)                                                                                                                                  |
| MUCOSAL INFLAMMATION                                     | 552                                                | (23.4%)                                            | 448                                                                                                                                      | (18.6%)                                                                                                                                  |
| MUCOSAL HAEMORRHAGE                                      | 1                                                  | (<0.1%)                                            | 0                                                                                                                                        |                                                                                                                                          |
| MUCOSAL PAIN                                             | 0                                                  |                                                    | 1                                                                                                                                        | (<0.1%)                                                                                                                                  |
| MUCOSAL TOXICITY                                         | 1                                                  | (<0.1%)                                            | 0                                                                                                                                        |                                                                                                                                          |
| MUCOSAL ULCERATION                                       | 1                                                  | (<0.1%)                                            | 0                                                                                                                                        |                                                                                                                                          |
| Total number of events                                   |                                                    | 751                                                |                                                                                                                                          | 588                                                                                                                                      |
| INFECTIONS AND INFESTATIONS                              |                                                    |                                                    |                                                                                                                                          |                                                                                                                                          |
| Total number of patients with at least one adverse event | 209                                                | ( 8.8%)                                            | 205                                                                                                                                      | ( 8.5%)                                                                                                                                  |
| PHARYNGITIS                                              | 99                                                 | ( 4.2%)                                            | 85                                                                                                                                       | ( 3.5%)                                                                                                                                  |
| GASTROENTERITIS                                          | 41                                                 | ( 1.7%)                                            | 47                                                                                                                                       | ( 2.0%)                                                                                                                                  |
| GINGIVITIS                                               | 38                                                 | 1.6%)                                              | 38                                                                                                                                       | ( 1.6%)                                                                                                                                  |
| ANGULAR CHEILITIS                                        | 26                                                 | ( ( 1.1%)                                          | 20                                                                                                                                       | ( 0.8%)                                                                                                                                  |
| LARYNGITIS                                               | 19                                                 | ( 0.8%)                                            | 26                                                                                                                                       | ( 1.1%)                                                                                                                                  |
| Total number of events                                   |                                                    | 258                                                |                                                                                                                                          | 246                                                                                                                                      |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS          |                                                    |                                                    |                                                                                                                                          |                                                                                                                                          |
| Total number of patients with at least one adverse event | 6                                                  | ( 0.3%)                                            | 3                                                                                                                                        | ( 0.1%)                                                                                                                                  |
| PHARYNGEAL INFLAMMATION                                  | 6                                                  | ( 0.3%)                                            | 3                                                                                                                                        | ( 0.1%)                                                                                                                                  |
| Total number of events                                   |                                                    | 6                                                  |                                                                                                                                          | 3                                                                                                                                        |

Investigator text for AEs encoded using MedDRA v19.1 .

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

Percentages are based on N in the column headings.

Mucositis events identified from the Roche Standard AEGT 'Mucositis of the GastroIntestinal Tract'.

For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once.  For frequency counts of 'Total number of events' rows, multiple occurrences of the same AE in an individual are counted separately. Table includes AEs with onset from first dose of any study treatment through 28 days after last dose of study treatment.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_ae.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_ae\\_TRT1A\\_MUCO\\_SE.out 21MAR2017 19:41                                                 Page 1 of 1

## Pregnancies

Up to the primary clinical cutoff date, 33 pregnancies were reported in 29 patients (19 pregnancies reported in 16 patients in the pertuzumab arm, and 14 pregnancies reported in 13 patients in the placebo arm). One pregnancy occurred during study treatment, and 32 pregnancies occurred during the post-treatment period (of these, 4 occurred within 7 months [210 days] of the last dose of study medication). Five pregnancies resulted in spontaneous abortions, and 4 pregnancies ended with therapeutic abortions. Nine pregnancies were  ongoing  at  the  time  of  the  clinical  cutoff,  and  15  pregnancies  resulted  in  live  births.  Of  the  5 pregnancies  that  occurred  during  or  within  7  months  of  the  last  dose  of  study  medication,  two  were

<div style=\"page-break-after: always\"></div>

terminated, two resulted in healthy live singleton births, and one resulted in premature delivery of twins who subsequently died. Of the 15 live births, 5 were premature - two of these were twin births.  No reports of pre-natal or post-natal complications attributable to Perjeta or Herceptin were received. The incidence of premature  delivery  (5/20  [23.8%])  was  higher  than  expected  based  on  the  general  population (approximately 8% [NHS Choices 2017]), and there was also a relatively high incidence of spontaneous abortion  (5/20  [23.8%],  expected  rate  15-20%  [FDA  Guidance  2014]).  However,  there  was  no  major difference in incidence between treatment arms.

## Hepatic dysfunction

A total of 340 patients (14.4%) vs. 368 patients (15.3%) had hepatic-related AEs. The most commonly reported PTs were ALT increased (9.3% vs. 10.1%, respectively) and AST increased (6.1% vs. 6.7%, respectively). The majority of these reported events were Grade 1 or 2 in severity; Grade ≥3 events of ALT increased was reported in 0.9% vs. 1.0% of patients respectively and AST increased was reported in 12 patients (0.5%) in each arm.

## Table 64 Drug-Related Hepatic Disorder (Safety Population)

Sumary of Drug-Related iepatic Digorder (SMQ) Adverse Events, Safety Evaluated Population Protoco1:BIG 4-11/B025126/10C4939G

| VedDRA 3ystem Orgen Class MedDRA'Preferred Term                 | Pertusumab + Trastuswmab Chenotherapy (N=2364)   | Placebo+ Trastuswmsb Chemotherapy (N=2405)   |
|-----------------------------------------------------------------|--------------------------------------------------|----------------------------------------------|
| Total number of patients with at least one acverse event        | 340 (14.4)                                       | 368 (15.3)                                   |
| Overall total number of events                                  | 666                                              | 764                                          |
| INVESTIGATIONS                                                  |                                                  |                                              |
| Total nunber of patients with at least one adverse event        | 290 (12.3)                                       | 317 (13.2)                                   |
| ALANINEAMTNOTRANSFERASEINCREASED                                | 221 9.3)                                         | 244 (10.1)                                   |
| ASPARTATEAMINOTRANSFERASEINCREASED                              | 145 6.1$)                                        | 162 6.7)                                     |
| BTOODAIKALINEFHOSPHATASEINCRPASED                               | 41 1.7$)                                         | 50 2.1$)                                     |
| GAMMA-GLUTAMYLTRANSFERASEINCREASED                              | 21 0.93)                                         | 39 1.6) 0.8)                                 |
| TRANSAMINASES INCREASED                                         | 22 0.95)                                         | 19                                           |
| BLOOD BILIRUBIN INCREASED                                       | 16 0.7)                                          | 14 (0.6)                                     |
| LIVERFUNCTION TESTINCREASED                                     | 7 0.3)                                           | 3 0.13)                                      |
| HEPATIC ENZYME INCREASED                                        | 2 (<0.15)                                        | 6 (0.25)                                     |
| BILIRUBINCONUUGATEDINCREASED                                    | 2 (<0.14)                                        | 1 (<0.1)                                     |
| HEPATIC ENZYMEABNORMAL                                          | 口                                                | (<0.1$)                                      |
| BLOOD BILIRUBIN UNCONJUGATED INCREASED                          | 1 (<0.1#)                                        | 2 0                                          |
| LIVER FUNCTION TEST AENORMAL                                    | 1 (<0.1)                                         | 0                                            |
| Total number of events                                          | 593                                              | 692                                          |
| HEPATOBTLIARYDISORDERS                                          |                                                  |                                              |
| Total nuber of patients with at least one adverse event         | 53 2.2)                                          | 57 (2.4)                                     |
| HEPATICFUNCTIONABNORMAL                                         | 13 0.5)                                          | 23 1.03) 18                                  |
| HEPATICSTPATOSIS                                                | 11 0.54)                                         | 0.43)                                        |
| LIVER INJURY                                                    | 5 0.2) 5                                         | 5 0.2) 4 0.25)                               |
| HEPATIC CYST                                                    | 0.25) 3                                          |                                              |
| HEPATOCELLULAR INJURY                                           | 0.14)                                            | 6 (0.2)                                      |
| HNPATOBILIARYDISPASE HEPATOTOXICITY                             | 6 0.3) 0.2$)                                     | 2 (<0.1) 3 (0.1$)                            |
| DRUG-INDUCED LIVER INJURY                                       | 3 0.1#)                                          | 0                                            |
| HEPATIC BATN                                                    | 1 (<0.1)                                         | 2 (<0.14)                                    |
| HYPERBTLIRUBINAEMIA                                             | 3 0.1$)                                          |                                              |
| CHOLESTASIS                                                     | 2 (<0.1)                                         | !                                            |
| HEPATICFATLURE                                                  | 1 (<0.14)                                        | 1 (<0.1)                                     |
| HEPATITIS                                                       | 口                                                | 2 (<0.15)                                    |
| HEPATITISACUTE                                                  | 0                                                | (<0.14)                                      |
| HEPATITIS TOXIC                                                 | (<0.1#) 口                                        | 1 (<0.14)                                    |
| HYPERTRANSAMINASAEMIA LIVER DISORDER                            | (<0.1#)                                          |                                              |
| OCULAR ICTERUS                                                  | 0                                                | (<0.14)                                      |
| Total nuber of events                                           | 61                                               | 65                                           |
| METAEOLISMAND NUIRITION DISORDERS                               |                                                  |                                              |
| Totalnuber of patientswith atleastoneadverseevent               | 10 (0.4#)                                        | 5 (0.2)                                      |
| HYPOALBUMTNAEMIA                                                | 10 (0.4)                                         | 5 (0.2)                                      |
| Total nuber of events                                           | 10                                               | 5                                            |
| SKIN AND SUECUTANEOUS TISSUE DISORDERS                          |                                                  |                                              |
| Total nunber of patients with at least one adverse event        | (<0.1) （<0.1）                                    | (<0.14)                                      |
| SPIDER NAEVUS YELLOW SKIN Total number of events                | D                                                | (<0.1#) 1                                    |
| GASTROINTESTINALDISORIERS                                       |                                                  |                                              |
| Total nuber of patients with at least one adverse event ASCITES | 0 0                                              | (<0.1#) (<0.1#)                              |
| Total number of events                                          |                                                  |                                              |
| NEOPLASMS BENIGN,MALIGNANT AND UNSPECIFIED (INCL CYSTS AND      |                                                  |                                              |
| POLYPS) Total nuber ofpatients with at least oneadverse event   | (<0.1#)                                          | 0 D                                          |
| HAEMANGIOMA OF LIVER Total number of events                     | (<0.1#)                                          | 0                                            |

1'6tn taupy bujen pposussgg xog axea xoaebtaeonui

Eor frequeney counts by preferred tem, multiple oceurrences\\_of the srme AE in an individual are counted only once. For frequency counts of 'Total number of events'rows, mltiple occurrences of the same AE in an individual are counted separately. Table includes go srop 46et 1eage 5p gz ubnory4 4ueue9a Apn4e Aue go s5op 45xty woxg 4eruo 4atn sgt study treatment.

Percentages are based on N in the column headings.

- Comprehensive Search'.

Hy's Law Definition of Drug-Induced Liver Injury

<div style=\"page-break-after: always\"></div>

For this study, potential cases of drug-induced liver injury were detected using the following criteria for Hy's law, as defined in the Data Analysis Plan (DAP): AST and/or ALT &gt; 3 x baseline and total bilirubin ≥ 2 x ULN at the same visit/date. Hy's Law criteria for drug-induced liver injury require there to be no alternative cause for hepatic dysfunction (such as coexistent liver disease) or confounding factors such as administration of a known hepatotoxic agent. In the APHINITY study, all patients were scheduled to receive other potentially hepatotoxic agents (notably anthracyclines and/or taxanes) so only laboratory criteria were used.

Five patients fulfilled the liver enzyme criteria for Hy's Law according to these laboratory criteria (3 patients vs. 2 patients).

All  5  patients  had confounding factors, as summarized below, and in none of the patients was Perjeta considered a likely causal factor.

With regard to the patients in the experimental arm, in one case (Patient 2316340014) the event occurred 203 days after last dose of study treatment and the patient was receiving concomitant treatment with glatiramer  acetate  for  multiple  sclerosis.  In  Patient  2332850008  Grade  3  drug-induced  hepatitis  was assessed  as  unrelated  to  Perjeta,  Herceptin  and  paclitaxel,  and  related  to  simvastatin  which  was  a concomitant medication at study entry. The patient's ALT and AST returned to normal despite continued treatment with Perjeta, Herceptin and paclitaxel. Patient 2351340011 was identified as having laboratory test results meeting the DAP-defined Hy's Law criteria. The narrative relating to this patient (who does not appear in the listing of liver laboratory test results meeting Hy's Law) is included below:

- Patient 2351340011: this 53-year old woman started treatment with docetaxel, carboplatin, Perjeta and Herceptin on Study Day 1 (Cycle 1). On Study Day 6, she was found to have a raised AST of 112 U/L (3.6 x ULN), ALT of 83 U/L (2.4 x ULN), alkaline phosphatase of 341 U/L (3.3 x ULN), and bilirubin of 82.08 umol/L (3.9 x ULN; Grade 3). On Study Day 9, a bone marrow biopsy was conducted and a diagnosis of hemophagocytic lymphohistiocytosis was made. The investigator assessed this as related to pre-existing/underlying disease (unspecified). Treatment with Perjeta, Herceptin, docetaxel and carboplatin was permanently discontinued. By Week 4 (Study Day 38), only the alkaline phosphatase remained elevated at 142 U/L (1.4 x ULN). This returned to the normal range by Study Day 61. The patient went on to receive non-study adjuvant treatment with etoposide from Study Day 11 to Study Day 20 (one cycle), paclitaxel from Study Day 63 to Study Day 141 (12 cycles), and trastuzumab from Study Day 42 to Study Day 463 (28 cycles).

## Adverse events starting during a Perjeta/placebo infusion

Overall, AEs started during a Perjeta/placebo infusion more frequently in the Ptz + H + Chemo arm compared to the Pla + H + Chemo arm (240 patients [10.2%] vs. 181 patients [7.8%], respectively). The majority of AEs reported were Grade 1 or 2 in severity (9.6% vs. 7.3%). However, 19 patients (0.8%) and 14 patients (0.6%) experienced Grade ≥ 3 events, respectively. No fatal events were reported.

AEs  started  more  frequently  during  the  first  Perjeta  infusion  than  during  the  first  placebo  infusion (139 patients [5.9%] vs. 71 patients [3.0%]). The majority of AEs were Grade 1 or 2 in severity (129 patients [5.5%] vs. 68 patients [2.9%]).

The frequency of AEs that started during a second Perjeta infusion was similar to the frequency during the second placebo infusion (2.2% vs. 1.8%).

## Adverse events during Anthracycline treatment

As  per  protocol,  HER2-targeted  therapy  did  not  commence  until  completion  of  anthracycline-based chemotherapy. Thus, during the anthracycline treatment period, patients in the Ptz + H + Chemo arm received exactly the same treatment (chemotherapy only) as patients in the Pla + H + Chemo arm.

<div style=\"page-break-after: always\"></div>

Of the 95,985 AEs reported during the APHINITY study, 28.7% of AEs were reported in the Ptz + H + Chemo arm versus 31.7% of AEs in the Pla + H + Chemo arm during the anthracycline treatment period.

A similar proportion of patients experienced at least one AE during the anthracycline treatment period. During the anthracycline treatment period, a similar proportion of patients experienced Grade ≥ 3 AEs in both arms (39.0% vs. 39.5%). The majority of Grade ≥ 3 AEs were in the Blood and Lymphatic System Disorders SOC (neutropenia: 13.1% vs. 12.7%).

## Adverse events during targeted therapy + taxane (TTTC) period

Of the 95,985 AEs reported during the APHINITY study, 45.5% of AEs were reported in the Ptz + H + Chemo arm versus 43.6% of AEs in the Pla + H + Chemo arm during the TTTC period.

The most common AEs ( ≥ 10% of patients) reported during the TTTC period were diarrhea (61.4% vs. 33.8%), nausea (24.4% vs. 21.0%), fatigue (24.2% vs. 20.7%), anemia (18.4% vs. 14.0%), myalgia (18.1% vs. 21.5%), arthralgia (13.3% vs. 17.8%), dysgeusia (17.3% vs. 13.4%), stomatitis (17.3% vs. 13.1%), rash (15.9% vs. 13.2%), vomiting (15.7% vs. 11.6%), epistaxis (15.0% vs. 11.3%), alopecia (14.6% vs. 15.3%), mucosal inflammation (14.8% vs. 10.9%), decreased appetite (13.8% vs. 8.9%), peripheral sensory neuropathy (13.4% vs. 13.7%), neutropenia (11.5% vs. 11.3%), oedema peripheral (11.0% vs.  13.1%),  pyrexia  (12.2%  vs.  11.4%),  neuropathy  peripheral  (11.7%  vs.  11.8%),  asthenia (11.5% vs. 11.1%), and constipation (10.4% vs. 13.8%).

During the TTTC period, a higher proportion of patients experienced Grade ≥ 3 AEs (42.0% vs. 33.5%), and the Grade ≥ 3 AEs commonly reported were febrile neutropenia (7.7% vs. 6.9%), neutropenia (7.1% vs. 7.4%), anaemia (5.2% vs. 3.2%), and diarrhea (8.4% vs. 2.5%).

## Adverse events during the post-chemotherapy targeted therapy (PCTT) period

Of the 95,985 AEs reported during the APHINITY study, 25.5% of AEs were reported in the Ptz + H + Chemo arm versus 24.6% of AEs in the Pla + H + Chemo arm during the PCTT period.

The most common AEs ( ≥ 10%) reported were diarrhea (18.1% vs. 9.2%), arthralgia (15.3% vs. 16.5%), and pruritus (10.0% vs. 5.8%).

A similar proportion of patients experienced Grade ≥ 3 AEs (13.0% vs. 11.1%), most frequently ejection fraction decreased (1.4% vs. 1.1%), hypertension (0.8% vs. 0.7%), neutropenia (0.5% vs. 0.4%), diarrhea (0.5% vs. 0.2%), and neutrophil count decreased (0.4% vs. 0.2%). The incidence of Grade ≥ 3 diarrhea events was 0.5% vs. 0.2% during the period of targeted treatment alone.

The proportion of patients who experienced at least one AE that led to the withdrawal of Perjeta or placebo during  the  PCTT  period  was  similar  in  the  two  treatment  arms  (125 patients  [5.3%]  vs.  110  patients [4.6%]).

## Adverse events post-treatment follow-up period

<div style=\"page-break-after: always\"></div>

## Table 65

Protocol: BIG 4-11/B025126/T0C4939G

| MedDRA System Organ Class MedDRA Preferred Term          | Pertuzumab + Trastuzumab+ Chemotherapy (N=2364)   | Placebo + Trastuzumab Chemotherapy (N=2405)   |
|----------------------------------------------------------|---------------------------------------------------|-----------------------------------------------|
| Total number of patients with at least one adverse event | 100 (4.2%)                                        | 116 (4.8%)                                    |
| Overalltotalnumberof events                              | 118                                               | 135                                           |
| INVESTIGATIONS                                           |                                                   |                                               |
| Totalnumber of patients with at least one adverse event  | 40 (1.7%)                                         | 51 2.1%)                                      |
| EJECTIONFRACTIONDECREASED                                | 39 1.6%)                                          | 51 2.1%)                                      |
| ELECTROCARDIOGRAMQTPROLONGED                             | 1 (<0.1%)                                         | 0                                             |
| HEART RATE INCREASED                                     | 1 (<0.1%)                                         | 0                                             |
| Totalnumberof events                                     | 42                                                | 56                                            |

<!-- image -->

Adverse events by chemotherapy type

<div style=\"page-break-after: always\"></div>

## Table 66

Safety Summary by Treatment Regimen and Chemotherapy Type, Safety Evaluated Population Protoco1:BIG 4-11/B025126/T0C4939G

|                                                                                      | Pertuzumab Trastuzumab Anthracycline (N=1834)   | Pertuzumab Trastuzumab Anthracycline (N=1834)   | Pertuzumab + Trastuzumab + Non- Anthracycline (N=528)   | Pertuzumab + Trastuzumab + Non- Anthracycline (N=528)   | Placebo + Trastuzumab + Anthracycline (N=1894)   | Placebo + Trastuzumab + Anthracycline (N=1894)   | Placebo + Trastuzumab + Non-Anthracycline (N=510)   | Placebo + Trastuzumab + Non-Anthracycline (N=510)   |
|--------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Total number of patients with at least one event (AE/death)*                         |                                                 | 1833 (>99.9%)                                   |                                                         | 526 (99.6%)                                             | 1882                                             | (99.4%)                                          |                                                     | 510 (100.0%)                                        |
| Total number of events (AE/ death)*                                                  | 38501                                           | 38501                                           | 11463                                                   | 11463                                                   | 35724                                            | 35724                                            | 10263                                               | 10263                                               |
| Total number of deaths Total number of patients                                      |                                                 | 55( 3.0%)                                       |                                                         | 18(3.4%)                                                |                                                  | 79(4.2%)                                         | 16                                                  | 3.1%)                                               |
| with at least one                                                                    |                                                 |                                                 |                                                         |                                                         |                                                  |                                                  |                                                     |                                                     |
| AE with fatal outcome                                                                | 6                                               | 0.3%)                                           | 4                                                       | (0.8%)                                                  | 11                                               | 0.6%)                                            | 3                                                   | 0.6%)                                               |
| Serious AE                                                                           | 512                                             | 27.9%)                                          | 180                                                     | (34.1%)                                                 | 444                                              | (23.4%)                                          | 141                                                 | 27.6%)                                              |
| AE leading to withdrawal from pertuzumab/placebo treatment                           | 131                                             | 7.1%)                                           | 35                                                      | (6.6%)                                                  | 113                                              | 6.0%)                                            | 26                                                  | 5.1%)                                               |
| AE leading to withdrawal                                                             | 235                                             | (12.8%)                                         | 74                                                      | (14.0%)                                                 | 237                                              | (12.5%)                                          | 40                                                  | 7.8%)                                               |
| from any treatment AE leading todose modification/interruption of pertuzumab/placebo |                                                 | 516 ( 28.1%)                                    | 207                                                     | (39.2%)                                                 | 482                                              | (25.4%)                                          |                                                     | 150（29.4%)                                          |
| AEleading todose modification/interruption of any study treatment                    |                                                 | 919 (50.1%)                                     | 297                                                     | (56.3%)                                                 | 840                                              | (44.4%)                                          |                                                     | 224(43.9%)                                          |
| Related (HER2-targeted) AE                                                           |                                                 | 1165 ( 63.5%)                                   | 372                                                     | (70.5%)                                                 | 1048                                             | (55.3%)                                          |                                                     | 320（62.7%)                                          |
| NCI-CTCAE Grade >=3 AE                                                               | 1133                                            | 61.8%)                                          | 384                                                     | (72.7%)                                                 | 1080                                             | (57.0%)                                          | 299                                                 | （58.6%)                                             |
| AE during pertuzumab/ placebo infusion                                               | 194                                             | 10.6%)                                          | 46                                                      | (8.7%)                                                  | 150                                              | (7.9%)                                           | 31                                                  | 6.1%)                                               |
| Cardiac Safety                                                                       |                                                 |                                                 |                                                         |                                                         |                                                  |                                                  |                                                     |                                                     |
| Symptomatic Cardiac Dysfunction (Primary                                             | 15                                              | 0.8%)                                           | 2                                                       | （0.4%)                                                  | 7                                                | 0.4%)                                            | 1                                                   | 0.2%)                                               |
| Cardiac Event) Heart failure (NYHA III                                               | 13                                              | 0.7%)                                           | 2                                                       | （0.4%)                                                  | 5                                                | (0.3%)                                           | 1                                                   | 0.2%)                                               |
| or Iv) and significant LVEF decline Cardiac death (definite or probable)             | 2                                               | 0.1%)                                           | 0                                                       |                                                         |                                                  | 2 (0.1%)                                         |                                                     | 0                                                   |
| Secondary cardiac endpoint                                                           | 55                                              | 3.0%)                                           |                                                         | (1.7%)                                                  |                                                  | 60(3.2%)                                         | 7                                                   | 1.4%)                                               |

Investigator text for AEs encoded using MedDRA vl9.1

* Includes deaths for patients that had no adverse events; 1 patient had a death without any AE in the Placebo arm.

Percentages are based on N in the column headings.

Muitiple occurrences of the same AE in one individual are counted only once except for 'Total number of AEs' row in which multiple occurrences of the same AE are counted separately.

Total number of deaths are counted over the whole study period, including post-treatment follow-up.

Table includes AEs with onset from first dose of any study treatment through 28 days after lastdose of studytreatment.

Significant LVEFdeclinedefined asadeclineof &gt;=l0% points to avalue&lt;50%.

Program: /opt/BI0STAT/prod/cdp11450/r25126a/t\\_saf\\_sum.sas Output:/opt/BI0STAT/prod/cd11450g/j25126a/reports/t\\_saf\\_sum\\_TRT2A\\_SE.out

07APR2017 11:22

Page 1 of 2

<div style=\"page-break-after: always\"></div>

Safety Summary by Treatment Regimen and Chemotherapy Type, Safety Evaluated Population Protoco1:BIG 4-11/B025126/T0C4939G

|                                         | Pertuzumab + Trastuzumab + Anthracycline (N=1834)   | Pertuzumab + Trastuzumab + Anthracycline (N=1834)   | Pertuzumab + Trastuzumab Non- Anthracycline (N=528)   | Pertuzumab + Trastuzumab Non- Anthracycline (N=528)   | Placebo + Trastuzumab + Anthracycline (N=1894)   | Placebo + Trastuzumab + Anthracycline (N=1894)   | Placebo + Trastuzumab + Non-Anthracycline (N=510)   | Placebo + Trastuzumab + Non-Anthracycline (N=510)   |
|-----------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Medical concepts: patients with         |                                                     |                                                     |                                                       |                                                       |                                                  |                                                  |                                                     |                                                     |
| Diarrhoea                               | 1237                                                | 67.4%)                                              | 447                                                   | (84.7%)                                               | 772                                              | (40.8%)                                          | 314                                                 | 61.6%)                                              |
| NCI-CTCAE Grade >=3                     | 138                                                 | 7.5%)                                               | 95                                                    | (18.0%)                                               | 59                                               | (3.1%)                                           | 31                                                  | 6.1%)                                               |
| Rash                                    | 968                                                 | 52.8%)                                              | 258                                                   | (48.9%)                                               | 789                                              | (41.7%)                                          | 213                                                 | 41.8%)                                              |
| NCI-CTCAE Grade >=3                     | 54                                                  | 2.9%)                                               | 5                                                     | (0.9%)                                                | 30                                               | (1.6%)                                           | 6                                                   | 1.2%)                                               |
| Leukopenia                              | 941                                                 | 51.3%)                                              | 236                                                   | (44.7%)                                               | 921                                              | (48.6%)                                          | 237                                                 | 46.5%)                                              |
| NCI-CTCAE Grade >=3                     | 713                                                 | 38.9%)                                              | 167                                                   | (31.6%)                                               | 673                                              | (35.5%)                                          | 168                                                 | 32.9%)                                              |
| Febrile neutropenia NCI-CTCAE Grade >=3 | 235                                                 | 12.8%)                                              | 51                                                    | 9.7%)                                                 | 204                                              | (10.8%)                                          | 62                                                  | 12.2%)                                              |
| Febrile neutropenia NCI-CTCAE Grade >=3 | 235                                                 | 12.8%)                                              | 51                                                    | 9.7%)                                                 | 204                                              | (10.8%)                                          | 62                                                  | 12.2%)                                              |
| Anaphylaxis and                         | 76                                                  | 4.1%)                                               | 40                                                    | 7.6%)                                                 | 61                                               | (3.2%)                                           | 25                                                  | 4.9%)                                               |
| hypersensitivity NCI-CTCAE Grade >=3    | 11                                                  | 0.6%)                                               | 7                                                     | (1.3%)                                                | 9                                                | (0.5%)                                           | 8                                                   | 1.6%)                                               |
| Mucositis                               | 1085                                                | 59.2%)                                              | 262                                                   | (49.6%)                                               | 948                                              | (50.1%)                                          | 232                                                 | 45.5%)                                              |
| NCI-CTCAE Grade >=3                     | 91                                                  | 5.0%)                                               | 24                                                    | 4.5%)                                                 | 44                                               | 2.3%)                                            | 11                                                  | 2.2%)                                               |
| Interstitial lung disease               | 17                                                  | 0.9%)                                               | 2                                                     | 0.4%)                                                 | 20                                               | 1.1%)                                            | 2                                                   | 0.4%)                                               |
| NCI-CTCAE Grade >=3                     | 3                                                   | 0.2%)                                               | 2                                                     | （0.4%)                                                | 3                                                | 0.2%）                                            | 1                                                   | 0.2%)                                               |

Percentages are based on N in the column headings.

Investigatortextfor AEsencodedusingMedDRAvl9.1

- Includes deaths for patients that had no adverse events;1 patient had a death without any AE in the Placebo arm.

Table includes AEs with onset from first dose of any study treatment through 28 days after last dose of study treatment.

Multiple occurrences of the same AE in one individual arecountedonly onceexcept for 'Total number of AEs' row in which multiple occurrences of the same AE are counted separately.

Total number of deaths are counted over the whole studyperiod,including post-treatment follow-up.

Significant LVEFdeclinedefined as a declineof &gt;=l0% pointstoa value&lt;50%.

Program:/opt/B10STAT/prod/cdp11450/r25126a/t\\_saf\\_sum.sas

07APR2017 11:22

Output:/opt/BI0STAT/prod/cd11450g/j25126a/reports/t\\_saf\\_sum\\_TRT2A\\_SE.out

## Laboratory findings

## Table 67 Laboratory Test Results with Highest NCI CTCAE Grade Post-Baseline by Treatment Regimen: Safety Population

Laboratory Test Results with Highest NCI CTCAE Grade Post-Baseline by Treatment Regimen,

Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

Hemoglobin

Leukocytes

Neutrophils

Platelets

| Laboratory Test Direction of Abnormality   | Highest CTC Grade   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364) _____________________________________________________________________   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364) _____________________________________________________________________   | Placebo + Trastuzumab + Chemotherapy (N=2405)   | Placebo + Trastuzumab + Chemotherapy (N=2405)   |
|--------------------------------------------|---------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Hemoglobin                                 |                     |                                                                                                                          |                                                                                                                          |                                                 |                                                 |
|                                            | n                   | 2363                                                                                                                     | 2363                                                                                                                     | 2395                                            | 2395                                            |
| Low                                        | 1                   | 1083                                                                                                                     | (45.8%)                                                                                                                  | 1164                                            | (48.6%)                                         |
|                                            | 2                   | 876                                                                                                                      | (37.1%)                                                                                                                  | 835                                             | (34.9%)                                         |
|                                            | 3                   | 197                                                                                                                      | ( 8.3%)                                                                                                                  | 141                                             | ( 5.9%)                                         |
|                                            | Any                 | 2156                                                                                                                     | (91.2%)                                                                                                                  | 2140                                            | (89.4%)                                         |
| High                                       | 1                   | 79                                                                                                                       | ( 3.3%)                                                                                                                  | 93                                              | ( 3.9%)                                         |
|                                            | 2                   | 1                                                                                                                        | (<0.1%)                                                                                                                  | 3                                               | ( 0.1%)                                         |
|                                            | 3                   | 4                                                                                                                        | ( 0.2%)                                                                                                                  | 3                                               | ( 0.1%)                                         |
|                                            | Any                 | 84                                                                                                                       | ( 3.6%)                                                                                                                  | 99                                              | ( 4.1%)                                         |
| Leukocytes                                 |                     |                                                                                                                          |                                                                                                                          |                                                 |                                                 |
|                                            | n                   | 2327                                                                                                                     | 2327                                                                                                                     | 2352                                            | 2352                                            |
| Low                                        | 1                   | 421                                                                                                                      | (18.1%)                                                                                                                  | 469                                             | (19.9%)                                         |
|                                            | 2                   | 572                                                                                                                      | (24.6%)                                                                                                                  | 538                                             | (22.9%)                                         |
|                                            | 3                   | 424                                                                                                                      | (18.2%)                                                                                                                  | 411                                             | (17.5%)                                         |
|                                            | 4                   | 278                                                                                                                      | (11.9%)                                                                                                                  | 274                                             | (11.6%)                                         |
|                                            | Any                 | 1695                                                                                                                     | (72.8%)                                                                                                                  | 1692                                            | (71.9%)                                         |
| High                                       | 3                   | 1                                                                                                                        | (<0.1%)                                                                                                                  | 10                                              | 0.4%)                                           |
| Neutrophils                                | Any                 | 1                                                                                                                        | (<0.1%)                                                                                                                  | 10                                              | ( ( 0.4%)                                       |
| Low                                        | n                   | 2321                                                                                                                     | 2321                                                                                                                     | 2351                                            | 2351                                            |
|                                            | 1                   | 210                                                                                                                      | ( 9.0%)                                                                                                                  | 206                                             | ( 8.8%)                                         |
|                                            | 2                   | 362                                                                                                                      | (15.6%)                                                                                                                  | 382                                             | (16.2%)                                         |
|                                            | 3                   | 285                                                                                                                      | (12.3%)                                                                                                                  | 296                                             | (12.6%)                                         |
|                                            | 4                   | 657                                                                                                                      | (28.3%)                                                                                                                  | 623                                             | (26.5%)                                         |
|                                            | Any                 | 1514                                                                                                                     | (65.2%)                                                                                                                  | 1507                                            | (64.1%)                                         |
| Platelets                                  | n                   | 2354                                                                                                                     | 2354                                                                                                                     | 2383                                            | 2383                                            |

Page 2 of 2

<div style=\"page-break-after: always\"></div>

Creatinine

Phosphate

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

| Low        | 1   | 484   | (20.6%)   | 464   | (19.5%)   |
|------------|-----|-------|-----------|-------|-----------|
|            | 2   | 57    | ( 2.4%)   | 50    | ( 2.1%)   |
|            | 3   | 39    | ( 1.7%)   | 38    | ( 1.6%)   |
|            | 4   | 114   | ( 4.8%)   | 112   | ( 4.7%)   |
|            | Any | 694   | (29.5%)   | 664   | (27.9%)   |
| Creatinine |     |       |           |       |           |
|            | n   | 2363  | 2363      | 2394  | 2394      |
| High       | 1   | 1872  | (79.2%)   | 1974  | (82.5%)   |
|            | 2   | 300   | (12.7%)   | 241   | (10.1%)   |
|            | 3   | 44    | ( 1.9%)   | 38    | ( 1.6%)   |
|            | 4   | 1     | (<0.1%)   | 1     | (<0.1%)   |
|            | Any | 2217  | (93.8%)   | 2254  | (94.2%)   |
| Phosphate  |     |       |           |       |           |
|            | n   | 2335  | 2335      | 2359  | 2359      |
| Low        | 1   | 127   | ( 5.4%)   | 114   | ( 4.8%)   |
|            | 2   | 430   | (18.4%)   | 405   | (17.2%)   |
|            | 3   | 84    | ( 3.6%)   | 61    | ( 2.6%)   |
|            | 4   | 41    | ( 1.8%)   | 41    | ( 1.7%)   |
|            | Any | 682   | (29.2%)   | 621   | (26.3%)   |

01JUN2017 13:58                                                                   Page 1 of 3

Laboratory Test Results with Highest NCI CTCAE Grade Post-Baseline by Treatment Regimen, Safety Evaluated Population

Protocol: BIG 4-11/BO25126/TOC4939G

Calcium

Magnesium

Sodium

Potassium

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

| Laboratory Test Direction of Abnormality   | Highest CTC Grade   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab + Chemotherapy (N=2405) _____________________________________________________________________   | Placebo + Trastuzumab + Chemotherapy (N=2405) _____________________________________________________________________   |
|--------------------------------------------|---------------------|----------------------------------------------------|----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Calcium                                    |                     |                                                    |                                                    |                                                                                                                       |                                                                                                                       |
|                                            | n                   | 2363                                               | 2363                                               | 2390                                                                                                                  | 2390                                                                                                                  |
| Low                                        | 1                   | 486                                                | (20.6%)                                            | 457                                                                                                                   | (19.1%)                                                                                                               |
|                                            | 2                   | 104                                                | ( 4.4%)                                            | 70                                                                                                                    | ( 2.9%)                                                                                                               |
|                                            | 3                   | 25                                                 | ( 1.1%)                                            | 14                                                                                                                    | ( 0.6%)                                                                                                               |
|                                            | 4                   | 86                                                 | ( 3.6%)                                            | 80                                                                                                                    | ( 3.3%)                                                                                                               |
|                                            | Any                 | 701                                                | (29.7%)                                            | 621                                                                                                                   | (26.0%)                                                                                                               |
| High                                       | 1                   | 325                                                | (13.8%)                                            | 360                                                                                                                   | (15.1%)                                                                                                               |
|                                            | 2                   | 6                                                  | ( 0.3%)                                            | 3                                                                                                                     | 0.1%)                                                                                                                 |
|                                            | 3                   | 2                                                  | (<0.1%)                                            | 3                                                                                                                     | ( ( 0.1%)                                                                                                             |
|                                            | 4                   | 22                                                 | ( 0.9%)                                            | 17                                                                                                                    | ( 0.7%)                                                                                                               |
|                                            | Any                 | 355                                                | (15.0%)                                            | 383                                                                                                                   | (16.0%)                                                                                                               |
| Magnesium                                  |                     |                                                    |                                                    |                                                                                                                       |                                                                                                                       |
|                                            | n                   | 2355                                               | 2355                                               | 2383                                                                                                                  | 2383                                                                                                                  |
| Low                                        | 1                   | 610                                                | (25.9%)                                            | 558                                                                                                                   | (23.4%)                                                                                                               |
|                                            | 2                   | 104                                                | ( 4.4%)                                            | 57                                                                                                                    | ( 2.4%)                                                                                                               |
|                                            | 3                   | 30                                                 | ( 1.3%)                                            | 13                                                                                                                    | ( 0.5%)                                                                                                               |
|                                            | 4                   | 54                                                 | ( 2.3%)                                            | 28                                                                                                                    | ( 1.2%)                                                                                                               |
|                                            | Any                 | 798                                                | (33.9%)                                            | 656                                                                                                                   | (27.5%)                                                                                                               |
| High                                       | 1                   | 147                                                | ( 6.2%)                                            | 146                                                                                                                   | ( 6.1%)                                                                                                               |
|                                            | 3                   | 55                                                 | ( 2.3%)                                            | 41                                                                                                                    | ( 1.7%)                                                                                                               |
|                                            | 4                   | 2                                                  | (<0.1%)                                            | 3                                                                                                                     | ( 0.1%)                                                                                                               |
|                                            | Any                 | 204                                                | ( 8.7%)                                            | 190                                                                                                                   | ( 8.0%)                                                                                                               |
| Sodium                                     |                     |                                                    |                                                    |                                                                                                                       |                                                                                                                       |
|                                            | n                   | 2363                                               | 2363                                               | 2392                                                                                                                  | 2392                                                                                                                  |
| Low                                        | 1                   | 395                                                | (16.7%)                                            | 441                                                                                                                   | (18.4%)                                                                                                               |
|                                            | 3                   | 33                                                 | ( 1.4%)                                            | 33                                                                                                                    | 1.4%)                                                                                                                 |
|                                            | 4                   | 46                                                 | ( 1.9%)                                            | 53                                                                                                                    | ( ( 2.2%)                                                                                                             |
|                                            | Any                 | 474                                                | (20.1%)                                            | 527                                                                                                                   | (22.0%)                                                                                                               |
| High                                       | 1                   | 291                                                | (12.3%)                                            | 278                                                                                                                   | (11.6%)                                                                                                               |
|                                            | 2                   | 24                                                 | ( 1.0%)                                            | 30                                                                                                                    | ( 1.3%)                                                                                                               |
|                                            | 3                   | 2                                                  | (<0.1%)                                            | 1                                                                                                                     | (<0.1%)                                                                                                               |
|                                            | 4                   | 11                                                 | 0.5%)                                              | 7                                                                                                                     | ( 0.3%)                                                                                                               |
|                                            | Any                 | 328                                                | ( (13.9%)                                          | 316                                                                                                                   | (13.2%)                                                                                                               |
| Potassium                                  |                     |                                                    |                                                    |                                                                                                                       |                                                                                                                       |
|                                            | n                   | 2362                                               | 2362                                               | 2393                                                                                                                  | 2393                                                                                                                  |
| Low                                        | 2                   | 530                                                | (22.4%)                                            | 434                                                                                                                   | (18.1%)                                                                                                               |
|                                            | 3                   | 88                                                 | ( 3.7%)                                            | 50                                                                                                                    | ( 2.1%)                                                                                                               |
|                                            | 4                   | 53                                                 | ( 2.2%)                                            | 53                                                                                                                    | ( 2.2%)                                                                                                               |
|                                            | Any                 | 671                                                | (28.4%)                                            | 537                                                                                                                   | (22.4%)                                                                                                               |
| High                                       | 1                   | 291                                                | (12.3%)                                            | 281                                                                                                                   | (11.7%)                                                                                                               |
|                                            | 2                   | 53                                                 | ( 2.2%)                                            | 53                                                                                                                    | ( 2.2%)                                                                                                               |
|                                            | 3                   | 30 11                                              | ( 1.3%) ( 0.5%)                                    | 23                                                                                                                    | ( 1.0%)                                                                                                               |
|                                            | 4                   |                                                    |                                                    | 10                                                                                                                    | ( 0.4%)                                                                                                               |
|                                            | Any                 | 385                                                | (16.3%)                                            | 367                                                                                                                   | (15.3%)                                                                                                               |

NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events. 'n' denotes the number of patients with a post-baseline lab value within this time interval. For a patient with multiple post-baseline lab abnormalities, the highest (worst) grade of these abnormalities for the given lab test is reported. 'Any' is the number of patients with a post-baseline abnormality of any grade for the specified lab test.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_lb\\_nci.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_lb\\_nci\\_PBASE\\_SE.out 01JUN2017 13:58                                                                   Page 2 of 3

<div style=\"page-break-after: always\"></div>

## Table 67 Laboratory Test Results with Highest NCI CTCAE Grade Post-Baseline by Treatment Regimen: Safety Population (cont.)

Laboratory Test Results with Highest NCI CTCAE Grade Post-Baseline by Treatment Regimen, Safety Evaluated Population Protocol: BIG 4-11/BO25126/TOC4939G

Alkaline Phosphatase

AST

ALT

Total Bilirubin

\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_

| Laboratory Test Direction of Abnormality   | Highest CTC Grade   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364) _____________________________________________________________________   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364) _____________________________________________________________________   | Placebo + Trastuzumab + Chemotherapy (N=2405)   | Placebo + Trastuzumab + Chemotherapy (N=2405)   |
|--------------------------------------------|---------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Alkaline Phosphatase                       |                     |                                                                                                                          |                                                                                                                          |                                                 |                                                 |
|                                            | n                   | 2363                                                                                                                     | 2363                                                                                                                     | 2394                                            | 2394                                            |
| High                                       | 1                   | 599                                                                                                                      | (25.3%)                                                                                                                  | 638                                             | (26.6%)                                         |
|                                            | 2                   | 16                                                                                                                       | ( 0.7%)                                                                                                                  | 14                                              | ( 0.6%)                                         |
|                                            | 3                   | 1                                                                                                                        | (<0.1%)                                                                                                                  | 1                                               | (<0.1%)                                         |
|                                            | Any                 | 616                                                                                                                      | (26.1%)                                                                                                                  | 653                                             | (27.3%)                                         |
| AST                                        |                     |                                                                                                                          |                                                                                                                          |                                                 |                                                 |
| High                                       | n                   | 950                                                                                                                      | 2358 (40.3%)                                                                                                             | 934                                             | 2392 (39.0%)                                    |
|                                            | 1 2                 | 46                                                                                                                       | ( 2.0%)                                                                                                                  | 45                                              | ( 1.9%)                                         |
|                                            |                     | 24                                                                                                                       | ( 1.0%)                                                                                                                  | 16                                              | ( 0.7%)                                         |
|                                            | 3 4                 |                                                                                                                          | (<0.1%)                                                                                                                  | 1                                               | (<0.1%)                                         |
|                                            |                     | 1                                                                                                                        |                                                                                                                          |                                                 |                                                 |
|                                            | Any                 | 1021                                                                                                                     | (43.3%)                                                                                                                  | 996                                             | (41.6%)                                         |
| ALT                                        |                     |                                                                                                                          |                                                                                                                          |                                                 |                                                 |
| High                                       | n 1                 | 1211                                                                                                                     | 2362 (51.3%)                                                                                                             | 1167                                            | 2394 (48.7%)                                    |
|                                            | 2                   | 105                                                                                                                      | 4.4%)                                                                                                                    | 109                                             | ( 4.6%)                                         |
|                                            | 3                   | 53                                                                                                                       | ( ( 2.2%)                                                                                                                | 40                                              | ( 1.7%)                                         |
|                                            | 4                   | 2                                                                                                                        | (<0.1%)                                                                                                                  | 6                                               | ( 0.3%)                                         |
|                                            | Any                 | 1371                                                                                                                     | (58.0%)                                                                                                                  | 1322                                            |                                                 |
| Total Bilirubin                            |                     |                                                                                                                          |                                                                                                                          |                                                 | (55.2%)                                         |
|                                            | n                   | 2359                                                                                                                     | 2359                                                                                                                     | 2393                                            | 2393                                            |
| High                                       | 1                   | 130                                                                                                                      | ( 5.5%)                                                                                                                  | 142                                             | ( 5.9%)                                         |
|                                            | 2                   | 34                                                                                                                       | 1.4%)                                                                                                                    | 45                                              | 1.9%)                                           |
|                                            | 3                   | 9                                                                                                                        | ( ( 0.4%)                                                                                                                | 12                                              | ( ( 0.5%)                                       |
|                                            | 4                   | 2                                                                                                                        | (<0.1%)                                                                                                                  | 2                                               | (<0.1%)                                         |
|                                            | Any                 | 175                                                                                                                      | ( 7.4%)                                                                                                                  | 201                                             | ( 8.4%)                                         |

NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events. 'n' denotes the number of patients with a post-baseline lab value within this time interval. For a patient with multiple post-baseline lab abnormalities, the highest (worst) grade of these abnormalities for the given lab test is reported. 'Any' is the number of patients with a post-baseline abnormality of any grade for the specified lab test.

Program: /opt/BIOSTAT/prod/cdp11450/r25126a/t\\_lb\\_nci.sas Output: /opt/BIOSTAT/prod/cd11450g/j25126a/reports/t\\_lb\\_nci\\_PBASE\\_SE.out 01JUN2017 13:58                                                                   Page 3 of 3

## Shifts from baseline in haematological parameters

At baseline, patients' laboratory values were generally within normal ranges for all laboratory parameters tested  (as  required  by  the  protocol).  Shifts  from  baseline  were  most  common  with  hematological parameters, in particular, hemoglobin and leukocytes. Table 68 summarizes the number of patients whose hematology values worsened during treatment, shifting to Grade ≥ 3.

Table 68 Summary of Newly Occurring Grade ≥ 3 Hematology Values During Treatment (Safety Population)

|               | Ptz + H + Chemo arm N = 2364   | Ptz + H + Chemo arm N = 2364   | Pla + H + Chemo arm N = 2405   | Pla + H + Chemo arm N = 2405   |
|---------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|               | Grade 3 n (%)                  | Grade 4 n (%)                  | Grade 3 n (%)                  | Grade 4 n (%)                  |
| ↓ Hemoglobin  | 178 (7.5%)                     | -                              | 115 (4.8%)                     | -                              |
| ↓ Leukocytes  | 424 (17.9%)                    | 261 (11.0%)                    | 410 (17.0%)                    | 255 (10.6%)                    |
| ↓ Platelets   | 39 (1.6%)                      | 105 (4.4%)                     | 38 (1.6%)                      | 98 (4.1%)                      |
| ↓ Neutrophils | 285 (12.1%)                    | 640 (27.1%)                    | 295 (12.3%)                    | 604 (25.1%)                    |

Source:.Table 77 in Primary APHINITY CSR.

<div style=\"page-break-after: always\"></div>

Table 69 shows the number of patients whose biochemistry values worsened during treatment, shifting to Grade ≥ 3. Grade 4 shifts occurred in &lt; 1% of patients, apart from potassium (low), sodium (low), magnesium (low),  calcium  (low),  and  phosphate  (low).  Grade ≥ 3  shifts  occurred  in  &lt;3%  of  patients,  apart  from potassium (low) and phosphate (low).

Table 69 Summary of Newly Occurring Grade ≥ 3 Biochemistry Values During Treatment (Safety Population)

|                        | Ptz + H + Chemo N = 2364   | Ptz + H + Chemo N = 2364   | Pla + H + Chemo N = 2405   | Pla + H + Chemo N = 2405   |
|------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                        | Grade 3 n (%)              | Grade 4 n (%)              | Grade 3 n (%)              | Grade 4 n (%)              |
| ↑ AST                  | 24 (1.0%)                  | 1 (<0.1%)                  | 16 (0.7%)                  | 1 (<0.1%)                  |
| ↑ Alkaline Phosphatase | 1 (<0.1%)                  | -                          | 1 (<0.1%)                  | -                          |
| ↑ ALT                  | 53 (2.2%)                  | 2 (<0.1%)                  | 40 (1.7%)                  | 6 (0.2%)                   |
| ↑ Total Bilirubin      | 9 (0.4%)                   | 2 (<0.1%)                  | 13 (0.5%)                  | 2 (<0.1%)                  |
| ↑ Serum Creatinine     | 44 (1.9%)                  | 1 (<0.1%)                  | 38 (1.6%)                  | 2 (<0.1%)                  |
| ↓ Potassium            | 88 (3.7%)                  | 41 (1.7%)                  | 50 (2.1%)                  | 46 (1.9%)                  |
| ↑ Potassium            | 30 (1.3%)                  | 13 (0.5%)                  | 23 (1.0%)                  | 12 (0.5%)                  |
| ↓ Sodium               | 32 (1.4%)                  | 33 (1.4%)                  | 33 (1.4%)                  | 44 (1.8%)                  |
| ↓ Magnesium            | 29 (1.2%)                  | 43 (1.8%)                  | 13 (0.5%)                  | 19 (0.8%)                  |
| ↑ Magnesium            | 53 (2.2%)                  | 1 ( < 0.1%)                | 40 (1.7%)                  | 2 (<0.1%)                  |
| ↓ Calcium              | 25 (1.1%)                  | 41 (1.7%)                  | 14 (0.6%)                  | 39 (1.6%)                  |
| ↑ Calcium              | 2 (<0.1%)                  | 18 (0.8%)                  | 3 (0.1%)                   | 14 (0.6%)                  |
| ↓ Phosphate            | 81 (3.4%)                  | 33 (1.4%)                  | 59 (2.5%)                  | 30 (1.2%)                  |

Source:  Table 78 in Primary APHINITY CSR.

## Vital signs and other observations

## Performance status

The majority of patients' ECOG status remained unchanged during treatment. The proportion of patients whose ECOG status worsened at any time point during treatment was 818 patients [34.6%] vs. 751 patients [31.2%]. At the end of treatment, the ECOG performance status was worse than at baseline in a small proportion  of  patients  in  both  treatment  arms:  319  patients  (13.5%)  and  261 patients  (10.9%), respectively.

## Vital signs

Based on a manual review of the data, there were no major differences between the treatment arms in any vital sign parameters (Blood pressure, heart rate, and weight).

## Safety in special populations

## Intrinsic factors

Adverse events by sex

<div style=\"page-break-after: always\"></div>

Table 70 Comparison of Key Events by Sex

|                                                   | % of patients experiencing an event   | % of patients experiencing an event   | % of patients experiencing an event   | % of patients experiencing an event   |
|---------------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                                                   | Male Patients                         | Male Patients                         | Female Patients                       | Female Patients                       |
|                                                   | Ptz+H+Chemo N= 3 (0.1%)               | Pla+H+Chemo N = 8 (0.3%) b            | Ptz+H+Chemo N = 2361 (99.9%)          | Pla+H+Chemo N= 2397 (99.7%)           |
| Overall Totalevents                               | 39                                    | 110                                   | 49949                                 | 45890                                 |
| Total number of patients with at least one AE     | 3 (100%)                              | 8 (100%)                              | 2358 (99.9%)                          | 2384 (99.5%)                          |
| Total number of patients with Grade ≥3 AEs        | 2 (66.7%)                             | 7 (87.5%)                             | 1516 (64.2%)                          | 1372 (57.2%)                          |
| Total number of patienls with Grade 5 (fatal) AEs |                                       | 1 (12.5%)                             | 10 (0.4%)                             | 13 (0.5%)                             |
| Total number of patients with SAEs                | 1 (33.3%)                             | 4 (50.0%)                             | 691 (29.3%)                           | 581 (24.2%)                           |
| Blood and Lymphatic System Disorder (SOC)         |                                       | 7 (87.5%)                             | 1252 (53.0%)                          | 1169 (48.8%)                          |
| Neutropenia (PT)                                  |                                       | 3 (37.5%)                             | 587 (24.9%)                           | 559 (23.3%)                           |
| Anemia (PT)                                       |                                       | 1 (12.5%)                             | 655 (27.7%)                           | 556 (23.2%)                           |
| Febrile Neutropenia (PT)                          |                                       | 2 (25.0%)                             | 287 (12.2%)                           | 264 (11.0%)                           |
| Gastrointestinal (SOC)                            | 3 (100%)                              | 7 (87.5%)                             | 2229 (94.4%)                          | 2150 (89.7%)                          |
| Nausea                                            | 1 (33.3%)                             | 3 (37.5%)                             | 1631 (69.1%)                          | 1572 (65.6%)                          |
| Diarrhea (PT)                                     | 2 (66.7%)                             | 2 (25.0%)                             | 1681 (71.2%)                          | 1084 (45.2%)                          |
| Stomatitis (PT)                                   | 2 (66.7%)                             | 2 (25.0%)                             | 669 (28.3%)                           | 571 (23.8%)                           |
| Skin and                                          | 2 (66.7%)                             | 6 (75.0%)                             | 2063 (87.4%)                          | 2002 (83.5%)                          |
| Alopecia (PT)                                     | 1 (33.3%)                             | 3 (37.5%)                             | 1576 (66.8%)                          | 1607 (67.0%)                          |
| Rash (PT)                                         | 1 (33.3%)                             | 2 (25.0%)                             | 608 (25.8%)                           | 486 (20.3%)                           |
| Cardiac disorders (SOC)                           |                                       |                                       | 269 (11.4%)                           | 254 (10.6%)                           |

AE=adverse event.Pla=placebo.PT=preferred term.Ptz=pertuzumab.SoC=system organ Class

Palients:2308140003,2312640002.2325820005.

Patients: 2102690010, 2308770003, 2312640004, 2312640019, 2312850028, 2312930002, 2314360017, 2323320002.

Adverse events by age

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 71 Comparison of Key Events by Age

| %of PatientsExperiencinganEvent        | %of PatientsExperiencinganEvent   | %of PatientsExperiencinganEvent   | %of PatientsExperiencinganEvent   | %of PatientsExperiencinganEvent   | %of PatientsExperiencinganEvent   | %of PatientsExperiencinganEvent   |
|----------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Age (years)                            | <40                               | <40                               | 40-64                             | 40-64                             | ≥65                               | ≥65                               |
| SOC PT                                 | Ptz+H+Chemo N=326                 | Pla+H+Chemo N= 324                | Ptz+H+Chemo N = 1737              | Pla+H+Chemo N=1788                | Plz+H+Chemo N= 302                | Pla+H+Chemo N=293                 |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS   | 58.2%                             | 48.5%                             | 51.8%                             | 47.5%                             | 54.3%                             | 58.0%                             |
| Neutropenia                            | 32.0%                             | 26.9%                             | 23.7%                             | 22.7%                             | 23.5%                             | 23.9%                             |
| Anemia                                 | 27.1%                             | 21.0%                             | 26.5%                             | 21.6%                             | 35.4%                             | 35 2%                             |
| Febrile Neutropenia                    | 12.0%                             | 13.3%                             | 11.9%                             | 9.7%                              | 13.9%                             | 16.7%                             |
| GASTROINTESTINAL DISORDERS             | 94.2%                             | 91.4%                             | 94.2%                             | 89.0%                             | 96.0%                             | 91.8%                             |
| Nausea                                 | 74.2%                             | 74.1%                             | 67.8%                             | 65.9%                             | 70.9%                             | 53.6%                             |
| Diarrhea                               | 68.3%                             | 44.4%                             | 70.7%                             | 44.5%                             | 77.2%                             | 49.8%                             |
| Stomatitis                             | 28.9%                             | 24.7%                             | 28.3%                             | 23.9%                             | 28.1%                             | 22.5%                             |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS | 90.5%                             | 84.3%                             | 87.4%                             | 83.7%                             | 83.8%                             | 81.2%                             |
| Alopecia                               | 70.5%                             | 68.2%                             | 67.0%                             | 67.7%                             | 60.9%                             | 61.1%                             |
| Rash                                   | 26.5%                             | 18.8%                             | 25.9%                             | 21.1%                             | 24.2%                             | 16.7%                             |
| CARDIAC DISORDERS                      | 11.4%                             | 10.5%                             | 11.0%                             | 10.5%                             | 13.6%                             | 11.3%                             |

Source:t\\_ae\\_TRT1A\\_AL40\\_SE,t\\_ae\\_TRT1A\\_A4064\\_SE.t\\_ae\\_TRT1A\\_AL65\\_SE.t\\_ae\\_TRT1A\\_AGE65\\_SE

## Adverse events by race

Table 72 Key Adverse Events by Race

|                                                            | %ofpatientsexperiencinganevent   | %ofpatientsexperiencinganevent   | %ofpatientsexperiencinganevent   | %ofpatientsexperiencinganevent   | %ofpatientsexperiencinganevent   | %ofpatientsexperiencinganevent   | %ofpatientsexperiencinganevent   | %ofpatientsexperiencinganevent   |
|------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| SOC                                                        | White                            | White                            | Asian                            | Asian                            | Black                            | Black                            | Other                            | Other                            |
| PT                                                         | Ptz+H+Chemo N= 1680              | Pla+H+Chemo N = 1691             | Ptz+H+Chemo N = 580              | Pla+H+Chemo N= 605               | Ptz+H+Chemo N= 32                | Pla+H+Chemo N= 39                | N = 66                           | Ptz+H+ChemoPla+H+Chemo N= 68     |
| Overall Totalevents                                        | 34581                            | 31833                            | 13488                            | 12442                            | 690                              | 953                              | 1105                             | 737                              |
| Total no. of patients with at least one Grade ≥3 AEs       | 63.0%                            | 57.4%                            | 68.6%                            | 57.2%                            | 81.3%                            | 61.5%                            | 50.0%                            | 55.9%                            |
| Total no. of patients with at least one Grade 5(fatal) AEs | 0.5%                             | 0.8%                             | 1.4%                             | 0.8%                             |                                  |                                  | 1.5%                             | 1.5%                             |
| Total no.of patients with at least one SAE                 | 31.0%                            | 26.0%                            | 25.0%                            | 19.5%                            | 34.4%                            | 33.3%                            | 24.2%                            | 20.6%                            |
| BLOOD &LYMPHATIC SYSTEM DISORDERS                          | 50.7%                            | 47.4%                            | 57.9%                            | 51.4%                            | 62.5%                            | 59.0%                            | 63.6%                            | 57.4%                            |
| Anemia                                                     | 26.1%                            | 22.7%                            | 30.5%                            | 21.8%                            | 40.6%                            | 46.2%                            | 36.4%                            | 32.4%                            |
| Neutropenia                                                | 23.3%                            | 22.2%                            | 26.9%                            | 25.6%                            | 37.5%                            | 25.6%                            | 37.9%                            | 30.9%                            |
| Febrile neutropenia                                        | 11.1%                            | 11.6%                            | 15.9%                            | %6'6                             | 3.1%                             | 5.1%                             | 10.6%                            | 10.3%                            |
| GASTROINTESTINAL DISORDERS                                 | 94.5%                            | 90.7%                            | 94.8%                            | 90.1%                            | 100%                             | 82.1%                            | 86.4%                            | 66.2%                            |
| Nausea                                                     | 70.2%                            | 67.2%                            | 66.9%                            | 63.8%                            | 84.4%                            | 66.7%                            | 50.0%                            | 36.8%                            |
| Diarhea                                                    | 73.4%                            | 46.8%                            | 63.8%                            | 41.0%                            | 87.5%                            | 48.7%                            | 71.2%                            | 36.8%                            |
| Stomatitis                                                 | 24.9%                            | 20.6%                            | 38.8%                            | 34.4%                            | 40.6%                            | 23.1%                            | 19.7%                            | 11.8%                            |
| SKIN & SUBCUTANEOUS TISSUE DISORDERS                       | 89.0%                            | 85.2%                            | 85.2%                            | 82.6%                            | 84.4%                            | 79.5%                            | 63.6%                            | 50.0%                            |
| Alopecia                                                   | 64.8%                            | 65.2%                            | 76.0%                            | 75.2%                            | 50.0%                            | 56.4%                            | 39.4%                            | 41.2%                            |
| Rash                                                       | 25.1%                            | 19.5%                            | 30.5%                            | 24.5%                            | 15.6%                            | 15.4%                            | 6.1%                             | 5.9%                             |
| CARDIAC DISORDERS                                          | 12.2%                            | 11.2%                            | 9.3%                             | 8.1%                             | 12.5%                            | 25.6%                            | 9.1%                             | 7.4%                             |

Pla=placebo, PT = Preferred tem. Piz=Perjeta, SAEs=Serious Adverse Events, SOC = System Organ Class

Source:White,Asian,Black,Other,I\\_ae\\_fatal\\_AP.I\\_ae\\_SER\\_AP

## Adverse events by nodal status and hormone receptor status

Key safety results in subgroups based on nodal status and central hormone receptor status were provided. The  safety profile of Ptz/Pla+H+Chemo  in  patients  with node-positive,  node-negative,  hormone receptor-positive and hormone receptor-negative disease was similar to that seen in the overall patient population.

## Extrinsic factors

There was no new information submitted with this application.

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

No PK drug-drug interaction was observed between pertuzumab and carboplatin, or pertuzumab and paclitaxel when given in combination with Herceptin.

## Discontinuation due to adverse events

## Adverse events that led to withdrawal

## Table 73

Evaluated Population Protoco1: BIG4-11/B025126/T0C4939G

| MedDRA System Organ Class MedDRA Preferred Term          | Pertuzumab + Trastuzumab- Chemotherapy (N=2364)   | Placebo + Trastuzumab Chemotherapy (N=2405)   |
|----------------------------------------------------------|---------------------------------------------------|-----------------------------------------------|
| Total number of patientswith at leastoneadverse event    | 166 (7.0%)                                        | 139(5.8%)                                     |
| Overalltotalnumber of events                             | 203                                               | 171                                           |
| INVESTIGATIONS                                           |                                                   |                                               |
| Totalnumber of patients with at least one adverse event  | 45 1.9%)                                          | 66(2.7%)                                      |
| EJECTIONFRACTIONDECREASED                                | 43 1.8%)                                          | 60(2.5%)                                      |
| ALANINE AMINOTRANSFERASEINCREASED                        | 0                                                 | 2 (<0.1%)                                     |
| ASPARTATEAMINOTRANSFERASEINCREASED                       | 0                                                 | 2 (<0.1%)                                     |
| PLATELET COUNT DECREASED                                 | 1 (<0.1%)                                         | 1 (<0.1%)                                     |
| WEIGHTDECREASED                                          | 1 (<0.1%)                                         | 1 (<0.1%)                                     |
| BLOOD ALKALINE PHOSPHATASEINCREASED                      | 0                                                 | 1 (<0.1%)                                     |
| BLOODCREATININE INCREASED                                | 0                                                 | 1 (<0.1%)                                     |
| BLOODLACTATEDEHYDROGENASEINCREASED                       | 0                                                 | (<0.1%)                                       |
| TRANSAMINASES INCREASED                                  | 0                                                 | (<0.1%)                                       |
| Total number of events                                   | 45                                                | 70                                            |
| CARDIAC DISORDERS                                        |                                                   |                                               |
| Total number of patients with at least one adverse event | 35 (1.5%)                                         | 25 (1.0%)                                     |
| CARDIAC FAILURE                                          | 28 (1.2%)                                         | 15 (0.6%)                                     |
| MYOCARDIAL INFARCTION                                    | 2 (<0.1%)                                         | 2 (<0.1%)                                     |
| PERICARDIAL EFFUSION                                     | 1 (<0.1%)                                         | 1 (<0.1%)                                     |
| ACUTE CORONARY SYNDROME                                  | 0                                                 | 1 (<0.1%)                                     |
| ANGINA PECTORIS                                          | 0                                                 | 1 (<0.1%)                                     |
| ATRIAL FIBRILLATION                                      | 0                                                 | 1 (<0.1%)                                     |
| BUNDLEBRANCHBLOCK LEFT                                   | 1 (<0.1%)                                         | 0                                             |
| CARDIAC FAILURE CONGESTIVE                               | 0                                                 | 1 (<0.1%)                                     |
| CARDIACVALVEDISEASE                                      | 0                                                 | 1 (<0.1%)                                     |
| DIASTOLICDYSFUNCTION                                     | 0                                                 | 1 (<0.1%)                                     |
| MITRALVALVEINCOMPETENCE                                  | 0                                                 | 1 (<0.1%)                                     |
| MYOCARDIAL ISCHAEMIA                                     | 1 (<0.1%)                                         | 0                                             |
| PALPITATIONS                                             | 1 (<0.1%)                                         | 0                                             |
|                                                          | 0                                                 |                                               |
| STRESSCARDIOMYOPATHY SUPRAVENTRICULAR TACHYCARDIA        | 1 (<0.1%)                                         | 1 (<0.1%) 0                                   |
| VENTRICULAR ARRHYTHMIA                                   | 1 (<0.1%)                                         | 0                                             |
| Totalnumberof events                                     | 36                                                | 26                                            |

Investigator text for AEs encoded using MedDRA vl9.1 Percentages are based on N in the column headings. s  sn d a so  o o o  e o multiple occurrences of the same AE in an individual are counted separately. Table includes AEs with onset from first dose of any study treatment through 28 days after last dose of study treatment.

Program:/opt/B10STAT/prod/cdp11450/r25126a/t\\_ae.Sas

Output:/opt/BI0STAT/prod/cd11450g/j25126a/reports/t\\_ae\\_TRT1A\\_DSCPP\\_SE.out

21MAR2017 19:33

Page 1 of 6

<div style=\"page-break-after: always\"></div>

Adverse Events Leading to Discontinuation of Pertuzumab/Placebo by Treatment Regimen, Safety Evaluated Population Prot0c0l: BIG 4-11/B025126/T0C4939G

| MedDRA System Organ Class MedDRA Preferred Term          | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab + Chemo therapy (N=2405)   |
|----------------------------------------------------------|----------------------------------------------------|--------------------------------------------------|
| GASTROINTESTINALDISORDERS                                |                                                    |                                                  |
| Total number of patients with at least one adverse event | 26 (1.1%)                                          | 5 (0.28)                                         |
| DIARRHOEA                                                | 20 0.8%)                                           | 2 (<0.1$)                                        |
| VOMITING                                                 | 4 (0.2%)                                           | 0                                                |
| COLITIS                                                  | 2 (<0.16)                                          | 1 (<0.1$)                                        |
| NAUSEA                                                   | 2 (<0.1%)                                          | 0                                                |
| STOMATITIS                                               | 2 (<0.1%)                                          | 0                                                |
| ABDOMINAL PAIN                                           | 0                                                  | 1 (<0.1$)                                        |
| ANAL INFLAMMATION                                        | 1 (<0.16)                                          |                                                  |
| APHTHOUS ULCER                                           | 1 (<0.1$)                                          | 0 0                                              |
| GASTROINTESTINALPAIN                                     | 1 (<0.1%)                                          |                                                  |
| INTUSSUSCEPTION                                          | 0                                                  | 0 1 (<0.18)                                      |
| PROCTITIS                                                | 1 (<0.1%)                                          | 0                                                |
| SMALL INTESTINAL OBSTRUCTION                             | 1 (<0.1%)                                          | 0                                                |
| TOOTHACHE                                                | 0                                                  | 1 (<0.1$)                                        |
| Total number of events                                   | 35                                                 | 6                                                |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS                   |                                                    |                                                  |
| Totalnumber of patients with at least one adverse event  | 16 0.78)                                           | 5 (0.28)                                         |
| RASH                                                     | 8 0.36)                                            | 1 (<0.1$)                                        |
| PRURITUS                                                 | 4 0.26)                                            | 1 (<0.1$)                                        |
| ANGIOEDEMA                                               | 0                                                  | 1 (<0.1$)                                        |
| DRY SKIN                                                 | 1 (<0.18)                                          | 0                                                |
| ERYTHEMA                                                 | 0                                                  | 1 (<0.18)                                        |
| EXFOLIATIVE RASH                                         | 0                                                  | 1 (<0.1$)                                        |
| NAIL TOXICITY                                            | 1 (<0.1%)                                          | 0                                                |
| ONYCHOCLASIS                                             | 1 (<0.1%)                                          | 0                                                |
| PSORIASIS                                                | 1 (<0.18)                                          | 0 0                                              |
| PURPURA                                                  | 1 (<0.16)                                          |                                                  |
| RASH PRURITIC                                            | 1 (<0.1%) (<0.1$)                                  | 0                                                |
| SKIN FISSURES                                            | 1                                                  | 0                                                |
| URTICARIA Total number of events                         | (<0.1$) 20                                         | 0 5                                              |
| GENERALDISORDERS AND ADMINISTRATION SITECONDITIONS       |                                                    |                                                  |
| Total number of patients with at least one adverse event | 6 (0.4%)                                           | 10 (0.48)                                        |
| PYREXIA                                                  | 1 (<0.1%)                                          | 4 (0.2$)                                         |
| ASTHENIA                                                 | 2 (<0.1%)                                          | 1 (<0.1%)                                        |
| FATIGUE                                                  | 0                                                  | 3 (0.1$)                                         |
| GENERALPHYSICALHEALTHDETERIORATION                       | 1 (<0.1$)                                          | (<0.1$)                                          |
| CHEST PAIN                                               | 1 (<0.1%)                                          | 2 1 (<0.18)                                      |
| GENERALISEDOEDEMA                                        | 2 (<0.16)                                          | 0                                                |
| CHILLS                                                   | 0                                                  | 1 (<0.18)                                        |
| FACE OEDEMA                                              | 1 (<0.1%)                                          | 0                                                |
| MUCOSAL INFLAMMATION                                     | 1 (<0.16)                                          | 0                                                |
| PERFORMANCESTATUS DECREASED Total number of events       | 0 9                                                | 1 (<0.1%) 13                                     |

Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. For frequency counts of 'Total number of events' rows, multiple occurrences of the same AE in an individual are counted separately. Table includes study treatment.

Program: /opt/B10sTAT/prod/cdp11450/r25126a/t\\_ae.Sas Output: /opt/BI0sTAT/prod/cd1i450g/j25126a/reports/t\\_ae\\_TRTiA\\_DSCPP\\_SE.out 21MAR2017 19:33

Page 2of 6

AEs  that  led  to  the  withdrawal  of  patients  from Perjeta  or  placebo occurred  most  commonly  in  the following SOCs:

- Investigations, mainly attributable to ejection fraction decreased (43 patients [1.8%] vs. 60 patients [2.5%], respectively).
- Cardiac Disorders, mainly attributable to cardiac failure (28 patients [1.2%] vs. 15 patients [0.6%], respectively).

<div style=\"page-break-after: always\"></div>

- Gastrointestinal Disorders, mainly attributable to diarrhea (20 patients [0.8%] vs. 2 patients [ &lt; 0.1%], respectively).

The  proportion  of  patients  who  experienced  at  least  one  AE  that  led  to  the  withdrawal  of any  study medication was  similar between  the arms  (309 patients [13.1%]  vs. 277 patients [11.5%], respectively).The most common AEs were in the following SOCs:

- Nervous  System  Disorders  (63  patients  [2.7%]  vs.  54  patients  [2.2%]),  mainly  attributable  to peripheral  sensory  neuropathy  (17  patients  [0.7%]  vs.  21  patients  [0.9%],  respectively),  and neuropathy peripheral (19 patients [0.8%] vs. 18 patients [0.7%], respectively).
- Gastrointestinal Disorders (59 patients [2.5%] vs. 21 patients [0.9%]), mainly attributable to diarrhea (38 patients [1.6%] vs. 7 patients [0.3%], respectively).
- Investigations (57 patients [2.4%] vs. 84 patients [3.5%]), mainly attributable to ejection fraction decreased (43 patients [1.8%] vs. 60 patients [2.5%], respectively).
- Cardiac Disorders (38 patients [1.6%] vs. 30 patients [1.2%]), mainly attributable to cardiac failure (28 patients [1.2%] vs. 15 patients [0.6%], respectively).

## Adverse events that led to dose modifications

## Table 74

Adverse Events Leading to Dose Modification(Dose Interruption or Dose Delay)of Pertuzumab/ Placebo by Treatment Regimen, Safety Evaluated Population Protocol:BIG 4-11/B025126/T0C4939G

| MedDRA System Organ Class MedDRA Preferred Term   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab Chemo therapy (N=2405)   |
|---------------------------------------------------|----------------------------------------------------|------------------------------------------------|
| Totalnumberofpatientswithatleastoneadverseevent   | 723 (30.6%)                                        | 632 (26.3%)                                    |
| Overalltotalnumber of events                      | 1247 1050                                          | 1247 1050                                      |
| BLOODANDLYMPHATICSYSTEMDISORDERS                  |                                                    |                                                |
| Totalnumberofpatientswithatleastone adverseevent  | 204 8.6%)                                          | 196 8.1%)                                      |
| NEUTROPENIA                                       | 123 5.2%)                                          | 109 4.5%)                                      |
| ANAEMIA                                           | 49 2.1%)                                           | 34 (1.4%)                                      |
| THROMBOCYTOPENIA                                  | 32 1.4%)                                           | 29 (1.2%)                                      |
| LEUKOPENIA                                        | 16 0.7%)                                           | 23 (1.0%)                                      |
| FEBRILENEUTROPENIA                                | 21 (0.9%)                                          | 16 (0.7%)                                      |
| BONEMARROWFAILURE                                 | 2 (<0.1%)                                          | 2 (<0.1%)                                      |
| GRANULOCYTOPENIA                                  | 1 (<0.1%)                                          | 2 (<0.1%)                                      |
| LEUKOCYTOSIS                                      | 2 (<0.1%)                                          | 0                                              |
| BLOOD DISORDER                                    | 1 (<0.1%)                                          | 0                                              |
| HAEMATOTOXICITY                                   | 0                                                  | 1 (<0.1%)                                      |
| PANCYTOPENIA                                      | 0                                                  | 1 (<0.1%)                                      |
| Totalnumber of events                             | 295                                                | 254                                            |

Percentages are based on N in the column headings.

For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once.For frequency counts of 'Total number of events' rows, multiple occurrencesof the sameAEin anindividualarecountedseparately.Tableincludes AEswith onset fromfirstdose of anystudytreatment through28days afterlast doseof study treatment.

Program:/opt/B10sTAT/prod/cdp11450/r25126a/tae.sas Output:/opt/BI0STAT/prod/cd11450g/j25126a/reports/t\\_ae\\_TRT1A\\_DSMPP\\_SE.out 21MAR2017 19:36

Page 1 of 13

<div style=\"page-break-after: always\"></div>

Adverse Events Leading to Dose Modification (Dose Interruption or Dose Delay) of Pertuzumab/ Placebo by Treatment Regimen, Safety Evaluated Population Prot0col: BIG4-11/B025126/T0C4939G

| MedDRA System Organ Class MedDRA PreferredTerm        | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab Chemo therapy (N=2405)   |
|-------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|------------------------------------------------|
| INVESTIGATIONS                                        |                                                    |                                                    |                                                |
| Totalnumber of patients withat leastone adverse event | 186                                                | 7.9%)                                              | 187 7.8%)                                      |
| NEUTROPHILCOUNTDECREASED                              | 72                                                 | 3.0%)                                              | 59 2.5%)                                       |
|                                                       | 50                                                 | 2.1%)                                              | 50 2.1%)                                       |
| ALANINE AMINOTRANSFERASE INCREASED                    | 32                                                 | 1.4%)                                              | 41 (1.7%)                                      |
| ASPARTATEAMINOTRANSFERASEINCREASED                    | 15                                                 | 0.6%)                                              | 25 1.0%)                                       |
| PLATELET COUNT DECREASED                              | 19                                                 | 0.8%)                                              | 18 0.7%)                                       |
| WHITE BLOODCELLCOUNTDECREASED                         | 20                                                 | 0.8%)                                              | 13 0.5%)                                       |
| BLOODALKALINEPHOSPHATASEINCREASED                     | 1                                                  | (<0.1%)                                            | 5 (0.2%)                                       |
| TRANSAMINASESINCREASED                                | 0                                                  |                                                    | 4 (0.2%)                                       |
| WEIGHT DECREASED                                      | 3                                                  | 0.1%)                                              | 1 (<0.1%)                                      |
| BLOOD BILIRUBIN INCREASED                             | 2                                                  | (<0.1%)                                            | 1 (<0.1%)                                      |
| GAMMA-GLUTAMYLTRANSFERASEINCREASED                    | 0                                                  |                                                    | 3 (0.1%)                                       |
| BLOODCREATININEINCREASED                              | 1                                                  | (<0.1%)                                            | 1 (<0.1%)                                      |
| C-REACTIVE PROTEIN INCREASED                          | 1                                                  | (<0.1%)                                            | 1 (<0.1%)                                      |
| HAEMOGLOBINDECREASED                                  | 1                                                  | (<0.1%)                                            | 1 (<0.1%)                                      |
| NEUTROPHILCOUNT                                       | 1                                                  | (<0.1%)                                            | 1 (<0.1%)                                      |
| PLATELET COUNT                                        | 0                                                  |                                                    | 2 (<0.1%)                                      |
| WHITE BLOODCELLCOUNT                                  | 1                                                  | (<0.1%)                                            | 1 (<0.1%)                                      |
| ALANINEAMINOTRANSFERASE                               | 1                                                  | (<0.1%)                                            | 0                                              |
| BODYTEMPERATUREINCREASED                              | 1                                                  | (<0.1%)                                            | 0                                              |
| CLOSTRIDIUM TEST POSITIVE                             | 1                                                  | (<0.1%)                                            | 0                                              |
| CREATININE RENALCLEARANCEDECREASED                    | 0                                                  |                                                    | 1 (<0.1%)                                      |
| ELECTROCARDIOGRAMTWAVEINVERSION                       | 0                                                  |                                                    | 1 (<0.1%)                                      |
| HAEMOGLOBIN                                           | 0                                                  |                                                    | 1 (<0.1%)                                      |
| HAPTOGLOBIN DECREASED                                 | 0                                                  |                                                    | 1 (<0.1%)                                      |
| HEPATIC ENZYME INCREASED                              | 0                                                  |                                                    | 1 (<0.1%)                                      |
| LIVER FUNCTION TEST INCREASED                         | 0                                                  |                                                    | 1 (<0.1%)                                      |
| TROPONIN INCREASED TROPONIN T INCREASED               | 1 0                                                | (<0.1%)                                            | 0 1 (<0.1%)                                    |
| WEIGHT INCREASED                                      |                                                    | (<0.1%)                                            | 0                                              |
| WHITE BLOOD CELL COUNT INCREASED                      | 1                                                  | (<0.1%)                                            | 0                                              |
| Totalnumberof events                                  |                                                    | 246                                                | 264                                            |
| INFECTIONS AND INFESTATIONS                           |                                                    |                                                    |                                                |
| Totalnumber of patients withat leastone adverse event | 185                                                | 7.8%)                                              | 156 6.5%)                                      |
| NASOPHARYNGITIS                                       | 22                                                 | 0.9%)                                              | 21 0.9%)                                       |
| INFLUENZA                                             | 15                                                 | 0.6%)                                              | 18 0.7%)                                       |
| UPPER RESPIRATORY TRACT INFECTION                     | 14                                                 | 0.6%)                                              | 11 0.5%)                                       |
| BRONCHITIS                                            | 7                                                  | 0.3%)                                              | 10 0.4%)                                       |
| HERPES ZOSTER                                         | 6                                                  | 0.3%)                                              | 9 0.4%)                                        |
| RESPIRATORY TRACTINFECTIONVIRAL                       | 9                                                  | 0.4%)                                              | 5 0.2%)                                        |
| URINARY TRACT INFECTION                               | 5                                                  | 0.2%)                                              | 9 0.4%)                                        |
| PNEUMONIA                                             | 5                                                  | 0.2%)                                              | 8 0.3%)                                        |
| CELLULITIS                                            | 6                                                  | 0.3%)                                              | 5 0.2%)                                        |
| GASTROENTERITIS                                       | 7                                                  | 0.3%)                                              | 4 0.2%)                                        |
| INFECTION DEVICE RELATED INFECTION                    | 5                                                  | 0.2%) 0.2%)                                        | 5 0.2%) 4 0.2%)                                |

InvestigatortextforAEsencodedusingMedDRAvi9.1

For frequency counts by preferred term, multiple occurrences\\_of the same AE in an individual are counted only once.For frequency counts of 'Total number of events'rows, multiple occurrences of the same AE in an individual are counted separately. Table includes study treatment.

Percentages are based on N in the column headings.

Program:/opt/B10sTAr/prod/cdp11450/r25126a/t\\_ae.sas

Output: /opt/BI0STAT/prod/cd11450g/j25126a/reports/t ae TRT1A DSMPP SE.out

21MAR2017 19:36

Page 2 of 13

<div style=\"page-break-after: always\"></div>

Adverse Events Leading to Dose Modification (Dose Interruption or Dose Delay) of Pertuzumab/ Placeboby Treatment Regimen,Safety Evaluated Population Protocol:BIG4-11/B025126/T0C4939G

| MedDRASystemOrganClass MedDRA Preferred Term             | Pertuzumab + Trastuzumab + Chemotherapy (N=2364)   | Placebo + Trastuzumab Chemo therapy (N=2405)   |
|----------------------------------------------------------|----------------------------------------------------|------------------------------------------------|
| GASTROINTESTINAL DISORDERS                               |                                                    |                                                |
| Total number of patients with at least one adverse event | 109 4.6%)                                          | 45 (1.9%)                                      |
| DIARRHOEA                                                | 69 2.9%)                                           | 18 0.7%)                                       |
| VOMITING                                                 | 12 0.5%)                                           | 13 0.5%)                                       |
| NAUSEA                                                   | 7 0.3%)                                            | 7 0.3%)                                        |
| STOMATITIS                                               | 10 0.4%)                                           | 3 0.1%)                                        |
| ABDOMINAL PAIN                                           | 5 0.2%)                                            | 1 (<0.1%)                                      |
| ABDOMINAL PAIN UPPER                                     | 4 0.2%)                                            | 1 (<0.1%)                                      |
| COLITIS                                                  | 1 (<0.1%)                                          | 2 (<0.1%)                                      |
| GASTROOESOPHAGEALREFLUXDISEASE                           | 2 (<0.1%)                                          | 1 (<0.1%)                                      |
| DENTAL CARIES                                            | 1 (<0.1%)                                          | 1 (<0.1%)                                      |
| DUODENAL ULCER                                           | 2 (<0.1%)                                          | 0                                              |
| GASTRIC ULCER                                            | 2 (<0.1%)                                          | 0                                              |
| GASTRIC ULCER HAEMORRHAGE                                | 2 (<0.1%)                                          | 0                                              |
| HAEMATOCHEZIA                                            | 1 (<0.1%)                                          | 1 (<0.1%)                                      |
| HAEMORRHOIDALHAEMORRHAGE                                 | 1 (<0.1%)                                          | 1 (<0.1%)                                      |
| ILEUS                                                    | 1 (<0.1%)                                          | 1 (<0.1%)                                      |
| ODYNOPHAGIA                                              | 1 (<0.1%)                                          | 1 (<0.1%)                                      |
| PERIODONTAL DISEASE                                      | 0                                                  | 2 (<0.1%)                                      |
| TOOTHACHE                                                | 2 (<0.1%)                                          | 0                                              |
| ABDOMINALDISTENSION                                      | 1 (<0.1%)                                          | 0                                              |
| ABDOMINAL HERNIA                                         | 0                                                  | 1 (<0.1%)                                      |
| ANAL FISSURE                                             | 1 (<0.1%)                                          | 0                                              |
| CONSTIPATION                                             | 0                                                  | 1 (<0.1%)                                      |
| DIVERTICULAR PERFORATION                                 | 0                                                  | 1 (<0.1%)                                      |
| DUODENALPERFORATION                                      | 0                                                  | 1 (<0.1%)                                      |
| DUODENALULCERPERFORATION                                 | 0                                                  | 1 (<0.1%)                                      |
| DYSPEPSIA                                                | 1 (<0.1%)                                          | 0                                              |
| GASTROINTESTINALDISORDER                                 | 1 (<0.1%)                                          | 0                                              |
| GASTROINTESTINALHAEMORRHAGE                              | 0                                                  | 1 (<0.1%)                                      |
| GLOSSODYNIA                                              | 1 (<0.1%)                                          | 0                                              |
| HAEMORRHOIDS                                             | 1 (<0.1%)                                          | 0                                              |
| INTESTINAL HAEMORRHAGE                                   | 1 (<0.1%)                                          | 0                                              |
| LIP OEDEMA                                               | 0                                                  | 1 (<0.1%)                                      |
| LOWER GASTROINTESTINALHAEMORRHAGE                        | (<0.1%)                                            | 0                                              |
| MOUTH ULCERATION                                         | 1 0                                                | 1 (<0.1%)                                      |
| OEDEMA MOUTH                                             | 1 (<0.1%)                                          | 0                                              |
| PANCREATITIS ACUTE                                       | 1 (<0.1%)                                          | 0                                              |
| Totalnumber of events                                    | 137                                                | 63                                             |

<!-- image -->

A total of 723 patients (30.6%) vs. 632 patients (26.3%) experienced an AE leading to a dose modification of Perjeta or placebo (i.e., dose interruption or dose delay). The SOCs were as follows:

- Blood and Lymphatic Systems Disorders: 204 patients (8.6%) compared to 196 patients (8.1%), mainly attributable to neutropenia (123 patients [5.2%] vs. 109 patients [4.5%]).
- Investigations:  186  patients  (7.9%)  compared  to  187 patients  (7.8%),  mainly  attributable  to neutrophil  count  decreased  (72  patients  [3.0%]  vs.  59  patients  [2.5%]),  and  ejection  fraction decreased (50 patients [2.1%] vs. 50 patients [2.1%]).
- Gastrointestinal  Disorders:  109  patients  (4.6%)  compared  to  45 patients  (1.9%),  mainly attributable to diarrhea (69 patients [2.9%] vs. 18 patients [0.7%]).

The incidence of AEs leading to any  study  drug modifications (i.e., including dose interruptions, dose delays, and dose reductions) were1217 patients (51.5%) vs. 1064 patients (44.2%). The higher incidence was mainly due to neutropenia (230 patients [9.7%] vs. 209 patients [8.7%]).

<div style=\"page-break-after: always\"></div>

## Additional SOCs were:

- Investigations:  288  patients  (12.2%)  compared  to  297 patients  (12.3%),  the  higher  incidence mainly attributable to neutrophil count decreased (121 patients [5.1%] vs. 116 patients [4.8%]).
- Gastrointestinal Disorders: 315 patients (13.3%) compared to 160 patients (6.7%), the higher incidence mainly attributable to diarrhea (210 patients [8.9%] vs. 74 patients [3.1%].

## Post marketing experience

As  of  30  March  2017  (the  Data  Lock  Point  [DLP]  for  the  Perjeta  EU  License  renewal),  an  estimated cumulative total of 160,282 patients have received Perjeta in the marketing experience.

In line with ICH-E2D guideline, for marketed medicinal products, spontaneously reported AEs usually imply at least a suspicion of causality by the reporter and are considered to be suspected adverse reactions for regulatory reporting purposes. A summary of the SOCs under which AEs were most frequently reported from post-authorization sources, is presented in Table 75.

Table 75 SOCs of the Most Frequently Reported AEs from Post-authorization Sources (from 8 June 2012 [IBD] to 30 March 2017 [DLP])*

| SOC                                                  | Spontaneous, including health authority (worldwide) and literature   | Spontaneous, including health authority (worldwide) and literature   | Non-interventional post-marketing study and reports from other solicited sources**   |
|------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|                                                      | Serious                                                              | Non-Serious                                                          | Serious                                                                              |
| General Disorders and Administration Site Conditions | 491                                                                  | 1487                                                                 | 667                                                                                  |
| Gastrointestinal Disorders                           | 539                                                                  | 1177                                                                 | 257                                                                                  |
| Skin and Subcutaneous Tissue Disorders               | 250                                                                  | 1149                                                                 | 23                                                                                   |

Source: Appendix 6 of EU License Renewal (available upon request): cumulative summary tabulations of serious and non-serious adverse reactions from post-marketing data sources

*Non-interventional studies (including post-authorization safety studies), reports from other solicited sources, and spontaneous Individual Case Safety Reports (i.e., reports from healthcare professionals, consumers, health authorities [worldwide], and scientific literature)

** This does not include interventional clinical trials

DLP = data lock point, IBD = international birth date, SOC = system organ class

The cumulative post-marketing data is consistent with the data submitted in previous Periodic Benefit-Risk Evaluation Reports (PBRERs), including the data that became available since the last Perjeta PBRER was submitted (Report 1069305 [reporting period 8 December 2015 to 7 June 2016]). No new safety concerns were identified.

## 2.5.1. Discussion on clinical safety

The  APHINITY study included patients with operable HER2-positive early breast cancer, and the study provides safety data on 2364 patients exposed to Perjeta plus trastuzumab and standard chemotherapy (Ptz + H + Chemo) in the adjuvant setting. In addition, safety data have previously been submitted for more

<div style=\"page-break-after: always\"></div>

than  2000  patients  treated  with  Perjeta  alone  or  in  combination  with  a  range  of  trastuzumab  and/or chemotherapy  regimens  in  registration-directed  and  supporting  clinical  trials  in  the  neoadjuvant  and metastatic settings. Due to the relatively short follow-up, follow-up safety data from the APHINITY study will allow to further characterise the safety profile..

At the time of the clinical cut-off for the primary analysis (19 December 2016), 2028 patients (84.5%) in the pertuzumab arm and 2100 patients (87.4%) in the Placebo arm had completed treatment. Thereof 372 [15.5%] and 304 [12.6%], respectively, did not complete, or never started, Perjeta or placebo treatment. The median duration of study treatment was 64 weeks (targeted treatment 55 weeks), which was the same in  both  treatment  arms.  The  median  cumulative  dose  of  pertuzumab  received  by  patients  in  the Ptz+H+Chemo  arm  was  7980  mg  (range:  420-9660  mg).  The  median  follow-up  is  approximately  45 months. The Applicant has prolonged the follow-up time by additional 5 years, and the obtained knowledge will be very informative both with regard to the number of relapses over time (especially in the CNS) and the extent of late toxicity from the adjuvant treatment given in the APHINITY trial.

In the pertuzumab arm, the incidence of any treatment-emergent AE was 99.9%, and the incidence of any grade ≥ 3 AE was 64.2%. The most common AEs were diarrhea (71.2% vs. 45.2%), nausea (69.0% vs. 65.5%), alopecia (66.7% vs. 66.9%), fatigue (48.8% vs. 44.3%), vomiting (32.5% vs. 30.5%), arthralgia (28.7% vs. 32.5%), and constipation (28.9% vs. 31.6%). Overall, most of the common adverse effects are assessed to be chemotherapy toxicities, as they are similar between the treatment arms.

The incidence of grade ≥ 3 AEs was overall higher in the pertuzumab arm (1518 patients [64.2%] vs. 1379 patients [57.3%], respectively), and consisted mainly of neutropenia, febrile neutropenia, and anemia, as well as diarrhea, and neutrophil count decreased. The higher incidence in the pertuzumab arm was mainly driven by diarrhea (9.8% vs. 3.7% in the placebo arm) was significant as &gt;grade 3 diarrhoea translate into more than 7 stools per day and hospitalization as indicated. It was evident that the adverse event of diarrhoea was earlier onset, worse in grade, and had longer duration in the pertuzumab arm. Even though reasonable measures were taken, such as early intervention with loperamide as well as fluid and electrolyte replacement, it is noted that the median duration of diarrhea was 8 days vs 6 days between the arms and that  the  event  was  coupled  especially  to  the  administration  of  docetaxel.  In  addition,  loperamide  was administered  to  more  than  double  as  many  patients  in  the  pertuzumab  arm  (35.6%  vs  14.8%).  The Applicant has sufficiently changed the SmPC to be more informative on the risk of diarrhea during taxane chemotherapy and in elderly patients, and proposed reasonable management and handling of this safety issue.

A higher incidence of febrile neutropenia was observed among Perjeta-treated Asian patients compared with other  races  in  the  APHINITY  trial  (15.9%  of  Perjeta-treated  patients  and  9.9%  of  placebo-treated patients).The number of deaths due to AEs were comparable between the treatment arms.

The most frequent treatment-related SAEs excluding diarrhoea were cardiac events. A total of 25 patients had a primary cardiac event : 17 patients (0.7%) vs. 8 patients (0.3%). Heart failure (NYHA III or IV) with an LVEF decline was reported in 15 patients (0.6%) vs. 7 patients (0.3%). The timing of the primary cardiac events was mostly within 2 years, reversible and the number of events was relatively small, so overall the rate is considered acceptable and expectable. Most of the cardiac events occurred in patients who received anthracycline-based  treatment.  In  particular,  all  cardiac  deaths  occurred  in  patients  who  received anthracycline-based  chemotherapy.  Radiotherapy  on  chest  wall,  smoking  history,  and  coronary  artery disease were other identified risk factors. All these factors are already well known to increase the risk of cardiac events with anti-HER2 therapies. At the time of data cut-off, LVEF recovery was achieved only in 7/15 patients (46.7%) experiencing a non-fatal primary cardiac event in the Pertuzumab arm versus 4/6 patients (66.7%) in the placebo arm of patients experiencing a non-fatal primary cardiac event in that treatment arm). The median time to LVEF recovery was much longer in the pertuzumab arm (27.0 weeks, range 3.1-52.4 weeks) compared to the placebo arm (16.3 weeks, range 11.0-30.1 weeks).   The updated

<div style=\"page-break-after: always\"></div>

incidence  for  recovery  by  the  new  data  cut-off  15  May  2017  was  8/15  (53.3%)  and  4/7  (57.1%)  for pertuzumab and placebo respectively. As no further data can be expected from the majority of the remaining patients,  due  to  2  deaths  and  several  patient  withdrawals  from  study,  it  may  be  concluded  that approximately 50% of the patients will recover from a primary cardiac event within a reasonable timeframe.

The majority of patients who experienced a secondary cardiac event , experienced the event in the first year after randomization (48 patients [75.0%] vs. 51 patients [76.1%]). LVEF recovery was achieved in 79.4%  vs.  80.6%  and  the  median  time  to  acute  recovery  was  comparable  between  treatment  arms. Therefore, secondary cardiac events were considered rare and within an acceptable range considering the study treatments toxicity profiles. However, it is important to get more long-term safety data regarding cardiac safety (see RMP).

Other relevant AEs included rash or similar skin adverse events; leukopenia and neutropenia, including febrile  neutropenia,  and infusion-related  reactions .  These  adverse  events  were  manageable  and considered primarily related to chemotherapy.

Patients with at least one AE in both treatment arms was also comparable across age groups &lt;40 years, 40-64  years,  and ≥ 65  years.  In  addition,  the  safety  profile  in  patients  regarding nodal  status and hormone-receptor  status was  similar  to  that  seen  in  the  overall  patient  population.  The  number  of patients aged 75 years or older was quite small (56 patients [1.2%]), and the MAH decided not to include as a separate group in the analyses to investigate the safety profile of study treatment by age.  Requested data from the Applicant show that diarrhea, vomiting, anaemia, decreased appetite and weight decreased were higher in this age-group compared to all patients.

The most common AE's that led to withdrawal of Perjeta or placebo were EF decreased, cardiac failure, and diarrhea. Generally, the incidences were small (&lt;3%) and the toxicities were well known and within an acceptable range. The most common AE's that led to withdrawal of any study medication were peripheral sensory neuropathy, neuropathy peripheral, diarrhea, EF decreased, and cardiac failure. The peripheral neuropathy is a known adverse event to taxanes and the events were few, so this is of no major concern. More patients stopped any treatment due to diarrhea, which was expected due to pertuzumab' s and the taxanes toxicity  profiles,  however  the  number  is  considered  within  an  acceptable  range,  and  mostly  a problem while both pertuzumab and taxanes were given concomitantly, which is only for approximately 9-12 weeks.  The  incidences  of  decreased  EF  and  cardiac  failures  are  within  the  known  range  with  these treatments, and although double as many patients discontinued treatment due to cardiac failure in the pertuzumab arm, the overall incidence is low (1.2% vs 0.6%).

The AE's that led to a dose modification of Perjeta or placebo were mainly neutropenia, neutrophil count decreased, EF decreased, and diarrhea. Dose modifications were more common in the pertuzumab arm (30.6% vs. 26.3%). The AEs that led to any study medication modifications were mainly neutrophil count decreased and diarrhea, and were overall more common in the pertuzumab arm (51.5% vs. 44.2%).

## 2.5.2. Conclusions on clinical safety

The addition of pertuzumab to standard chemotherapy is well-tolerated, but is associated with increased incidence  of  diarrhea,  cardiac  events,  mucositis,  and  infusion-related  reactions.  Especially,  the  risk  of primary cardiac events tended to increase, particularly heart failure, apparently with a lower chance and longer time to recovery.  However, in the updated set the chance of recovery appeared similar. Diarrhoea was observed much more frequently with Perjeta, and was among the main AEs leading to treatment withdrawal  or  dose  modifications.  Most  toxicities  appear  manageable  and  related  to  chemotherapy, however, it is evident that many of the toxicities are more pronounced in elderly patients, and this is reflected in the SmPC. The high frequency and severity of diarrhoea related to Perjeta, are likely to affect quality of life.

<div style=\"page-break-after: always\"></div>

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP endorsed the Risk Management Plan version 10.2 with the following content:

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                      |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Infusion-related reactions, Hypersensitivity reactions / anaphylaxis Congestive heart failure / Left ventricular dysfunction Grade ≥ 3 Diarrhea |
| Important potential risks    | Oligohydramnios* Risk in fertility in humans Risk in patients aged 75 years or older Lack of efficacy due to immunogenicity                     |
| Missing information          | Risk in patients with cardiovascular impairment Risk in pregnant or lactating women                                                             |

## Pharmacovigilance plan

| Study Status                                                                                                                                         | Summary of Objectives                                                                                                                                                                                                                                                                                                                                | Safety concerns addressed                                                                                                  | Milestones                                                                                                                 | Due dates                                                                                                                  |
|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                           | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                                                                                           | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization |
| PERUSE study (MO28047) A Phase IIIb study to evaluate the safety and tolerability of pertuzumab in combination with trastuzumab and a taxane Ongoing | The study will mainly evaluate the safety and tolerability of Perjeta in combination with Herceptin and a taxane. Additionally, it will evaluate pertuzumab in combination with trastuzumab and a taxane with respect to PFS, OS, ORR, CBR, Duration of response, Time to response, Quality of life (FACT-B questionnaire for female patients only). | Congestive heart failure / Left ventricular dysfunction Risk in patients with cardiovascular impairment                    | Final CSR submission                                                                                                       | Sept 2020                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                                                  | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                    | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                                                                                                                                                                                                                                                                                                                | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| NA                                                                                                                                                                                                                                            | NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         | NA                                                                                                                                                                                                                         |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                 | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| Study H4621g (MotHE R) An observational study of pregnancy and pregnancy outcomes in women with breast cancer treated with Herceptin or Perjeta in combination with Herceptin during pregnancy or within 6 months prior to conception Ongoing | The objective of this study is to describe adverse pregnancy complications (e.g., oligohydramnios), delayed renal development) pregnancy outcomes (i.e., live births, stillbirths, and abortions), fetal/infant outcomes (e.g., major malformations, deformations, and disruptions), and fetal or infant functional deficits among women with breast cancer treated with Herceptin (either in combination with chemotherapies, or as a single agent),and the subset of women treated with Perjeta plus Herceptin during pregnancy or within 6 months prior to conception. | Oligohydramnios                                                                                                                                                                                                            | Submission of annual reports with PSUR                                                                                                                                                                                     | Ongoing                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                               | The objective of this study is to describe adverse pregnancy complications (e.g., oligohydramnios), delayed renal development) pregnancy outcomes (i.e., live births, stillbirths, and abortions), fetal/infant outcomes (e.g., major malformations, deformations, and disruptions), and fetal or infant functional deficits among women with breast cancer treated with Herceptin (either in combination with chemotherapies, or as a single agent),and the subset of women treated with Perjeta plus Herceptin during pregnancy or within 6 months prior to conception. | Oligohydramnios                                                                                                                                                                                                            | Final report                                                                                                                                                                                                               | 2022                                                                                                                                                                                                                       |

CBR = Clinical benefit rate, CSR = Clinical study report, FACT-B = Functional Assessment of Cancer Therapy-Breast, HER2 = human epidermal growth factor receptor 2, ORR = Overall response rate, OS = Overall survival, PFS = Progression-free survival, PSUR = Periodic Safety Update Report.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

| Safety concern                                                     | Risk minimization measures                                                         | Pharmacovigilance activities                                                                                                                                                                                                                                |
|--------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Infusion-related reactions, Hypersensitivity reactions/anaphylaxis | Sections 4.4 and 4.8 of the EU SmPC: Additional risk minimization measures: None   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Other forms of routine pharmacovigilance activities: Presentation of cumulative data in PSURs Additional pharmacovigilance activities: None                   |
| Congestive heart failure / Left ventricular dysfunction            | Sections 4.2; 4.4; 4.8 of the EU SmPC: Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Other forms of routine pharmacovigilance activities: Presentation of cumulative data in PSURs Additional pharmacovigilance activities: PERUSE study (MO28047) |
| Grade ≥ 3 Diarrhea                                                 | Sections 4.4 and 4.8 of the EU SmPC:                                               | Routine pharmacovigilance activities beyond adverse                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Safety concern                   | Risk minimization measures                                               | Pharmacovigilance activities                                                                                                                                                                                                                                                   |
|----------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                  | Additional risk minimization measures: None                              | reactions reporting and signal detection: Other forms of routine pharmacovigilance activities: Presentation of cumulative data in PSURs Additional pharmacovigilance activities: None                                                                                          |
| Oligohydramnios                  | Section 4.6 of the EU SmPC: Additional risk minimization measures: None  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Global Enhanced PV Pregnancy Program Additional pharmacovigilance                                                                                                                |
| Risk in fertility in humans      | Sections 4.6 of the EU SmPC: Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Global Enhanced PV Pregnancy Program Other forms of routine pharmacovigilance activities: Presentation of cumulative data in PSURs Additional pharmacovigilance activities: None |
| Risk in patients aged ≥ 75 years | Routine risk communication: Section 4.2 and 4.4 of the EU SmPC           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Other forms of routine pharmacovigilance activities: Presentation of cumulative data in                                                                                          |

<div style=\"page-break-after: always\"></div>

| Safety concern                                  | Risk minimization measures                                                       | Pharmacovigilance activities                                                                                                                                                                                                                                |
|-------------------------------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 |                                                                                  | PSURs Additional pharmacovigilance activities: None                                                                                                                                                                                                         |
| Risk of lack of efficacy due to immunogenicity  | Section 5.1 of the EU SmPC                                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Other forms of routine pharmacovigilance activities: Presentation of cumulative data in PSURs Additional pharmacovigilance activities: None                   |
| Risk in patients with cardiovascular impairment | Sections 4.2 and 4.4 of the EU SmPC: Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Other forms of routine pharmacovigilance activities: Presentation of cumulative data in PSURs Additional pharmacovigilance activities: PERUSE study (MO28047) |
| Risk in pregnant or lactating women             | Section 4.6 of the EU SmPC Additional risk minimization measures: None           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Global Enhanced PV Pregnancy Program Other forms of routine pharmacovigilance activities: Presentation of cumulative data in                                  |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimization measures   | Pharmacovigilance activities                  |
|------------------|------------------------------|-----------------------------------------------|
|                  |                              | Additional pharmacovigilance activities: None |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

This extension of indication is for the use of Perjeta in the adjuvant setting, in combination with trastuzumab and chemotherapy, for the treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.

## 3.1.2. Available therapies and unmet medical need

Patients with early breast cancer are treated with 6-8 cycles of chemotherapy in addition to 1 year of trastuzumab.

Despite the current available adjuvant treatment (chemotherapy and trastuzumab), up to 1 in 4 women with HER2-positive early breast cancer will experience recurrence or death within 10 -11 years of diagnosis. As the median age of patients presenting with HER2-positive breast cancer is in the mid-50s, around five years younger than the general breast cancer population, the median loss of life-years per patient is around two decades for patients dying of HER2-positive breast cancer.

Of the patients diagnosed with HER2-positive metastatic breast cancer, approximately 67% initially present with early disease and subsequently relapse, while the remaining patients present with metastases at first diagnosis ('de novo' metastatic breast cancer) (Yardley et al, 2014). Patients who relapse with metastatic or unresectable disease are generally incurable, whereas the few patients with resectable loco-regional recurrence may still be cured with salvage therapy. In the case of metastatic disease, life expectancy is a median OS of 56.5 months (Swain et al, 2015), so more than 50% of the patients die within 5 years.

<div style=\"page-break-after: always\"></div>

There is an unmet medical need for reducing the risk of frequent relapses, despite current available adjuvant treatments, and thereby decrease the risk of early death for the majority of the patients who relapse.

## 3.1.3. Main clinical studies

The pivotal and only study in this application is the APHINITY study. The APHINITY study is an ongoing, randomized, double-blind, two-arm, phase III study of adjuvant trastuzumab and standard chemotherapy plus Perjeta or placebo, in patients with primary operable breast cancer. For each patient, investigators chose  from  pre-specified  adjuvant  chemotherapy  regimens,  including  standard  anthracycline-and/or taxane-based chemotherapy. In total, 4804 patients were randomized 1:1 to Perjeta plus trastuzumab and standard  chemotherapy  (Ptz + H + Chemo)  or  placebo  plus  trastuzumab  and  standard  chemotherapy (Pla + H + Chemo) in the adjuvant setting from 08 November 2011 to 31 August 2013.

The primary endpoint was invasive disease-free survival (IDFS) and secondary endpoints included IDFS-including second primary non-breast cancer (IDFS-SPNBC), disease-free survival (DFS), overall survial (OS), recurrence-free interval (RFI), and distant recurrence-free interval (DRFI). Exploratory endpoints included breast cancer-free interval (BCFI), and patient-reported outcomes.

## 3.2. Favourable effects

The study met its primary endpoint at the time of primary analysis. A statistically relevant improvement in IDFS, corresponding to a 19% reduction in the risk of recurrence or death, HR 0.81 (95%CI 0.66; 1.00, p=0.446) was demonstrated. The K-M  IDFS curves tend to overlap  up to 2 years.  Estimates  of  IDFS event-free  rates  at  3  years  were  94.06%  vs.  93.24%  in  the  pertuzumab  arm  vs.  the  placebo  arm, respectively, and at 4 years were 92.28% vs. 90.58%, suggesting a sustained benefit over time after the end of treatment (1-year duration). As expected, distant recurrence was the most frequent IDFS event.

Key secondary endpoints were invasive disease-free survival excluding second non-breast malignancies (IDFS-SPNBC), disease-free survival (DFS), and overall survival (OS). Results for IDFS-SPNBC was similar to  IDFS,  and  also  showed  a  statistical  difference  favouring  the  pertuzumab  arm.  DFS  also  showed  a significant benefit with the addition of pertuzumab.

Overall survival data was immature, with only 3.3% and 3.7% events in each arm.

The exploratory endpoints were recurrence-free interval (RFI), distant recurrence-free interval (DRFI), and breast  cancer-free  interval  (BCFI).  RFI  showed  a  statistically  significant  improvement  as  well  as  BCFI, however DRFI was not different between the arms, probably due to too few events at the present time (5% vs. 6%, respectively).

Patients with node-positive disease showed statistically significant benefit with Ptz + H + Chemo treatment with IDFS event-free rates of 91.99% vs. 90.15% at 3 years (HR 0.77, 95%CI 0.62, 0.96) (KM curve below). These  results  indicate  a  23%  reduction  in  risk  of  recurrence  or  death  in  patients  randomized  to Ptz + H + Chemo; the event-free rates at 4 years were 89.88% vs. 86.68%, respectively. For patients with hormone receptor-negative disease the results were HR 0.76 (95%CI 0.56, 1.04). At 4 years, the IDFS event-free rates for this subgroup were 90.96% vs. 88.67%, respectively.

## 3.3. Uncertainties and limitations about favourable effects

The results from the primary analysis of the APHINITY study were after only 4 years of follow-up and this is a relatively short time for an adjuvant study of early breast cancer. Consistently, there were rather few

<div style=\"page-break-after: always\"></div>

events at this point in time, as 171 patients (7.1%) in the pertuzumab arm and 210 patients (8.7%) in the placebo arm have had an IDFS event so far. Especially, limited conclusions can be drawn regarding OS and many of the secondary endpoints due to the low number of events so far. This is, however, expected, and is not considered an issue with regard to the B/R assessment of the present application. Furthermore, based on the available data there was no reason to expect a detrimental effect in the long term. Further data are expected.

## 3.4. Unfavourable effects

The addition of pertuzumab to standard chemotherapy is associated with increased incidence of diarrhea, cardiac events, mucositis, and infusion-related reactions. Among the most common treatment-emergent AEs, the highest difference between the two arms was observed for diarrhea (71.2% vs. 45.2%, grade ≥ 3 9.8% vs 3.7%). This is reflected in the results of PROs, showing an imbalance between the two arms only for diarrhoea, with a clinically meaningful worsening observed in the experimental arm that persisted until the end of treatment. Most toxicities appear manageable and related to chemotherapy, however, it is evident that many of the toxicities are more pronounced in elderly patients, and this is now reflected in the SmPC.

The most common AE's that led to withdrawal of Perjeta or placebo were EF decreased, cardiac failure, and diarrhoea. Generally, the incidences were small (&lt;3%) and the toxicities were well known with the given therapies. The most common AE's that led to withdrawal of any study medication were peripheral sensory neuropathy, neuropathy peripheral, diarrhoea, EF decreased, and cardiac failure. The peripheral neuropathy is a known adverse event to taxanes and the events were few. More patients stopped any treatment due to diarrhoea, which was expected due to the toxicity profile of pertuzumab and taxane. Heart failure (NYHA III or IV) with LVEF decline of at least 10 Ejection Fraction points from baseline AND to below 50% was reported in 15 patients in the Ptz + H + Chemo arm (0.6%) versus 7 patients in the Pla + H + Chemo arm (0.3%). The incidences of decreased EF and cardiac failures are within the known range with these treatments, and although double as many patients discontinued treatment due to cardiac failure in the pertuzumab arm, the overall incidence was low (1.2% vs 0.6%).

The AE's that led to a dose modification of Perjeta or placebo were mainly neutropenia, neutrophil count decreased, EF decreased, and diarrhoea. Dose modifications were more common in the pertuzumab arm (30.6% vs. 26.3%). The AEs that led to any study medication modifications were mainly neutrophil count decreased and diarrhoea, and were overall more common in the pertuzumab arm (51.5% vs. 44.2%).

## 3.5. Uncertainties and limitations about unfavourable effects

The median follow-up time in the submitted primary analysis is 4 years, so there are no long-term safety data. Perjeta has been used for longer periods in the metastatic setting, but due to the median survival time in  this  patient  group,  there  are  no  long-term  data  from  this  population.  In  the  neoadjuvant  setting, pertuzumab has been used for 18-24 weeks prior to operation, but this is a shorter time than what is applicable for this application i.e. exposure of approximately 1 year. Long-term follow-up is considered especially  relevant  regarding  cardiac  toxicity,  in  order  to  allow  a  better  assessment  of  the  long-term outcome (see RMP). Currently, available data show apparent longer time to recovery with Perjeta compared to placebo. Regarding the long-term outcome of cardiac toxicity, the Applicant will also assess this at the time of the next planned IA.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Effects Table for addition of pertuzumab to standard chemotherapy and trastuzumab in adjuvant treatment of adult patients with HER2-positive early breast cancer (data cut-off: 19 Dec 2016).

| Effect                                                      | Short description     | Unit                  | Treatment Ptz+H+ Chemo N=2400   | Control Pla+H+ Chemo N=2404   | Uncertainties / Strength of evidence                   | References            |
|-------------------------------------------------------------|-----------------------|-----------------------|---------------------------------|-------------------------------|--------------------------------------------------------|-----------------------|
| Favourable Effects                                          | Favourable Effects    | Favourable Effects    | Favourable Effects              | Favourable Effects            | Favourable Effects                                     | Favourable Effects    |
| Primary endpoint                                            | Primary endpoint      | Primary endpoint      | Primary endpoint                | Primary endpoint              | Primary endpoint                                       | Primary endpoint      |
| IDFS                                                        | Patients with event   | N (%)                 | 171 (7.1)                       | 210 (8.7)                     | HR 0.81 (95%CI: 0.66; 1.00) p=0.0446                   |                       |
| Secondary endpoints                                         | Secondary endpoints   | Secondary endpoints   | Secondary endpoints             | Secondary endpoints           | Secondary endpoints                                    | Secondary endpoints   |
| IDFS-SPNBC                                                  | Patients with event   | N (%)                 | 189 (7.9)                       | 230 (9.6)                     | HR 0.82 (95%CI: 0.68; 0.99) p=0.0430                   |                       |
| DFS                                                         | Patients with event   | N (%)                 | 192 (8.0)                       | 236 (9.8)                     | HR 0.81 (95%CI: 0.67; 0.98) p=0.0327                   |                       |
| OS                                                          | Patients with event   | N (%)                 | 80 (3.3)                        | 89 (3.7)                      | HR 0.89 (95%CI: 0.66; 1.21) p=0.4673 Data are immature |                       |
| Exploratory endpoints                                       | Exploratory endpoints | Exploratory endpoints | Exploratory endpoints           | Exploratory endpoints         | Exploratory endpoints                                  | Exploratory endpoints |
| RFI                                                         | Patients with event   | N (%)                 | 138 (5.8)                       | 173 (7.2)                     | HR 0.79 (95%CI: 0.63; 0.99) p=0.0430                   |                       |
| DRFI                                                        | Patients with event   | N (%)                 | 119 (5.0)                       | 145 (6.0)                     | HR 0.82 (95%CI: 0.64; 1.04) p=0.1007                   |                       |
| BCFI                                                        | Patients with event   | N (%)                 | 147 (6.1)                       | 190 (7.9)                     | HR 0.77 (95%CI: 0.62; 0.96) p=0.0186                   |                       |
| Unfavourable Effects                                        | Unfavourable Effects  | Unfavourable Effects  | Unfavourable Effects            | Unfavourable Effects          | Unfavourable Effects                                   | Unfavourable Effects  |
| AE grade 3-5                                                |                       | %                     | 64.2                            | 57.3                          |                                                        |                       |
| SAE                                                         |                       | %                     | 29.3                            | 24.3                          |                                                        |                       |
| AE leading to interruption/modification of any treatment    |                       | %                     | 51.5                            | 44.2                          |                                                        |                       |
| AE leading to interruption/modification of Perjeta/ placebo |                       | %                     | 30.6                            | 26.3                          |                                                        |                       |
| AE leading to treatment withdrawal                          |                       | %                     | 13.1                            | 11.5                          |                                                        |                       |
| AE leading to withdrawal of Perjeta/ placebo                |                       | %                     | 7.0                             | 5.8                           |                                                        |                       |
| AEs leading to death                                        |                       | %                     | 0.8                             | 0.8                           |                                                        |                       |
| Death due to recurrent disease                              |                       | %                     | 2.0                             | 2.6                           |                                                        |                       |

<div style=\"page-break-after: always\"></div>

| Effect                    | Short description   | Unit   | Treatment Ptz+H+ Chemo N=2400   | Control Pla+H+ Chemo N=2404   | Uncertainties / Strength of evidence   | References   |
|---------------------------|---------------------|--------|---------------------------------|-------------------------------|----------------------------------------|--------------|
| Death due to other causes |                     | %      | 0.3                             | 0.5                           |                                        |              |
| Cardiac safety            |                     |        |                                 |                               |                                        |              |
| Primary cardiac event     |                     | %      | 0.7                             | 0.3                           | Lack of                                |              |
| Secondary cardiac event   |                     | %      | 2.7                             | 2.8                           | long-term data                         |              |

Abbreviations: IDFS=Invasive disease-free survival; IDFS-SPNBC=Invasive disease-free survival incl. second primary non-breast cancer; DFS=Disease-free survival; OS=Overall survival; RFI=Recurrence-free survival; DRFI=Distant recurrence-free interval; BCFI=Breast cancer-free interval.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The target population of patients with HER2-positive early breast cancer still have an unmet medical need, since the risk of recurrence is high with available adjuvant treatment, as up to 1 in 4 women will experience recurrence or death within 10 -11 years of diagnosis. Because the median age of patients presenting with HER2-positive breast cancer is in the mid-50s, around five years younger than the general breast cancer population,  the  median  loss  of  life-years  per  patient  is  around  two  decades  for  patients  dying  of HER2-positive breast cancer. In the case of metastatic disease, life expectancy is a median OS of 56.5 months, so more than 50% of the patients die within 5 years.

Whereas the availability of a new treatment option to be added to the present therapeutic armamentarium in  the  adjuvant  setting  is  considered  clinically  relevant,  as  a  proportion  of  patients  still  relapses,  the magnitude of benefit is not considered outstanding in the ITT population; however, the treatment effect seems to be sustained over time (4 years observation period), which is encouraging considering that OS data, as expected, are largely immature. Importantly, the treatment effect seems to be driven by the subgroup of patients with node-positive disease, who represent also the largest proportion of recruited patients.

It cannot be excluded that with a longer follow-up, a benefit could be shown also for node-negative patients, but this is for the time being not self-evident.

Conversely, the efficacy outcome of a 19% reduction in recurrence or death (IDFS HR 0.81 (95%CI: 0.66; 1.00),  p=0.0446) is  comparable  with  the  improved  efficacy  outcomes  in  other  adjuvant  breast  cancer studies, such as docetaxel (HR 0.72); epirubicin (HR~0.77); exemestane (HR 0.68); letrozole (HR 0.81) and anastrozole (HR 0.87). In addition, it is noted that the control arm of the APHINITY study performed better than anticipated, which is in line with other recent adjuvant breast cancer trials (BETH, ALTTO), and may be due to better staging and treatment over the years.

Results from 11 years of follow up shows an improvement of adding trastuzumab compared to observation was within the same range (HR 0.76, 95%CI 0.68; 0.86) (Cameron et al. Lancet 2017).

The safety profile does not raise major concerns. The unfavourable effect of most significance is the high incidence of diarrhoea (71.2%), with an incidence of more than grade 3 of 9.8% in the pertuzumab arm. Although no fatal events, diarrhoea led to dose modifications and discontinuations, however, within an acceptable range. The event was more pronounced and affected PRO during chemotherapy.

Other  common  toxicities  that  may  affect  quality  of  life,  such  as  nausea,  alopecia,  fatigue,  vomiting, mucositis,  neutropenia  and  anaemia  were  almost  exclusively  related  to  the  chemotherapy  treatment, although mucositis seem worsened by pertuzumab. There were also an increased number of infusion-related

<div style=\"page-break-after: always\"></div>

reactions, but this is known with pertuzumab and manageable. However, a slight increase in the incidence of heart failure (NYHA III or IV) with LVEF decline of at least 10 Ejection Fraction points from baseline AND to below 50% associated with Perjeta is noted, together with tendency to a lower rate of recovery from the event, and a much longer median time to LVEF recovery.

Deaths due to AEs were uncommon and no imbalances were observed.

## 3.7.2. Balance of benefits and risks

Overall, patients with HER2-positive early breast cancer have a quite good prognosis thanks to development of  good  treatments  over  the  last  decades.  Thus,  the  results  seen  in  the  APHINITY  study  reflects  this situation.  Nonetheless,  there  is  a  statistically  significant  difference  between  the  two  arms  in  the  ITT population,  reflecting  a  risk  reduction  of  19%  for  relapse  or  death  in  the  target  population.  However, available data do not allow to conclude for a positive B/R in the overall population at this point in time. It is considered that benefit is clearly shown in the high-risk population therefore supporting an indication of adjuvant Perjeta in the high-risk subgroups of HR-negative, node-positive patients.

The risks of adding pertuzumab to standard chemotherapy are most importantly diarrhoea and increased cardiotoxicity.  Other  common  unfavourable  effects  are  manageable  and  affect  PRO  primarily  during chemotherapy.

Therefore, the B/R balance in the finally agreed restricted indication is considered favourable.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall B/R of Perjeta in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence is established to be positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends, the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication for Perjeta, in combination with trastuzumab and chemotherapy, for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. The submission is based on the primary analysis of efficacy and safety data from the pivotal Phase III study

<div style=\"page-break-after: always\"></div>

BIG-4-11/BO25126/TOC4939g (APHINITY). Sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated to reflect the study results. The Package Leaflet and RMP version 10.2 have been updated accordingly.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) ) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the following measures:

| Description                                                                                                                                                                                                                              | Due date       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| MO28047 (PERUSE) A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurrent) breast cancer | September 2020 |

These conditions do reflect the advice received from the PRAC.

## Additional market protection

Furthermore, the CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers, that the new therapeutic indication brings

<div style=\"page-break-after: always\"></div>

significant clinical benefit in the absence of existing therapies (see appendix 1).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of indication for Perjeta, in combination with trastuzumab and chemotherapy, for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. The submission is based on the primary analysis of efficacy and safety data from the pivotal Phase III study BIG-4-11/BO25126/TOC4939g (APHINITY). Sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated to reflect the study results. The Package Leaflet and RMP version 10.2 have been updated accordingly.

## Summary

Please refer to the published Assessment Report Perjeta H-2547 -II-34-AR.